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ABSTRACT 
Nicholas Peter Vitko: Metabolic Adaptation of Staphylococcus aureus to Low-
Respiratory Conditions Encountered During Invasive Infection 
(Under the direction of Anthony R. Richardson) 
  
 Staphylococcus aureus is one of several Staphylococcus species that colonizes 
human skin. Several of these Staphylococcus species are also capable of causing 
human disease, including S. aureus. However, S. aureus infections occur far more 
frequently, exhibit greater variability in their presentation, and are generally much more 
severe. The widely recognized explanation for this observation is that S. aureus has 
acquired a large number of unique toxins and adhesins that promote enhanced tissue 
penetration and destruction. Our results support a complementary hypothesis: that S. 
aureus has metabolically adapted to invasive infection. Importantly, inflamed tissue 
spaces exhibit low levels of oxygen, low levels of free iron, and high levels of nitric 
oxide. These factors contribute to the inhibition of bacterial respiration. We show that S. 
aureus exhibits enhanced non-respiratory growth compared to other pathogenic 
Staphylococci and identify S. aureus acquisition of unique carbohydrate importers, a 
unique lactate export channel, and unique fermentative metabolic genes as the primary 
mechanism by which these divergent phenotypes have arisen. We then demonstrate 
that several of these unique metabolic genes contribute to S. aureus virulence in animal 
models of infection. Our data implicate metabolic adaptation to invasion infection as one
! iv 
mechanism responsible for the speciation of S. aureus from other skin-colonizing 
Staphylococci and show that a novel mechanism for the maintainence of genetic 
redundancy may be driving this adaptation. Additionally, our findings implicate the host 
metabolic state (e.g., hyperglycemia) as a susceptibility factor for S. aureus disease, 
partially explaining the known association of S. aureus infections with uncontrolled 
diabetes mellitus. 
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CHAPTER 1: INTRODUCTION 
 
DISCOVERY AND CLASSIFICATION OF THE STAPHYLOCOCCI 
 The genus Staphylococcus is comprised of skin dwelling Gram-positive cocci that 
were discovered in 1880 by the surgeon Alexander Ogston. Upon microscopic 
examination of pus from human abscesses, he noted the existence of a novel type of 
cocci that grew in “grape-clusters” (1). This was distinct from the appearance of cocci 
also frequently isolated from human abscesses that could be found growing in 
“extremely long chains” (1). Ogston noted that although “sufficient evidence was not 
obtained to decide whether these different appearances indicated different species of 
micrococci… the constancy with which the chains produce only chains, and groups only 
groups… favoured the suspicion of their being so” (1). Prior to this observation, the 
Viennese surgeon Theodor Billroth had named the chain forming cocci, Streptococcus 
(2). The name Streptococcus is derived from the Greek words strepto, meaning chain, 
and kokkos meaning berry. Ogston eventually introduced the name Staphylococcus for 
the cocci growing in grape-like clusters. The name Staphylococcus is derived from the 
Greek words staphyle, meaning bunches of grapes, and kokkos, meaning berry.  
 Soon thereafter, the genus Staphylococcus was quickly subdivided based on 
various phenotypic traits. The German physician Friedrich Julius Rosenback was the 
first to distinguish the Staphylococci based on pigmentation (2). In 1884, he named the 
Staphylococci that formed golden colonies, Staphylococcus aureus (S. aureus) and 
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those that formed white colonies, Staphylococcus albus (S. albus). The name aureus is 
derived from the Latin word aurum, which means gold, while the word albus is Latin for 
white. However, Staphylococcus albus was soon referred to as Staphylococcus 
epidermidis (S. epidermidis) due to its frequent isolation from human skin (3). By the 
1930’s, S. aureus was reliably distinguished from S. epidermidis based on its’ ability to 
coagulate blood, hemolytic activity, ability to ferment mannitol, virulence in animals, and 
serum agglutination testing (4-6). The ease of blood coagulation testing, and the varied 
nature of pigmentation formation, resulted in the general reference of S. aureus as 
coagulase positive Staphylococci, and S. epidermidis as coagulase negative 
Staphylococci (CoNS).  
 Soon, it was discovered that CoNS was actually a collection of several 
Staphylococcus species. In the 1950’s and 1960’s, CoNS was identified as the 
causative agent of several cases of subacute bacterial endocarditis, septicemia, and 
urinary tract infections (7-11). Observation that CoNS could be pathogenic spurred 
further experimentation to characterize these bacteria, resulting in the classification of 
CoNS isolates that exhibited different phenotypes as separate species of Staphylococci 
(12). In 1965, Baird-Parker produced an exhaustive study on the classification of 
Staphylococci and other Micrococci that included up to 40 differential tests for the 
identification of Staphylococcus species (13). By 1975, Kloos et al. produced a 
simplified scheme for the identification of 12 different Staphylococcus species (including 
S. aureus) that utilized only 13 differential tests, including: pigmentation, anaerobic 
growth, hemolysis, nitrate reduction, lysostaphin susceptibility, novobiocin resistance, 
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and the ability to catabolize/grow on multiple different sugars (14). This made possible 
the routine identification of Staphylococcus species from clinical specimens.  
 The discovery and implementation of modern genetic techniques in the 1980’s 
and 1990’s greatly enhanced the capacity of researchers and clinicians to taxonomically 
characterize the Staphylococci. First, there was the implementation of DNA-DNA 
hybridization, which estimates homology between two bacterial isolates based on the 
rate of hybridization and the thermal stability of duplexes formed when single stranded 
DNA from each isolate is mixed together. It was in this manner that Schleifer and 
Fischer first identified the CoNS species Staphylococcus carnosus (S. carnosus) in 
1982 (15). Next came the implementation of ribotyping, or the differentiation of species 
based on the restriction fragment patterns of an organism’s 16S rRNA gene hybridized 
to a RNA probe. By 1992, ribotyping could differentiate between 28 Staphylococcus 
species (16). Ultimately, however, researchers settled on using 16S rRNA sequence to 
classify isolated bacteria. This new technique resulted in the identification of 38 species 
of Staphylococci that were separated phylogenetically into 11 groups by 1999 (17).  
 The number of identified Staphylococcus species has fluctuated in the years 
since. This is partially due to a reclassification of Staphylococcus caseolyticus as 
Macrococcus caseolyticus (M. caseolyticus), other species being reclassified as 
subspecies, and the identification of previously unknown species (18). In their 
comprehensive review of Staphylococcus and Macrococcus that was published in 2006, 
Götz et al. provide a table (Table 2) that lists 35 species and 18 subspecies of 
Staphylococci, as well as 4 species of Macrococci (19). This table includes references 
for the initial identification of each species/subspecies. Currently, there 47 accepted 
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species and 23 accepted subspecies of Staphylococci that are divided into 15 distinct 
groups based on phylogenetic analysis (20, 21). A useful historical timeline for the 
identification of all 47 Staphylococcus species is provided by Becker et al. in their 2014 
review on CoNS (20). 
 Despite regular advances in the classification of the Staphylococci, 
implementation of new nomenclature was often haphazard or lagged far behind the 
scientific evidence for its usefulness. For instance, S. aureus and S. albus were often 
referred to as Staphylococcus pyogenes, Microccocus pyogenes, Aurococcus aureus, 
and Albococcus epidermidis in the late 1800’s and early 1900’s (2, 22, 23). This was 
primarily due to their frequent isolation from infected abscesses (pyogenes is derived 
from the Greek words pyo and genes, which together mean pus producing) as well as 
the difficulty in distinguishing the Staphylococci from another genus of Gram-positive 
cocci that exhibits clustering called, Micrococci. Another prominent example is the 
frequent usage of S. albus as late as the 1960’s, even though S. albus was renamed S. 
epidermidis in 1908 and CoNS was correctly identified as comprising several different 
species of bacteria that could be phenotypically differentiated in the 1960s (24). This 
confusion continued with the frequent inclusion of S. caseolyticus as a species of 
Staphylococcus well past its reclassification in 1998 as M. caseolyticus (17, 18). 
 Further confusing classification of the Staphylococci is that two primary 
phenotypic methodologies used historically to distinguish and group the Staphylococci 
(i.e., coagulase activity and pigmentation) have been shown to have exceptions. For 
instance, the term CoNS is generally used to refer to all non-S. aureus Staphylococci. 
However, this usage was proven false with the discovery of a second coagulase 
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positive Staphylococcus species, Staphylococcus intermedius (S. intermedius), in 1976 
(25, 26). Additional coagulase positive Staphylococcus species were subsequently 
discovered, including: Staphylococcus hyicus (S. hyicus), Staphylococcus delphini (S. 
delphini), and Staphylococcus pseudintermedius (S. pseudintermedius) (27-29). 
Additionally, pigmentation is still widely accepted as a phenotypic characteristic of S. 
aureus isolates, despite the recent discovery of an S. aureus lineage in Australia that 
never acquired the biosynthetic operon for Staphyloxanthin, the carotenoid pigment that 
produces the distinct gold coloration for which S. aureus is named (30). Although 
confusing, these discoveries highlight common themes inherent to the genus 
Staphylococcus that prove to be clinically relevant, namely phenotypic variation and 
shared traits amongst small subsets of Staphylococcus species. 
 
CLASSFICATION OF STAPHYLOCOCCUS AUREUS STRAINS 
 Due to the early recognition that S. aureus was more virulent than the other 
Staphylococci, substantially more effort has been put forth historically to characterize S. 
aureus than the other Staphylococci (20). As such, it was observed very early on that 
there could be substantial phenotypic variation between S. aureus clinical isolates. As 
early as 1917, researchers had isolated S. aureus strains that differed in pigment 
production, growth on sugars, serum agglutination, and virulence in mice (4). 
Additionally it was noted that “after frequent sub-culturing most of the [S. aureus] strains 
would gradually lose their pigment entirely” (4). A concerted effort was put forth to 
classify the S. aureus strains using a common methodology. Two methods were widely 
investigated for such a feat, serum agglutination and phage typing (6, 31-34). Initially, 
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phage typing, or the susceptibility of an S. aureus strain to lysis by panel of phages, 
proved to be more differential. However, serum agglutination, or the clumping of S. 
aureus cells mixed with serum from individuals/animals pre-exposed to set strains of S. 
aureus proved to be more rapid and less costly, and thus was employed widely in 
clinics. Ultimately, both methods proved to be useful (35, 36).  
  Another common phenotype used to distinguish S. aureus isolates in the mid 
1900’s was resistance to antibiotics. It was first noted in the 1920’s that S. aureus was 
resistant to the bactericidal effects of the disinfectant phenol (37). Phenol resistance, 
combined with the fact that S. aureus resides on human skin, likely explains the early-
recognized association of S. aureus with hospitals. Perhaps due to this association, S. 
aureus strains quickly developed antibiotic resistance. By the 1940’s S. aureus isolates 
were found that were resistant to sulfonamides and penicillin, despite the relatively 
recent clinical implementation of these antibiotics (38-40). Due to the widespread 
emergence of penicillin resistant bacteria, a new β-lactam antibiotic was developed and 
approved for usage in the U.S. in 1959, called methicillin (Celbenin; Beecham 
Pharmaceuticals). Within the same year, the first methicillin-resistant S. aureus (MRSA) 
strains were isolated from patients in a U.K. hospital (41). These patients had not been 
treated with methicillin, suggesting that methicillin resistance existed in the natural 
population of Staphylococci prior to the introduction of this antibiotic. Since the 1960s, 
S. aureus isolates have been routinely divided into MRSA and methicillin susceptible S. 
aureus strains (MSSA). By the 1980’s MRSA had become a predominant etiology of 
hospital acquired infections (42). The genetic determinant of methicillin resistance was 
identified in 1989 as an alternative penicillin binding protein (PBP2a) encoded by the 
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mecA gene(43, 44). Importantly, the mecA gene is encoded on a mobile genetic 
element called the staphylococcal cassette chromosome (SCCmec), which varies 
between S. aureus strains and Staphylococcus species (20, 45). Currently, there are 11 
identified SCCmec types, some of which contain additional antibiotic resistance factors 
and even virulence determinants (20, 46, 47).  Although clinically relevant, SCCmec 
typing does not provide a robust method for distinguishing between S. aureus strains.  
 Coinciding with the epidemic spread of MRSA worldwide throughout the 1990’s 
was the implementation of novel molecular tools that allowed a genotypic study of 
MRSA strain spread and evolution. The primary methods employed in this 
characterization of S. aureus strains were pulsed field gel electrophoresis and sequence 
typing. Pulsed field gel electrophoresis involves the separation of SmaI digested 
chromosomal DNA via gel electrophoresis. Relatedness amongst S. aureus isolates is 
reflected in the banding patterns of the separated DNA, as genomic rearrangements, 
insertions, and deletions will affect the migration patterns of the digested chromosomal 
DNA. Pulsed field gel electrophoresis was first utilized as an epidemiological tool for the 
study of MRSA in 1991 and was quickly discovered to be more effective and 
reproducible than phage typing (48-50). S. aureus strains characterized in this manner 
are divided into 11 PFGE types (USA100-1200) (51).   
 Sequence typing, on the other hand, differentiates S. aureus isolates based on 
sequence differences in select genes. SCCmec typing is one example of sequence 
typing, although it is limited to only MRSA strains and is not highly differential. A more 
discriminatory example is spa-typing, which was first utilized in 1999 to differentiate S. 
aureus strains (52). The spa allele encodes Protein A, which is used by all S. aureus 
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strains to reversibly bind antibodies. Importantly, there is a highly variable region of 
DNA immediately upstream of the spa allele, termed a short sequence repeat (SSR) 
region. Sequencing this region revealed 24-different spa types that reflected 
epidemiologically relevant S. aureus lineages. However, a more robust utilization of 
sequence typing is the simultaneous sequencing of several housekeeping genes and 
subsequent comparison of sequence profiles between isolates. This technique was 
developed by Maiden et al. in 1998 to discriminate between Neisseria meningiditis 
isolates and was termed multilocus sequence typing (MLST) (53). MLST was first 
implemented for S. aureus in 2000 by Enright et al. and involved sequencing fragments 
of seven housekeeping genes (aroC, aroE, glpF, gmk, pta, tpi, and yqiL) (54). 
Subsequent use of MLST by Enright et al. in 2002 revealed 162 sequence types (STs) 
amongst 912 isolates of S. aureus. To simplify matters, Enright et al. organized related 
STs into clonal complexes (CCs) based on shared sequence types at a majority of the 
sequenced loci (45). While PFGE and MLST are equally discriminatory, the high labor 
intensity of PFGE and the decreasing cost of sequencing technologies have favored the 
use of MLST over PFGE in recent years (55).  
 In fact, sequencing costs have decreased enough such that it has precipitated a 
robust usage of whole genome sequencing to characterize S. aureus isolates. The first 
S. aureus genomes to be sequenced were two MRSA isolates N315 and Mu50 in 2001 
(56).  Both isolates had genomes that were ~2.8Mb with a G+C content of ~33%. The 
nucleotide sequence identity between the two strains was ~96%, as it was determined 
that Mu50 possessed a variety of unique mobile genetic elements. Currently, there are 
44 fully sequenced S. aureus genomes provided for analysis by NCBI 
! 9 
(http://www.ncbi.nlm.nih.gov/genome/154). Importantly, whole genome sequencing 
efforts have provided valuable insights into the in vivo evolution of S. aureus antibiotic 
resistance and virulence as well as the emergence of new epidemic MRSA clones (57-
59). It has since been determined that both large chromosomal rearrangements as well 
as the acquisition of accessory genetic elements contributed to the evolution S. aureus 
(60, 61). Specifically, various S. aureus toxins were discovered to have been acquired 
via phage-mediated horizontal gene transfer and are found in the S. aureus genome in 
collections called Staphylococcus aureus pathogenicity islands (SaPIs)(62). Additional, 
non-phage and non-SCC genomic islands named νSas (νSaα, νSaβ, and νSaγ) also 
carry virulence genes. Both the presence/absence of SaPI’s as well as polymorphisms 
in νSas have been shown to drastically affect virulence of individual S. aureus strains 
(63).  
 
STAPHYLOCOCCUS ECOLOGY 
 The Staphylococci are a prominent group of skin colonizing bacteria that have 
been isolated from a wide variety of animals including: humans, primates, cats, dogs, 
goats, cows, poultry, sheep, horses, pigs, squirrels, mice, bats, dolphins, whales, and 
clams (20). Additionally, many Staphylococci are found in or on various foods, including: 
milk, cheese, meat (especially sausages), and soy sauce (20). Due to the frequent 
colonization of domesticated animals and foodstuffs, the identification of Staphylococci 
indigenous to humans can be difficult. Many Staphylococci have been isolated from 
human skin, but only 7 of the 47 species of Staphylococci are generally considered to 
regularly colonize humans (20, 64, 65). These 7 species include 6 CoNS species (S. 
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epidermidis, S. lugdunensis, S. saprophyticus, S. haemolyticus, S. hominis, and S. 
capitis) and 1 coagulase positive Staphylococci (CoPS)(S. aureus). Although little is 
known about the lifestyle of Staphylococci on non-human animals, it has been shown 
that human colonizing staphylococci comprise a large percentage of the bacteria on the 
occiput (back of the head/neck), popliteal fossa (back of the knee), heel, toe web, 
gluteal crease, inguinal crease, and antecubital fossa (back of the elbow) (66). 
Histological examination of skin biopsies shows that Staphylococci may be found in a 
variety of skin locations but mostly grow in close association with pilosebaceous glands 
(i.e., sebaceous glands with hair follicles), aprocrine glands (i.e., sweat glands), and 
mucous membranes (67-69).  
 Human-skin colonizing staphylococci exhibit niche habitation that differs across 
species (19, 20, 70). S. epidermidis is the most abundant and widespread human 
colonizing staphylococci, and can be found over much of the human body surface (12). 
S. hominis and S. haemolyticus exhibit an affinity for colonizing skin with high densities 
of apocrine glands (i.e., axillae, inguinal, and perineal surfaces), although S. hominis is 
also known to colonize drier skin (i.e., arms and legs) far better than the other 
Staphylococci (12, 70). S. capitis is commonly found on the human head and scalp, S. 
auricularis exclusively colonizes the external auditory meatus, and S. lugdunensis is 
primarily found on the abdomen, groin, and lower extremities (71-73). S. saprophyticus 
can colonize human extremities, but is most well known for colonizing the female 
rectum and urogenital tract (70, 74).  
 S. aureus exhibits a strong preference for colonizing the anterior nares of 
humans, but is also found prominently in the perineum, axillae, oropharynx, and hands 
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(70, 75). Colonization of the anterior nares by S. aureus can be permanent or transient, 
depending on the individual (70, 76). It is estimated from nasal swabs that 
approximately 20% of all individuals are permanently colonized by S. aureus, while an 
additional 30% are transiently colonized (76). However, a high prevalence of strict 
extranasal colonization may indicate that S. aureus carriage rates are drastically 
underestimated (75). A table listing the environmental, animal, and human locations that 
each Staphylococcus species has been detected is available in Table 2 of a review by 
Becker et al. on CoNS published in 2014 (20). 
 
EPIDEMIOLOGY OF THE STAPHYLOCOCCI 
 Only a small subset of Staphylococci regularly causes disease in humans (S. 
aureus, S. epidermidis, S. haemolyticus, S. hominis, S. saprophyticus, S. capitis, and S. 
lugdunensis) (20, 64). For this subset of Staphylococci, the clinical presentations and 
epidemiological associations vary between species (77, 78). Despite this, clinicians 
rarely distinguish between CoNS species present in patient specimens. This is largely 
because CoNS were historically considered avirulent clinical contaminants (79). 
However, over the past few decades, CoNS have become recognized as an important 
etiology of nosocomial infections, predominantly affecting patients that have undergone 
surgery, have an in-dwelling device, or are generally immunocompromised (20, 64, 80-
82). Contributing to the awareness of these infections was an increase in resistance to 
the β-lactam, methicillin (83, 84). Similar to MRSA, methicillin-resistant CoNS isolates 
were found to vary in the type of SCCmec cassettes they possess. The fact that the 
SCCmec cassettes are shared across species indicates that horizontal transfer between 
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the Staphylococci has contributed to enhanced virulence amongst the genus (20). A list 
of SCCmec types encoded by each CoNS species can be found in Table 8 of a review 
by Becker et al. on CoNS published in 2014 (20). 
 Infections caused by CoNS are typically subacute or chronic and are generally 
associated with the use of medical devices (81, 85, 86). Foreign body related infections 
can be localized to the tissue immediately surrounding the medical device or can lead to 
systemic infections (87). Perhaps because of this, CoNS species also cause infective 
endocarditis (IE) (88). S. epidermidis is by far the most common cause of CoNS 
infections (78, 89, 90). In fact, in 2005 it was shown that most S. epidermidis infections 
are actually caused by a single clone (ST27) that preferentially resides in hospitals (91). 
Most other CoNS species cause similar infections to S. epidermidis, albeit less 
frequently. However, there are two notable exceptions: S. saprophyticus and S. 
lugdunensis. S. saprophyticus rarely causes bloodstream infections but is actually the 
second leading cause of uncomplicated urinary tract infections (UTIs) amongst women 
(92, 93). S. lugdunensis, on the other hand, is known to cause infections more 
reminiscent of S. aureus (i.e., destructive and invasive) (94). In particular, S. 
lugdunensis has been reported as an infrequent, but deadly, cause of native valve 
endocarditis as well as a frequent cause of skin and soft tissue infections (SSTIs) in the 
community (95, 96). A list of clinical associations for each CoNS species can be found 
in Table 2 of a review by Becker et al. on CoNS published in 2014 (20).  
 S. aureus infections are notably distinct from those of CoNS species, in that they 
are generally more invasive, severe, and present with greater clinical variation (20, 97, 
98). In fact, S. aureus is a leading cause of SSTIs, bloodstream infections, toxic shock 
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syndrome, and IE worldwide and additionally can cause food poisoning and pneumonia 
(88, 98-102). Risk factors for S. aureus infections include nasal colonization, diabetes, 
cancer, IV drug use, hemodialysis, surgery, and hospitalization (98, 103-105). 
Historically, nasal colonization has been considered the primary risk factor for S. aureus 
disease (106). Thus, extensive research has been undertaken to identify bacterial and 
host factors that promote S. aureus nasal colonization (107). Additionally, intranasal 
administration of the topical antibiotic mupirocin has been widely used in patients at risk 
for S. aureus infection. The benefit of mupirocin treatment and/or nasal eradication of S. 
aureus remains questionable. For various reasons, mupirocin treatment does not 
always result in effective S. aureus eradication from the nares or produce a significant 
reduction in S. aureus disease (108-111). These findings highlight the importance of 
both extranasal colonization and person-to-person transmission in promoting S. aureus 
disease.  
 Over the past two decades, epidemiological investigation of S. aureus infections 
has revealed a major paradigm shift in S. aureus disease. Historically, S. aureus has 
been regarded as a prominent nosocomial infection. This association was dramatically 
reinforced in the 1980’s when numerous hospitals in North America (US and Canada), 
South America (Argentina and Brazil), Europe (Belgium, Denmark, France, Germany, 
Greece, Italy, Netherlands, Spain, and the U.K.), Asia (Malaysia, Hong Kong, Japan, 
Singapore, Taiwan), the Middle East (Saudi Arabia), Africa (Nigeria), and Australia 
reported MRSA outbreaks (112). It was subsequently determined that 5 major clonal 
complexes (CC5, CC8, CC22, CC30, and CC45) were responsible for approximately 
70% this disease burden (51, 113, 114).  
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 However, beginning in the early 1990’s, several new clones of S. aureus 
emerged in Australia and North America that caused disease in individuals without any 
recent hospital contact (115, 116). The first of these new strains belonged to CC1 
(USA400 PFGE type, ST1) and its emergence precipitated usage of the term 
community-acquired MRSA (CA-MRSA) (114, 117). In the early 2000’s, another CA-
MRSA clone arose (USA300 PFGE type, ST8), but this time from CC8 (USA500 PFGE 
type) (113, 114, 118). USA300 clones have since overtaken USA400 clones in North 
America as the dominant infectious S. aureus isolates (119-123). USA300 isolates 
cause severe SSTIs (124). Schematics on the evolution of MRSA can be found in 
Figure 1 of a review by Thurlow et al. on USA300 published in 2012 and in Figure 2 of 
Robinson and Enright’s MRSA evolution manuscript published in 2003 (113, 114). 
 
PATHOGENESIS OF THE STAPHYLOCOCCI 
 Over the past few decades, the molecular mechanisms of Staphylococcal 
virulence have been widely studied. The large majority of these studies have focused on 
S. aureus due to its worldwide epidemiological importance. Likewise, studies on CoNS 
pathogenesis have largely focused on S. epidermidis, as it is the primary CoNS species 
isolated from human clinical specimens. While still ongoing, these studies have 
revealed that the characteristically enhanced virulence of S. aureus, over that of the 
other Staphylococci, can largely be explained by the acquisition of a variety of unique 
virulence factors. Importantly, the molecular aspects of S. aureus and CoNS 
pathogenesis have been extensively reviewed in recent years (19, 20, 85, 101, 102, 
114, 125, 126). Additionally, the regulation of S. aureus virulence factors has also been 
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widely reviewed (127-129). As such, only a brief overview of these mechanisms is 
provided below.  
 Investigations of S. epidermidis pathogenesis have revealed that CoNS species 
cause disease via two primary mechanisms: attachment to surfaces and biofilm 
formation (20, 85). These two mechanisms combine to promote S. epidermidis disease 
in two stages: 1) attachment and growth on abiotic surfaces, and 2) attachment and 
growth on biotic structures deposited in and around the medical device following 
insertion into patients. The S. epidermidis factors that mediate these stages were found 
to be both proteinaceous and non-proteinaceous (130). The proteinaceous factors are 
grouped into cell wall anchored (CWA) proteins that are covalently attached to the cell 
surface and autolysins and adhesins that are non-covalently attached to the cell. The 
major non-proteinaceous factors include polysaccharide intracellular adhesin (PIA), wall 
techoic acid (WTA), and lipotecoic acid (LTA).  
 The primary factors mediating surface attachment of S. epidermidis are the 
autolysin, AtlE, and a subgrouping of the CWA proteins called microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMS) (130, 131). AtlE is 
thought to mediate surface attachment of S. epidermidis to abiotic surfaces both directly 
and via autolysis (131, 132). Additionally, AtlE binds the serum glycoprotein vitronectin, 
thus promoting aggregation and virulence of S. epidermidis in tissue (131, 133). Several 
other Staphylococcus species encode homologs of AtlE  (S. caprae, S. saprophyticus, 
S. lugdunensis, S. warneri, and S. aureus) (134-138). MSCRAMMs, on the other hand, 
exclusively promote attachment to biotic structures (139). All MSCRAMMs exhibit a 
conserved structure that includes an N-terminal export motif, a host-factor recognizing 
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region, a repeat region, a cell wall spanning domain, and a LPXTG motif (130). The 
LPXTG motif is utilized by an enzyme called Sortase A to link MSCRAMMs to the cell 
wall (140, 141). CoNS strains encode a variable number of MSCRAMMs, which 
themselves may vary in terms of the host matrix molecules they recognize (20). The 
most well characterized S. epidermidis MSCRAMM is Fbe, which is thought to mediate 
attachment of S. epidermidis cells to fibrinogen and promote platelet aggregation (142-
144). Notably, fbe deletion results in in vivo attenuation of S. epidermidis cells (145).  
 Ultimately, S. epidermidis surface attachment leads to biofilm formation, which is 
also mediated by both proteinaceous and non-proteinaceous molecules. The most well 
recognized S. epidermidis biofilm promoting molecule is poly-N-acetyl-glucosamine 
(PNAG), or what is commonly referred to as polysaccharide intercellular adhesin (PIA) 
(146). PIA is responsible for the characteristic slime phenotype often described for S. 
epidermidis clinical isolates (147, 148). S. epidermidis PIA production is encoded by the 
icaADBC operon and is thought to promote biofilm formation via ionic interactions with 
WTAs (146, 149). Interestingly, loss of PIA production results in attenuation of S. 
epidermidis in various animal models of device related infection, despite the fact S. 
epidermidis can form PIA-independent biofilms (133, 149-151). Biofilm formation by S. 
epidermidis is thought to promote pathogenesis by preventing phagocytosis and 
shielding bacteria from the toxic effects of both immune factors (e.g., complement, 
antibodies, and reactive oxygen/nitrogen species) and antibiotics (149, 152). A list of 
known S. epidermidis virulence factors can be found in Table 1 of Michael Otto’s S. 
epidermidis review from 2009 (153). 
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 Similar to CoNS, S. aureus genomes encode a variety of molecules, both 
proteinaceous and non-proteinaceous that promote surface attachment and biofilm 
formation. In fact, several of these molecules are identical to those used by CoNS. For 
instance, S. aureus encodes the icaADBC operon and has a homolog of AtlE called, Atl. 
While the contribution of PIA production to S. aureus virulence in animals has not been 
tested, Atl was shown not to contribute to acute S. aureus virulence in mice (154). 
However, icaADBC was found to be one of seven significant predictors of 
virulence/invasiveness amongst human S. aureus isolates and vaccination with PIA has 
been shown to protect mice against deadly infection with S. aureus strains that produce 
little PIA (155, 156). Perhaps more important, S. aureus also uses MSCRAMMs to 
mediate attachment to host proteins, although S. aureus genomes commonly encode 
many more LPXTG containing proteins than CoNS genomes (130). The most well 
studied S. aureus MSCRAMMs are clumping factors A and B (ClfA and ClfB), 
fibronectin binding proteins A and B (FnbpA and FnbpB), and the collagen binding 
protein Cna (157-163). Animal data suggests that Cna is the most important of these 
adhesion proteins, with deletion causing attenuation in multiple models of infection (164-
166). Experimental evidence for the role of the Clfs and Fnpbs in S. aureus virulence is 
lacking, aside from a study showing a contribution of ClfA to S. aureus endocarditis 
(167). However, similar to ica, both fnbA and cna were found to be significant predictors 
of S. aureus virulence in humans, and various tissue culture models have implicated a 
role for the Fnbp’s in promoting uptake of S. aureus into non phagocytic cells (156, 168, 
169). Unsurprisingly, S. aureus Sortase A deletion mutants have been shown to be 
severely attenuated in experimental models of infection (170, 171).  
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 A second category of S. aureus virulence factors includes host resistance 
factors. This category contains detoxification enzymes (Hmp, KatA, AhpCF, SodA, and 
SodM), cell wall acting enzymes (DltA and MprF), a protease (Aur), a biosynthetic 
operon (crtOPQMN), and a Sortase A anchored cell wall protein (Protein A), as well as 
other important factors. The detoxification enzymes help S. aureus resist host 
production of antimicrobial chemicals including: nitric oxide (NO·, Hmp), hydrogen 
peroxide (H2O2, KatA), alkyl hydroperoxide (AhpCF), and superoxide (O2-, SodA and 
SodM) (172-175). With the exception of SodM, each of these enzymes is found 
amongst CoNS isolates (176). The cell wall acting enzymes and protease promote S. 
aureus resistance to host antimicrobial peptides/complement via modification of the cell 
surface charge and direct cleavage of host peptides, respectively (177-182). Both MprF 
and DltA are found in CoNS species, but Aur is unique to S. aureus (153). The 
biosynthetic operon crtOPQMN is similarly unique to S. aureus, and encodes the 
machinery for production of the carotenoid pigment, Staphyloxanthin (183). Aside from 
providing S. aureus its unique golden pigmentation, Staphyloxanthin protects S. aureus 
from oxidative stress (184). Finally, and perhaps most importantly, Protein A binds the 
Fcγ domain of human immunoglobulin’s (Igs), thus preventing antibody opsonization of 
S. aureus cells (185). Protein A is found in practically all S. aureus isolates, but not in 
CoNS, and contributes to S. aureus virulence (153, 186, 187). More recently, Protein A 
has been implicated in S. aureus immune evasion via effects on B-cell maturation in 
germinal centers (188).  
 Aside from Protein A, the genetic determinants predominantly held responsible 
for the enhanced virulence of S. aureus over CoNS are those encoding toxins. As a 
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species, S. aureus possesses over 30 different toxins that are grouped into three main 
categories: pore-forming, exfoliative, and superantigens (SAgs) (189, 190). The pore-
forming toxins (α-toxin, Hlg, Hlg2, PVL, LukED, LukFM, LukAB, and Hld) are used by S. 
aureus to lyse host cells, including: epithelial cells, erythrocytes, fibroblasts, monocytes, 
macrophages, and neutrophils (189). The pore forming toxins vary in their cellular 
targets, species specificity, and presence in S. aureus genomes. Exfoliative toxins 
(ETs), on the other hand, cleave human and murine desmoglein 1, an important 
intercellular keratinocyte adhesion molecule (191). There are only three known S. 
aureus ETs (ETA, ETB, and ETD) and although their activity promotes skin invasion, 
they are very uncommon amongst S. aureus isolates (192). The last group, the S. 
aureus SAgs, are potent T-cell mitogens (193, 194). Currently, there are over 23 
different identified S. aureus Sags, divided into two main categories: those that cause 
vomiting in primates (Staphylococcal enterotoxins, SEs) and those that do not 
(Staphylococcal enterotoxin-like toxins, SEls and toxic shock-syndrome toxin 1, or 
TSST-1) (189). Perhaps reflecting their importance, SAgs are highly abundant amongst 
S. aureus clinical isolates (192). However, none of the toxins (pore-forming, ETs, or 
SAgs) are regularly found in CoNS species (153, 189, 190).  
  Studies of S. aureus virulence factors have highlighted significant limitations in 
current approaches to characterizing S. aureus pathogenesis. For instance, while most 
experimental models of bacterial infection suffer from the use of animals instead of 
human subjects, several S. aureus virulence factors have been shown to display a high 
degree of host specificity. Specifically, a unique S. aureus heme uptake system (the isd 
system) exhibits specificity for human hemoglobin over that of mice, α-toxin lyses rabbit 
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erythrocytes at lower concentrations than human erythrocytes, panton-valentine 
leukocidin (PVL) kills human and rabbit neutrophils at lower concentrations than murine 
or primate neutrophils, and LukAB preferentially kills human and primate 
polymorphonuclear leukocytes (PMNs) over those of murine and rabbit origin (195-200). 
Furthermore, despite the fact that S. aureus primarily presents as a SSTI, there are no 
animal models that accurately reflect S. aureus skin disease progression. This is 
because there are no clearly representative bacterial skin colonization models, due to 
the fact that animal skin typically has fur and most mammals do not sweat (201). 
Instead, bacterial SSTI models are established via subcutaneous injection of bacteria, 
thus bypassing the skin phase of SSTIs. As with the other S. aureus animal infection 
models, the SSTI model also uses very high doses of bacteria (107-108 cfu) in order to 
produce observable disease. This likely leads to an overemphasis of the importance of 
destructive factors and underemphasizes the importance of growth related factors, as S. 
aureus growth is limited following injection of such high numbers of bacteria. Therefore, 
as with all animal models of infection, caution must be used when extrapolating the 
importance of S. aureus virulence factors to the progression of S. aureus disease in 
humans.  
 
STAPHYLOCOCCUS AUREUS METABOLISM 
Cell Composition, Central Metabolism, and Substrate Utilization 
 Researchers have recently used whole genome sequencing, sequence based 
homology comparisons, proteomics, and metabolomics to construct in silico metabolic 
networks for two S. aureus strains (202, 203). These networks predict that S. aureus 
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uses 640 metabolic reactions involving 619 genes, 537 proteins, and 571 metabolites 
(202). Most of these reactions are connected in some manner to three central metabolic 
pathways: glycolysis (Figure 1.1), the pentose phosphate pathway (PPP) (Figure 1.1 
and 1.2), and the citric acid cycle (TCA cycle) (Figure 1.2). These pathways are utilized 
by S. aureus cells to generate both energy and precursor metabolites for biomass 
production (i.e., cell division). The primary energy costs associated with biomass 
production in S. aureus are the polymerization of DNA, RNA, and protein (16.3 mmol 
ATP/g dried cell weight), with protein polymerization being the major energy consumer 
(~98% of the ATP)(GTP is the actual molecule used for protein polymerization) (203). S. 
aureus cells grown in complex media were found to be ~40% protein, 3% DNA, 12% 
RNA, 7% lipid, 24% cell wall (i.e., carbohydrates), and 14% solutes by weight (203).  
 In aerobic environments, S. aureus is capable of growing on both carbohydrates 
and amino acids (203). Interestingly, S. aureus is auxotrophic for several amino acids, 
but in a strain-dependent manner (204). In general, most S. aureus strains are 
auxotrophic for arginine and valine (90-100%), while fewer (10-30%) are auxotrophic for 
proline, cysteine, leucine, isoleucine, glycine, and histidine. Growth of S. aureus strains 
not auxotrophic for proline and arginine is dramatically reduced in the absence of these 
amino acids. Unsurprisingly, S. aureus is predicted to encode a variety of amino acid 
and peptide transporters (Table 1.1). Very few of these genes have been characterized. 
Experimental evidence shows that S. aureus has a proton driven di- and tri-peptide 
permease (DtpT), at least 12 different amino acid transporters that individually catalyze 
uptake of structurally related amino acids (i.e., Gly/Ala, Leu/Ile/Val, Ser/Thr, Aps/Glu, 
Asn/Gln, Lys, His, Arg, Phe/Tyr/Trp, Cys, Met, and Pro), and that only one of the four 
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predicted oligopeptide permeases (Opp3) actually transports peptides (205, 206). Six of 
the S. aureus free amino acid permeases (PutP, GlnP, PheP, BRNQ1, BRNQ2, OpuD) 
have been experimentally characterized, although to varying degrees. Via radiolabeled 
uptake assays, PutP was shown to be a S. aureus high affinity proline permease, OpuD 
was shown to be a low affinity proline permease, BRNQ1 was shown to transport all 
three branched chain amino acids (Leu, Ile, Val), and BRNQ2 was shown to transport 
isoleucine (207-209). GlnP and PheP have been implicated in glutamine and 
phenylalanine uptake, respectively, via various growth analyses (210, 211). 
Interestingly, S. aureus has only been shown to catabolize a limited number of amino 
acids (Gln, Glu, and Thr), suggesting that amino acid uptake is predominantly for direct 
incorporation into protein (212).  
 In contrast, S. aureus is has been shown to catabolize a wide variety of 
carbohydrates (glucose, fructose, mannose, ribose, galactose, sucrose, maltose, 
lactose, trehalose, mannitol, GlcNAc, glycerol, G6P, and F6P), suggesting that they 
may also support growth (212). Uptake of carbohydrates into bacterial cells is typically 
catalyzed via a family of sugar transporters called the phosphotransferase (PTS) 
system (213). The PTS system uses phosphate from intracellular PEP to both power 
simultaneous transport and phosphorylation of sugars. The phosphoryl group is 
transferred from PEP to the transporters by two proteins, EI and Hpr. In S. aureus, 
inactivation of Hpr resulted in a complete loss of uptake for 7 sugars (α-methyl 
glucoside, lactose, fructose, maltose, galactose, sucrose, and mannitol) and partial loss 
for uptake for glucose (214). Fittingly, S. aureus is predicted to encode 14 PTS 
transporters. Although none of these transporters have been characterized 
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biochemically, inactivation of two putative S. aureus PTS transporters (mtlAF and fruA) 
resulted in attenuated growth of S. aureus on mannitol and fructose, respectively (215, 
216). These data suggest that MtlAF encodes a mannitol transporter and FruA encodes 
a fructose transporter. Inactivation of three putative S. aureus glucose transporters 
(individual inactivation) resulted in no observable growth phenotypes (216).  
 Environmental factors affecting S. aureus usage of the TCA cycle and glycolysis, 
and thus amino acid and sugar catabolism, respectively, are oxygen, iron, and 
carbohydrates. Under aerobic conditions S. aureus is predicted to catabolize glucose to 
acetate/CO2 and glutamate to unknown end-products via the combined activities of 
glycolysis, PPP, and the TCA cycle (203). In line with these predictions, deletion of the 
S. aureus acetogenesis pathway results in increased flux of catabolized glucose into the 
TCA cycle and PPP under aerobic conditions (217). Anaerobiosis and glucose have 
both been shown to transcriptionally activate genes from the S. aureus glycolytic 
pathway while low iron and low oxygen have both been demonstrated to increase 
glycolytic protein abundance (218-220). These same studies demonstrated that low 
iron, low oxygen, and glucose concomitantly reduce the levels of TCA cycle genes and 
proteins. Furthermore, it was shown in the 1960s that glucose, low iron, and respiratory 
inhibitors inhibit activity of S. aureus TCA cycle enzymes (221-223). Because the S. 
aureus TCA cycle is predicted to utilize at least two substrate:quinone oxidoreductases 
(Mqo and Sdh), low iron and low oxygen are assumed to inhibit TCA cycle activity via 
reduced respiratory activity (see respiration section below). As such, growth of S. 
aureus on amino acid containing substrates is predicted to be respiration-dependent, 
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while growth on carbohydrates is predicted to be respiration-independent. This 
hypothesis has yet to be experimentally confirmed.  
  
Cellular Respiration 
 Cellular respiration is a process by which cells convert energy released from the 
catabolism of substrates to energy stored across a cellular membrane via the 
generation of an electrical (i.e., ∆Ψ) and/or a chemical gradient. This process occurs via 
a series of redox reactions, whereby electrons removed from substrates are passed 
along a succession of membrane molecules that have increasing electrode potentials. 
With each redox reaction, free energy is released and, to various degrees, harvested by 
respiratory enzymes to transport intracellular cations across the cellular membrane, 
thereby establishing an electrochemical gradient. Since the most widely studied 
respiratory chains transport protons (H+), the concentration gradient is typically referred 
to as ∆pH and the combined generation of both ∆Ψ and ∆pH is referred to as proton 
motive force, or PMF. Cells use PMF to catalyze the uptake of substrates and the 
generation of adenine triphosphate (ATP). The most well studied respiratory ATPase is 
a H+ translocating ATPase called the F1F0 ATPase. Importantly, cellular respiration ends 
with the reduction of a terminal electron acceptor. Due to its abundance and high 
electrode potential, molecular oxygen is a common terminal electron acceptor. 
Respiration performed using oxygen is called aerobic respiration. However, bacteria can 
often use a variety of terminal electron acceptors, including: nitrate (NO3-), fumarate, 
DMSO, etc. (224). 
! 25 
 The molecules of bacterial respiratory chains can be divided into passive electron 
carriers (e.g., NADH and quinones) and various enzymes/enzyme complexes (e.g., 
NADH:quinone oxidoreductases, substrate:quinone oxidoreductases, and cytochrome 
oxidases). When substrates are oxidized via dehydrogenases or quinone 
oxidoreductases, their electrons are first transferred to soluble NADH and membrane 
bound quinones, respectively. Under certain circumstances, membrane bound NADH 
dehydrogenases will then transfer NADH bound electrons to quinones. There are three 
types of bacterial NADH dehydrogenases (NDH-1, NDH-2, and Nqr) (225). NDH-1 and 
Nqr also transport cations across the cellular membrane, thus contributing to the 
generation of an electrochemical gradient. Quinones are mobile, membrane-bound, lipid 
electron carriers. There are many types of bacterial quinones, differing both in structure 
and electrode potential. The primary importance of quinones is to donate electrons to 
cytochrome containing molecules and enzymes (e.g., quinone and cytochrome 
oxidases). Cytochromes are electron carriers that use heme prosthetic groups to carry 
electrons and are classified by the types of heme they contain (i.e., a, b, c, d, and o). 
Cytochromes are found in quinone oxidases that transfer electrons from quinones to 
terminal electron acceptors. Similar to NDH-1, quinone oxidases may transport protons 
across the cellular membrane, thereby directly contributing to the generation of PMF.  
 Recent interest in the S. aureus respiratory chain largely originates from the 
isolation of S. aureus respiration deficient mutants from chronically infected patients as 
well as historical observations that respiration deficiency promotes enhanced antibiotic 
resistance (226-228). Several components of the S. aureus respiratory chain have been 
identified, although research in the area is still ongoing. Menaquinone (MQ) was found 
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in both S. aureus and S. epidermidis membranes in the late 1960’s and was 
subsequently shown to be the only quinone present in Staphylococci (229-231). Despite 
the isolation and preliminary characterization of MQ deficient mutants of S. aureus in 
the 1970s, biochemical characterization of MQ biosynthesis linked to the identification of 
genetically encoded enzymes has not been performed for any Staphylococci in a 
systematic fashion. Instead, the MQ biosynthetic pathway encoded by S. aureus has 
largely been inferred based on homology to the known Escherichia coli (E. coli) MQ 
biosynthetic enzymes (MenF, MenD, MenH, MenC, MenE, MenB, MenA, and UbiE) 
(232). Mutations in the genes menD and menB have been shown to result in a loss of S. 
aureus menaquinone production and respiration, thus partially confirming the sequence 
based identification MQ biosynthetic enzymes in S. aureus (212, 226).  
 Donation of electrons to the S. aureus MQ pool proceeds via a membrane bound 
NADH:quinone oxidoreductase (NDH2) or via a series of substrate specific quinone 
oxidoreductase called flavoproteins (Figure 1.3). Central metabolic flux in S. aureus is 
known and/or predicted to generate NADH via the activity of at least 6 dehydrogenases 
(PDHC, Ldh2, Fdh, GluD, OdhB, and GapA) and direct quinone reduction via at least 5 
flavoproteins (CidC, SdhCAB, Lqo, Mqo, and GlpD) (233-240) (Figure 1.3). Recently, 
two S. aureus genes ndhF (NCBI gi: 3793682; SAB0804c) and ndhC (NCBI gi: 
3793685; SAB0807) were shown biochemically to encode type-II NADH 
dehydrogenases (i.e., FADH2 containing, non-proton pumping) (241). A study published 
the following year by separate group of researchers showed that S. aureus is predicted 
to encode only one NADH dehydrogenase and that all cellular NADH:quinone 
oxidoreductase activity was eliminated by insertional inactivation of this gene (ndhF, 
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renamed ndh2) (242). This discrepancy is explained by the differential use of S. aureus 
strains by the two groups. Examination of the S. aureus genome used by the first group 
(RF122) revealed that ndhC and ndhF are not only encoded next to each other but 
share 100% sequence identity, suggesting that the presence of two alleles in this strain 
is likely the result of a gene duplication event. The structure of Ndh2 was solved in 2015 
and the activity of the enzyme was additionally shown to be rate limited by MQ 
reduction (243).  
 Adding to the confusion surrounding the identification of the S. aureus NADH 
dehydrogenase is the presence of two multilocus genes (mpsABC and mnhABCEFG) in 
the S. aureus genome that share some similarity to a type-I NADH dehydrogenase 
encoded by E. coli called, Nuo (242, 244). Oddly, mnhABCDEFG was renamed 
snoABCEDFG for Staphylococcal nuo-like orthologues, despite 1) limited homology of 
mnhABCDEFG to the nuo locus, 2) absence of a Rossman-fold (NADH binding domain) 
in the predicted protein sequence of MnhABCDEFG, and 3) no demonstrated 
NADH:quinone oxidoreductase activity for the MnhABCDEFG protein (244). In fact, 
mnhABCDEFG is predicted to encode a Na+/H+ antiporter and has been implicated in S. 
aureus halotolerance (244).  Similarly, MpsABC lacks a predicted Rossman-fold, and 
has been implicated in S. aureus halotolerance. However, unlike mnhABCDEFG, 
mpsABC has been biochemically shown to encode a Na+ translocation protein (242). 
Interestingly, both mnhABCDEFG and mpsABC contribute to the maintenance of S. 
aureus membrane potential and MpsABC inactivation has been shown to drastically 
affect the oxygen consumption rate of S. aureus cells (242, 244). Whether the impact of 
MpsABC activity on S. aureus oxygen consumption is direct, via reduction of quinones, 
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or indirect, via the transport of cations (i.e., production of ∆Ψ), has yet to be determined.  
 S. aureus encodes three terminal oxidases: qoxABCD, cydAB, and narGH 
(Figure 1.3). QoxABCD and CydAB are heme-dependent quinol oxidases that donate 
electrons to molecular oxygen (245). Individual inactivation of QoxABCD and CydAB 
results in lowered membrane potential and a reduced growth rate for the QoxABCD 
deficient strain. Inactivation of both terminal oxidases results in a membrane potential 
equivalent to S. aureus cells grown anaerobically and in the production of fermentative 
end products (245). Interestingly, qoxABCD is expressed at high levels during aerobic 
growth whereas cydAB expression is induced in response to low oxygen 
(246)(unpublished observations). Together, these data indicate that QoxABCD is likely 
a low-affinity oxygen reductase that translocates H+ across the cell membrane and 
CydAB is likely a high-affinity oxygen reductase without translocation capabilities. 
Additionally, these data show that QoxABCD and CydAB are the only aerobic S. aureus 
terminal oxidases. Both QoxABCD and CydAB were found to contribute to S. aureus 
virulence in a murine model of sepsis, but in different organs (245). The predicted role 
of NarGH in S. aureus nitrate respiration is based on high sequence homology to 
characterized NarGH systems (247). S. aureus cells have been shown to reduce nitrate 
into nitrite, but the role of narGH in producing these phenotypes has not been 
genetically or biochemically confirmed (247). Similarly, biochemical characterization of 
S. aureus QoxABCD and CydAB has yet to be performed.  
 During aerobic growth, S. aureus produces three primary cytochromes: 
cytochrome a3 (602-608 nm absmax), cytochrome b-557 (557 nm absmax), and 
cytochrome b-555 (555 nm absmax, also called cytochrome o or cytochrome bo) (221, 
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248). The presence of additional cytochromes has been postulated (249). Both 
cytochrome o (cyt o) and cytochrome a (cyt a3) have been implicated as terminal 
oxidases, but the cytochrome profiles of the three S. aureus terminal oxidases have yet 
to be biochemically determined (248, 250).  
 
Fermentative Metabolism 
 In the absence of a terminal electron acceptor (e.g., O2, NO3-, etc.) or in the 
presence of a respiratory inhibitor (e.g., NO·, CN-, etc.), cells may ferment. 
Fermentation is a process by which ATP is generated from the oxidation of substrates 
independent of cellular PMF. In fact, fermenting bacteria often generate PMF via 
reversal of the F1F0 ATPase using ATP generated from substrate level-phosphorylation. 
Fermentative products are often catabolic end products, which, despite being more 
reduced than the initial catabolic substrate, generally have a much lower electrode 
potential than the terminal electron acceptors utilized for cellular respiration. This means 
that fermentation is energetically less favorable than respiration, which is also apparent 
from the fact that fermentative reactions do not directly contribute to the generation of 
membrane potential. For these reasons, the carbon costs of fermentation are larger 
than respiratory metabolism (i.e., more carbon must be consumed to produce the same 
amount of ATP). Importantly, fermentative reactions only utilize NADH-dependent 
substrate dehydrogenases or else quinone-independent substrate:substrate 
oxidoreductases (236, 251, 252). Thus, NAD+ can be regenerated from NADH using 
fermentative metabolism, but oxidized quinones cannot.  
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 S. aureus performs fermentative metabolism using NADH-dependent substrate 
dehydrogenases. During respiration inhibition, S. aureus ferments glucose into lactate, 
formate, and ethanol (234, 236). Additionally, S. aureus is predicted to ferment glucose 
into 2,3-butanediol (219). Lactate is by far the predominant fermentative end product 
produced by S. aureus under these conditions and is generated as two separate 
enantiomers (L- and D-lactate) (236). S. aureus produces L-lactate from pyruvate using 
two NADH-dependent dehydrogenases, Ldh1 and Ldh2 (236). Transcriptional analysis 
of the genes encoding these enzymes (ldh1 and ldh2) revealed that ldh2 is 
constitutively expressed while ldh1 is expressed only under conditions of respiration 
inhibition (i.e., low iron, low oxygen, NO·, etc.)(236). S. aureus produces D-lactate from 
pyruvate via the activity of another NADH-dependent dehydrogenase called, Ddh. The 
gene encoding this enzyme (ddh) is coregulated with ldh1 (253). Formate is generated 
by S. aureus via the activity of an enzyme complex called pyruvate formate lyase 
(PflAB)(234). Similar to ldh1 and ddh, pflAB is expressed only under low respiratory 
conditions (219). Additionally, because PflAB utilizes radical chemistry to catalyze the 
conversion of pyruvate into acetyl-CoA and formate, it is not functional in the presence 
of molecular oxygen (254). The identity of the EtOH fermentation enzymes has yet to be 
determined, but they are predicted to be encoded by adhE and adhP (219). The 
presence of additional fermentative reactions in S. aureus has not been thoroughly 
studied. Interestingly, S. epidermidis has been shown to ferment serine into lactate, 
suggesting similar fermentative reactions may exist in S. aureus (255).  
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Metabolic Regulation 
 Metabolism in S. aureus is largely controlled by five regulators: CcpA, CodY, 
SrrAB, Rex, and Fur. CcpA and Fur have both been demonstrated to regulate S. aureus 
glycolytic and TCA cycle genes (218, 256). Catabolite control protein A, or CcpA, is a 
highly conserved regulator in low-GC Gram-positive bacteria that regulates metabolic 
genes in response to glycolytic flux (257). More specifically, glycolytic intermediates 
activate a kinase called HprK that phosphorylates the PTS phospho-carrier protein Hpr 
at an alternative phosphorylate site (Ser-46)[(257-259)]. Hpr-Ser46 then forms a 
complex with CcpA, which in turn, promotes attachment of CcpA to cis-acting DNA 
sequences called cre-sites (catabolite responsive elements). In this manner, CcpA has 
been shown to activate expression of S. aureus glycolytic genes (tpi and pgk) and 
repress expression of TCA cycle genes (citB, citC, citZ, sdhB, sucCD, and odhAB) in 
response to glucose (220). Additionally, CcpA was shown to down-regulate the 
Gluconeogenic gene, pckA, as well as a handful of genes encoding putative amino acid 
degrading enzymes (rocA, arg, rocD, glnA, hutL, hutU, aldA, ald, gudB, etc.). Fur, on 
the other hand, is a repressor whose affinity for DNA is affected by binding of ferrous 
iron (Fe2+) (260). Fe2+ binding promotes attachment of Fur to sequences called fur 
boxes. Under iron-limited condition, Fur loses affinity for DNA, which results in the 
expression of a wide variety of genes encoding various iron acquisition proteins. S. 
aureus Fur has been shown to repress production of three glycolytic proteins (GapA, 
Tpi, and FbaA) and induce production of two TCA cycle proteins (SdhA and CitB) (218).  
 CodY is a highly conserved regulatory protein found in low-GC Gram-positive 
bacteria that has been shown to regulate gene expression in response to GTP and 
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branched chain amino acids (BCAAs) (261, 262). These metabolites increase the 
affinity of CodY for DNA binding sites, which for the most part represses gene 
expression. S. aureus CodY responds exclusively to GTP and isoleucine (263). 
Importantly, GTP is the energy source for translation initiation and elongation while 
isoleucine (Ile) is one of the most abundant amino acids encoded in S. aureus proteins 
(203). As such, it is unsurprising that S. aureus CodY represses expression of many 
predicted amino acid permeases and biosynthetic genes and activates expression of 
many ribosomal proteins (263-265). In this manner, S. aureus can induce expression of 
amino acid biosynthetic genes and permeases when intracellular amino acids are low, 
while simultaneously reducing cellular protein production. S. aureus CodY additionally 
represses the sucAB (TCA cycle), pyc (anaplerosis), ldh1 (lactate fermentation), 
icaADCB (PIA biosynthesis), hla (α-toxin), and a variety of other virulence factors (263).  
  SrrAB and Rex regulate S. aureus respiratory and fermentative metabolism. 
SrrAB (staphylococcal respiratory response proteins AB) is a two-component regulatory 
system orthologous to the ResDE system found in B. subtilis. Both SrrAB and ResDE 
are thought to activate gene expression in response to the build up of reduced quinone 
(246). Specifically, when respiration is restricted a build up of reduced quinone is 
sensed by the membrane bound kinase (ResD) causing it to phosphorylate ResE. 
Phosphorylation of ResE promotes DNA binding and subsequent activation of gene 
expression. In S. aureus, SrrAB has been shown to activate expression of the two 
oxygen-dependent terminal oxidases (qoxABCD and cydAB), heme biosynthesis genes 
(hemX, hemD, hemC, hemA, and ctaB), fermentative genes (adhE and pflAB), a NO· 
detoxification enzyme (hmp), and the anaerobic ribonucleotide-triphosphate reductase 
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(nrdDG) in response to respiration inhibition induced by NO· exposure (246). 
Inactivation of S. aureus srrAB results in attenuated growth during exposure to 
respiration inhibited conditions (e.g., NO· exposure and low oxygen). Rex is a repressor 
protein whose affinity for DNA is influenced by competitive binding of NAD+ and NADH 
to an allosteric effector site (266, 267). NAD+ promotes Rex-DNA interactions, while 
NADH causes Rex to lose affinity for DNA. S. aureus Rex has been shown to directly 
regulate a variety of fermentative genes (known: ldh1, ddh, pflAB; putative: adhE, adhP, 
and ald1), srrAB, and the nitrate reductase, narGH (253). Thus, under conditions of 
respiration inhibition (i.e., low oxygen, low iron, NO·, etc.), intracellular NADH levels will 
build up, resulting in derepression of various fermentative and respiratory enzymes.  
 
Metabolism and Virulence 
 While there are many studies on S. aureus metabolism, very little is known about 
the contribution of these reported activities to growth of S. aureus during infection. What 
is known is that S. aureus metabolic factors vary in importance during infection by time, 
tissue, and inoculum. For instance, Hammer et al. found that hemA, qoxB, and cydB 
mutants each display significantly decreased organ burdens in a murine model of sepsis 
8 days post-injection (245). However, attenuation of the mutants was tissue specific, 
with none exhibiting a significant burden defect in the kidney (∆hemA exhibited a bi-
modal distribution in the kidneys). Using the same strain of S. aureus, Johnsson et al. 
found that a hemB mutant did display a significantly decreased burden in murine 
kidneys following IV injection, but in a dose and time-dependent manner (268). This 
group also found that the hemB mutant caused an increased incidence of septic arthritis 
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in comparison to wild-type S. aureus, but did not cause increased weight loss or 
mortality. A third group, Bates et al., showed that hemB also exhibits a small decrease 
in vegetative growth in a rabbit endocarditis model (269). Importantly, S. aureus is 
known to acquire host heme (195). Therefore, loss of hemA, similar to individual 
deletions of cydB and qoxABCD, does not equate to a respiratory deficient mutant in 
vivo. Likewise, in vivo trans-complementation of S. aureus MQ deficient mutants via the 
use of host ubiquinone may also be possible (241). Thus, only a qoxABCD/cydAB 
double mutant can demonstrate a strict requirement for S. aureus respiration during 
infection. Infections with the mutant have yet to be performed.   
 Less is known about the importance of S. aureus fermentation during infection. 
Research conducted by Richardson et al. shows that S. aureus lactate fermentation 
contributes to virulence in a murine model of sepsis (236). Specifically, mice infected 
with individual ldh1 and ldh2 S. aureus mutants displayed enhanced survival compared 
to mice infected with wild-type S. aureus, while mice infected with a double ldh1ldh2 S. 
aureus mutant survived even better than those infected with the single ldh mutants. 
Additionally, the double ldh1ldh2 S. aureus mutant did not produce the characteristic 
kidney abscesses seen during wild-type infection. In the same manuscript, Richardson 
et al. demonstrated that S. aureus lactate dehydrogenase activity contributes to S. 
aureus resistance to the innate immune radical NO·. Importantly, inhibition of host nitric 
oxide production reversed attenuation of the ldh1 mutant during murine sepsis as 
determined by decreased murine survival and increased kidney burden. However, 
inhibition of host nitric oxide production did not fully reverse the attenuation of the 
ldh1ldh2 double mutant, suggesting that other factors necessitate S. aureus 
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fermentative metabolism during infection. To the best of our knowledge, no other 
fermentative factors have been identified as contributing to S. aureus virulence.  
 The dual implication of respiration and fermentation as contributing to S. aureus 
virulence likely indicates that both carbohydrate and amino acids catabolism (i.e., 
glycolysis and TCA cycle, respectively) contribute to the growth of S. aureus in vivo. 
Despite this, only one carbohydrate transporter (FruA) and three amino acid 
transporters (PutP, BRNQ1, and BRNQ2) have been shown to be important for S. 
aureus virulence in animal models of infection (207, 208, 216). Furthermore, only two 
studies have examined the importance of glycolytic and TCA cycle genes (excluding 
tissue culture studies). The first study showed that the S. aureus allele acn encodes a 
TCA cycle protein called aconitase, which catalyzes the conversion of citrate into 
isocitrate (i.e., the second step of the TCA cycle)(270). Insertional inactivation of 
aconitase did not affect murine survival following IP injection of S. aureus, despite the 
fact that this mutant exhibited deceased in vitro production of several important 
virulence factors (e.g., α-toxin, β-hemolysin, lipase, SEC, capsule). The second study 
demonstrated that S. aureus gapA encodes a NADH-dependent glyceraldehyde-3-
phophate dehydrogenase (GAPDH) and gapB encodes a NADPH-dependent GAPDH 
(237). Individual deletion of gapA and gapB resulted in reduced growth of S. aureus on 
glycolytic substrates and loss of growth on gluconeogenic substrates, respectively. 
Thus, gapA encodes one of at least two S. aureus glycolytic GAPDHs while gapB 
encodes the only gluconeogenic GAPDH. Both mutants were subsequently shown 
exhibit reduced killing of Galleria mellonella larvae, in comparison to wild-type S. 
aureus.  
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 Slightly more has been revealed about S. aureus metabolism in vivo from studies 
of the S. aureus metabolic regulators. Mutants of Fur, CodY, and SrrAB have all been 
examined in murine models of infection. A S. aureus fur mutant was found to have a 1-
log burden defect in a murine SSTI model on day 7 post-infection (inoculum = 5x108 cfu 
of strain 8325-4) while a S. aureus srrAB mutant was shown to be significantly 
attenuated for virulence in a murine sepsis model over the course of 14 days (inoculum 
= 5x107 cfu of strain Newman), as measured by murine survival (172, 271). In contrast, 
a S. aureus codY mutant was shown to exhibit increased killing in a murine pneumonia 
model (IN inoculum = 1.5x108 cfu of strain 923) and increase dermonecrosis in a murine 
SSTI model (subcutaneous inoculum = 1.5x107 cfu of strain 923) (272). Unfortunately, 
attributing these phenotypes to the dysregulation of S. aureus metabolism is 
confounded by the observation that these proteins also directly and indirectly regulate a 
wide variety of importance virulence factors. For instance, SrrAB directly regulates 
icaADBC expression, CodY is thought to directly regulate sodA, capsule, hla (α-toxin), 
hlb, and icaADBC expression, while Fur has been shown to regulate katA expression 
(263, 271, 273). Thus, we now understand that S. aureus respiration inhibition promotes 
PIA biosynthesis (i.e., biofilm formation), environmental amino acid abundance inhibits 
capsule production, biofilm formation, and the production of certain toxins, while iron 
abundance promotes catalase expression. Given the importance of these virulence 
factors to S. aureus infection, we postulate that the coregulated metabolic factors are 
utilized by S. aureus cells at various points during infection, and thus also contribute to 
virulence.   
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Metabolic Adaptation of Staphylococcus aureus to Invasive Infection 
 It is generally assumed that the enhanced virulence of S. aureus in comparison 
the other Staphylococci has resulted from the acquisition of a large number of unique 
traditional virulence factors (i.e., mainly toxins). However, the wide variety of clinical 
presentations for S. aureus infections, in comparison to the primarily device related 
infections caused by CoNS strains, suggests that S. aureus is capable of growing in a 
more diverse set of environments that other Staphylococci. While this could simply be 
the result of enhanced immune cell killing (i.e., toxin expression), several factors 
indicate this may also be due to metabolic adaptation of S. aureus to invasive infection. 
First, S. aureus infection environments (e.g., lungs, skin, bone, blood, heart, vaginal 
tract, etc.) differ from each other and the skin surface in ways that are documented to 
affect S. aureus metabolism (e.g., variable substrate, oxygen, and micronutrient 
availability as well as variable pH and innate immune effector concentrations). 
Secondly, the metabolic regulation of S. aureus virulence factors suggests that 
metabolism is intricately linked with the ability of S. aureus to cause invasive infection. 
Thirdly, there are at least two metabolic factors  (the isd system and ldh1) known to 
contribute to S. aureus virulence in animal models of infection that are unique to this 
species of Staphylococci (195, 236). 
 The S. aureus isd system is responsible for the uptake and degradation of 
human hemoglobin for the purpose of liberating heme-bound iron (195). Humans 
reduce the concentrations of free iron in serum in response to infection via a set of 
processes collectively called nutritional immunity. Because iron is important for the 
functioning of many bacterial enzymes, especially TCA cycle and respiratory enzymes, 
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bacteria have evolved a variety of systems to acquire host iron in the face of nutritional 
immunity (274, 275). These systems rely on two strategies, the production and 
secretion of iron chelating compounds (e.g., siderophores) and the expression of high 
affinity transporters and degrading enzymes for human factors that bind iron, including: 
heme, hemoglobin, ferritin, transferrin, and lactoferrin. As stated, the S. aureus isd 
system binds, transports, and degrades human hemoglobin, thereby increasing the 
availability of free iron for use by TCA cycle and respiratory enzymes and repressing 
glycolytic gene expression via the activity of Fur. Inactivation of isdB reduces S. aureus 
burdens in the heart and livers of infected mice at 96-hrs post infection (intravenous 
inoculum = 107 cfu) (195). The combined absence of hemolytic toxins and isd in other 
Staphylococci suggests that S. aureus is better able to respire during invasive infection.   
 The other unique S. aureus metabolic factor shown to contribute to S. aureus 
virulence is the fermentative enzyme, Ldh1 (236). Via the conversion of pyruvate to L-
lactate, S. aureus Ldh1 contributes to NADH oxidation during conditions of respiration 
inhibition. One such condition was found to be NO· exposure. NO· is a chemical radical 
produced by activated innate immune cells via the molecular conversion of arginine into 
citrulline in the presence of oxygen (276). The enzyme responsible for this activity is 
called iNOS. While iNOS is not the only mammalian nitric oxide synthase, it is the only 
one induced in response to infection (thus the name inducible nitric oxide synthase, 
iNOS)(276). Unlike other radicals produced by innate immune cells, NO· is a membrane 
permeable gas. This means that while iNOS activity is localized to the phagosome, NO· 
is found both inside the phagosome and in the extracellular space, albeit in 
concentrations that reflect the diffusion of NO· away iNOS (277, 278). Host NO· acts as 
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a broad spectrum antimicrobial, disrupting cellular metabolism, cell membranes, and 
DNA (279, 280). These effects are caused by the direct binding of NO· to transition 
metals and/or organic radicals, as well as the reactivity of NO· with O2 and O2- that 
produces reactive nitrogen species (RNS). RNS bind and disrupt thiols, amines, and 
aromatic amino acids. Due to the high concentration of iron and thiols in bacterial 
respiratory chains, a primary effect of host NO· production is the inhibition of bacterial 
respiration (281). In fact, NO· has been shown to bind to S. aureus cytochromes and 
inhibit S. aureus oxygen consumption (221, 236).  
 Despite this, S. aureus has been shown to be uniquely resistant to high level NO· 
exposure in comparison to other pathogens, including other Staphylococci (unpublished 
data)(172). This phenotype is largely attributed to the acquisition of ldh1, which allows 
for enhanced fermentative activity during NO· induced respiration inhibition (236). 
Interestingly, S. aureus does not produce EtOH or formate during NO· exposure, nor is 
anaerobically grown S. aureus resistant to NO· (unpublished data)(236). These data 
suggest that the S. aureus NO· resistant metabolic state is different from that of the 
anaerobically induced S. aureus metabolism state. Also, other Staphylococci do not 
produce lactate following NO· exposure, despite possessing two lactate 
dehydrogenases (ldh2 and ddh) capable of generating lactate during anaerobic growth 
(236). These data indicate that additional differences may exist in metabolic pathways 
upstream of lactate fermentation, or even in the regulation of fermentative metabolism 
(i.e., Rex), that account for the unique resistance of S. aureus to NO· exposure. 
Recently, we demonstrated that ldh1 expression is induced by NO· in a glucose-
dependent manner (282). Thus, it seems likely that differences in glycolysis or 
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carbohydrate acquisition during NO· exposure may account for the differential growth 
phenotypes of the Staphylococci.  
 In the following chapters, we provide evidence that S. aureus resistance to high-
level NO· exposure is glycolysis-dependent. We demonstrate that this is because 
glycolysis allows for respiration-independent production of both ATP and precursor 
metabolites in a redox-balanced manner using enzymes that are not susceptible to 
direct NO· inhibition. We further show that glycolysis is required for S. aureus virulence 
and that this requirement is likely the result of several host selective pressures. We then 
demonstrate S aureus cells also grow better than other Staphylococci under anaerobic 
conditions. To explain the enhanced growth of S. aureus under non-respiratory 
conditions, we demonstrate that S. aureus possesses a variety of unique carbohydrate 
transporters and Rex-regulated genes that contribute to fermentative growth. Ultimately, 
these data suggest that in addition to acquiring unique virulence factors, the enhanced 
virulence of S. aureus can be partially explained by the metabolic adaptation of S. 
aureus to low respiratory conditions. These data have implications for the development 
of novel anti-MRSA therapeutics and provide a mechanism that may partially explain 
the unique susceptibility of diabetics to S. aureus infections.  
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!
Figure!1.1. Metabolic Pathways of Carbohydrate Metabolism in S. aureus. The gray shaded region highlights the reactions of glycolysis 
while the orange shaded region highlights the reactions of the PPP.
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Figure 1.2. Metabolic Pathways of Amino Acid Metabolism in S. aureus. The blue shaded region highlights the reactions of the TCA 
cycle while the orange shaded region highlights the reactions of the PPP.
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Figure 1.3. The S. aureus Respiratory Chain. Electrons are donated to the S. aureus respiratory chain by NADH or direct from substrates. 
Cytoplasmic NADH is generated from the oxidation of substrates by a variety of NADH-dependent dehydrogenases, notable examples include 
(PDHC, Ldh2, Fdh, GluD, SucA/OdhB, GapA/GapB). Electrons from NADH are donated to the menaquinone (MQ) pool via the activity of the 
NADH dehydrogenase NDH2. Direct donation of electrons from substrates to the S. aureus menaquinone pool is accomplished via the activity of a 
variety of flavoproteins (CidC, SdhCAB, Lqo, Mqo, and GlpD). Electrons are subsequently transferred from the menaquinone pool to either oxygen 
or nitrate via the activity of three terminal oxidases: CydAB, QoxABCD, and NarGH. Two additional enzymes (MpsABC and MnhABCDEFG) have 
been shown to contribute to S. aureus ΔΨ and may interact with/donate electrons to the menaquinone pool (i.e. dashed line). Only two 
components (QoxABCD and NarGH) of the S. aureus respiratory chain are predicted to translocate protons across the membrane, and thus 
directly contribute to PMF. Under respiratory conditions, the energy stored in the S. aureus PMF is harnessed to generate ATP via the activity of 
the F1F0 ATPase.  
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TABLE 1.1. S. aureus Amino Acid and Peptide Transporters 
    Gene Locus Gene Name Substrate TCDB # 
SACOL0171 brnQ1 Ile, Leu, Val* 2.A.26.1 
SACOL0302 brnQ2 Ile* 2.A.26.1 
SACOL0620 proP Pro/Betaine 2.A.1.6 
SACOL0630   Polyamines 2.A.3 
SACOL0788 dtpT Di- and tripeptides 2.A.17.1 
SACOL0996-99 opp4 Oligopeptides 3.A.1.5 
SACOL1367 pheP Phe/Lys 2.A.3.1 
SACOL1384 opuD (opuD1) Pro* 2.A.15.1 
SACOL1443 brnQ3 Not BCAAs* 2.A.26.1 
SACOL1476   Thr 2.A.3.8 
SACOL1728 lysP Lys 2.A.3.1 
SACOL1743   D-Ser/D-Ala/Gly 2.A.3.1 
SACOL1916-15 glnPQ Gln 3.A.1.3 
SACOL1963 putP Pro* 2.A.21.2 
SACOL2309   Ser/Ala/Gly 2.A.3.1 
SACOL2382 gltT Glu 2.A.23.1 
SACOL2412-10   Unknown 3.A.1.3 
SACOL2441   Ser/Ala/Gly 2.A.3.1 
SACOL2451-50 opuCC Gly/Betaine/Carnitine/Choline 3.A.1.12 
SACOL2453-52 opuCA Gly/Betaine/Carnitine/Choline 3.A.1.12 
SACOL2458   Unknown 2.A.3 
SACOL2619   BCAAs 2.A.3.3 
SACOL2655 arcD Arg/Orn 2.A.3.2.3 
    * indicates substrate specificity confirmed by radiolabeled uptake assay 
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CHAPTER 2: GLYCOLYTIC DEPENDENCY OF HIGH-LEVEL NITRIC OXIDE 
RESISTANCE AND VIRULENCE OF STAPHYLOCOCCUS AUREUS1 
 
SUMMARY 
 Staphylococcus aureus is a prolific human pathogen capable of causing severe 
invasive disease with a myriad of presentations. The ability of S. aureus to cause 
infection is strongly linked with its capacity to overcome the effects of innate immunity, 
whether by directly killing immune cells or expressing factors that diminish the impact of 
immune effectors. One such scenario is the induction of lactic acid fermentation by S. 
aureus in response to host nitric oxide (NO·). This fermentative activity allows S. aureus 
to balance redox during NO·-induced respiration inhibition. However, little is known 
about the metabolic substrates and pathways that support this activity. Here, we identify 
glycolytic hexose catabolism as being essential for S. aureus growth in the presence of 
high NO·. We determine that glycolysis supports S. aureus NO· resistance by allowing 
for ATP and precursor metabolite production in a redox-balanced and respiration-
independent manner. We further demonstrate that glycolysis is required for NO· 
resistance during phagocytosis and that increased levels of extracellular glucose limit 
the effectiveness of phagocytic killing by enhancing NO· resistance. Finally, we 
demonstrate that S. aureus glycolysis is essential for virulence in both sepsis and
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!Nicholas!P.!Vitko,!Nicole!A.!Spahich,!Anthony!R.!Richardson.!2015.!Glycolytic!Dependency!of!HighBLevel!Nitric!Oxide!Resistance!and!Virulence!of!Staphylococcus,aureus.!Mbio!6(2):!00045B15.!
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skin/soft tissue models of infection, in a time frame consistent with the induction of 
innate immunity and host NO· production. 
 
IMPORTANCE 
 S. aureus is a leading human bacterial pathogen capable of causing a wide 
variety of diseases that, as a result of antibiotic resistance, are very difficult to treat. The 
frequency of S. aureus tissue invasion suggests that this bacterium has evolved to 
resist innate immunity and grow using the nutrients present in otherwise sterile host 
tissue. We have identified glycolysis as an essential component of S. aureus virulence 
and attribute its importance to promoting nitric oxide resistance and growth under low 
oxygen conditions. Our data suggests that diabetics, a patient population characterized 
by excess serum glucose, may be more susceptible to S. aureus as a result of 
increased glucose availability. Furthermore, the essential nature of S. aureus glycolysis 
indicates that a newly developed glycolysis inhibitor may be a highly effective treatment 
for S. aureus infections.  
 
INTRODUCTION 
 Staphylococcus aureus is a Gram-positive bacterium capable of causing a wide 
variety of clinical manifestations in humans, including: skin and soft tissue infections 
(SSTIs), pneumonia, bacteremia, endocarditis, and osteomyelitis. S. aureus infections 
are more common, invasive, and severe than those caused by coagulase-negative 
Staphylococci (CNS), despite the shared colonization of human skin and frequent 
resistance to antibiotics (283, 284). The traditional explanation for this difference has 
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been the acquisition of many unique virulence factors by S. aureus that promote 
colonization of fresh wounds and destruction of host tissues (285). Complementary to 
this concept is the hypothesis that an increased incidence of tissue invasion by S. 
aureus has led to metabolic adaptation that further distinguishes S. aureus from CNS. 
One instance where this is particularly evident is for the growth of S. aureus in the 
presence of the innate immune radical, nitric oxide (NO·).  
  NO· is a small membrane permeable gas produced by activated phagocytes via 
an inducible nitric oxide synthase (iNOS or NOS2) (286). In this context, NO· acts as a 
broad spectrum antimicrobial with a strong propensity for disrupting microbial 
metabolism, DNA replication, and lipid integrity (287). The effects of NO· are caused by 
direct binding of NO· to transition metals and/or organic radicals and indirectly via the 
formation of reactive nitrogen species (RNS), which themselves bind thiols, amines, and 
hydroxyl aromatic groups (280). Due to the dense concentration of iron and thiol 
containing enzymes in bacterial respiratory chains, a primary effect of NO· at levels ≥ 
500 nM is the disruption of cellular respiration (236, 288). In the context of infection, 
activated phagocytes can generate ≥ 1 µM NO· intracellularly (278, 289). While S. 
aureus strains can enzymatically detoxify NO· using the flavohemoprotein, Hmp, 
mutants lacking this enzyme are still capable of replicating during nitrosative stress 
(172). Furthermore, despite possessing Hmp, CNS are incapable of growing in the 
presence of high levels of NO· (levels sufficient to inhibit cellular respiration) (236).  
Instead, what distinguishes S. aureus from CNS during growth under high NO· is lactic 
acid fermentation.  
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 Fermentation promotes S. aureus NO·-resistant growth by converting NADH into 
NAD+ (i.e. balancing redox), which allows for continued carbon catabolism via NAD+ 
dependent pathways. During NO· exposure, S. aureus performs heterolactic acid 
fermentation using three lactic acid dehydrogenases (Ldh1, Ldh2, and Ddh) (236). 
Interestingly, CNS lack the ldh1 allele and do not ferment lactate in response to NO· 
stress, despite possessing anaerobically responsive ddh and ldh2 alleles (236).  The 
reason for this discrepancy is currently unknown. However, we have demonstrated that 
NO·-dependent induction of ldh1 in S. aureus is glucose-dependent, leading us to 
consider the possibility that S. aureus growth in the presence of high NO· may itself be 
carbon source dependent (282).  
 Given the large contribution of NO· resistance to S. aureus infection, and the 
metabolic basis for this unique resistance, we undertook a more extensive examination 
of the substrates that support S. aureus resistance to high NO· (47).  Our results 
indicate that S. aureus requires specific glycolytic substrates to grow in the presence of 
high NO· in vitro and during phagocytosis. Furthermore, we demonstrate that glycolysis, 
but not gluconeogenesis, is required for S. aureus pathogenesis during murine infection. 
Together these results clearly establish the metabolic programming required for S. 
aureus to establish invasive infection, and in agreement with clinical observations, 
implicate the host glycemic state as an important factor in determining susceptibility to 
this pathogen.  
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RESULTS 
Fermentative Growth of S. aureus During NO· Stress is Glycolysis-Dependent.  
 Unlike other pathogenic bacteria, including closely related staphylococci, S. 
aureus is capable of growing in the presence of high levels of nitric oxide (.2-1 mM NO·) 
(172, 236). The identification of ldh1 as a unique S. aureus NO·-resistance factor 
implicates metabolic adaptation, specifically the induction of fermentative metabolism, 
as an important feature of high-level NO· resistance. However, little is known about the 
metabolic substrates and central metabolic pathways that support this resistance. 
Therefore, we examined the ability of ten different carbon sources (carbon balanced) to 
support growth of S. aureus under high NO· stress. High NO· stress was achieved 
using a mixture of NO· donors (1 mM DEANO and 10 mM NOC-12), which achieve 
maximal [NO·] = ~ 1mM by 1.5 h and maintain levels ≥500 nm for ~5hrs. The carbon 
sources are loosely divided into two groups: glycolytic (glucose, sorbitol, mannose, and 
mannitol) and non-glycolytic (glycerol, gluconate, ribose, pyruvate, L-lactate, and 
casamino acids) (Figure 2.1). Only a subset of glycolytic carbon sources (hexoses) 
supported the growth of S. aureus in the presence of high NO· concentrations, while all 
of the non-glycolytic carbon sources failed to support growth (Figure 2.2). These 
phenotypes were confirmed using two additional S. aureus strains (Newman and 
SF8300, data not shown).  
 Given the glycolytic dependency of S. aureus NO· resistance, we examined the 
contribution of the glycolysis responsive regulator CcpA to growth under high nitrosative 
stress. However, there was no significant difference in the normalized maximum growth 
rate of wild type and ccpA::SpR  S. aureus during high nitrosative stress (47.1% +/- 5.5% 
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and 51.9% +/- 5.4% respectively). These data suggest that the dependency on hexoses 
for NO·-resistance does not stem from CcpA-mediated induction of an unknown NO· 
resistance factor.  
 
Respiration-Inhibition Partially Explains the Glycolysis-Dependence of S. aureus NO· 
Resistance.  
 The primary effect of high NO· levels is the inhibition of cellular respiration. Thus, 
we postulated that anaerobic growth of S. aureus would also be glycolysis dependent. 
Consistent with this hypothesis, growth of S. aureus during anaerobiosis was restricted 
to the same set of carbon sources that support NO· resistance, with one exception, 
pyruvate (Figure 2.3A). Addition of the alternative electron acceptor nitrate (50mM) to 
the media improved the anaerobic growth of S. aureus on all carbon sources. These 
anaerobic growth phenotypes were confirmed in two additional S. aureus strains 
(Newman and SF8300, data not shown). Furthermore, the respiration-deficient S. 
aureus mutant menD::ErR, which lacks the ability to synthesize menaquinone electron 
carriers, exhibited the same carbon source-dependent growth under aerobic conditions 
as wild type S. aureus grown anaerobically (e.g. glucose and pyruvate supported 
growth, but amino acids did not) (Figure 2.3B). These data are consistent with NO·-
dependent respiration inhibition as the primary cause of the observed carbon source 
constraints for S. aureus NO· resistant growth, albeit not for pyruvate.  
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Fermentative Growth of S. aureus on Pyruvate Requires Acetogenesis. 
 The observation that S. aureus growth on pyruvate is respiration-independent, 
suggests that NO· may directly inhibit enzymes necessary for fermentative growth on 
this substrate. To identify what these targets may be we first compared the excretion of 
several key metabolic end products (acetate, formate, lactate, and ethanol) during 
anaerobic growth of S. aureus on either glucose or pyruvate (Figure 2.1 and 2.4). 
Growth on glucose resulted in a mixture of end product metabolites, a large proportion 
of which are important for balancing redox stress (L-lactate, D-lactate, formate and 
EtOH). S. aureus grown anaerobically on pyruvate, on the other hand, generated 
significantly less lactate and ethanol and significantly more acetate and formate. This 
result is consistent with high-level flux of pyruvate to acetate for energy production 
concomitant with a shift from energy-producing glycolysis (2xATP/glucose consumed) to 
energy-consuming gluconeogenesis (4xATP/glucose produced) (Figure 2.1).  
 To confirm that gluconeogenic catabolism of pyruvate proceeds via the predicted 
ATP consuming pathway in S. aureus (Figure 2.1), we measured the growth of wild 
type, ∆pyc (encodes pyruvate carboxylase), and ∆pckA (encodes phosphoenolpyruvate 
carboxykinase) S. aureus anaerobically on pyruvate (Figure 2.4). Both mutants failed to 
grow under these conditions. Additionally, we confirmed that acetogenesis (generates 
1xATP/pyruvate, Figure 2.1) was required for anaerobic growth of S. aureus on 
pyruvate, but not on glucose, using a ∆ackA (encodes acetate kinase) S. aureus mutant 
(Figure 2.4). These data suggest that S. aureus requires acetogenesis in order to 
produce sufficient ATP to maintain cellular homeostasis and run gluconeogenesis while 
growing on pyruvate under non-respiratory conditions.  
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Partial Inhibition of PDHC by NO· Limits Acetogenesis and Growth of S. aureus on 
Pyruvate.  
 The requirement for acetogenesis during anaerobic growth on pyruvate suggests 
that NO· may directly inhibit acetogenic enzymes in S. aureus and thus limit growth. 
Indeed, previous work has shown that PDHC (pyruvate dehydrogenase complex) and 
PFL (pyruvate formate lyase), enzymes that catalyze the first committed step in 
acetogenesis from pyruvate (Figure 2.1), are susceptible to NO· inactivation (236). 
Furthermore, oxygen also inhibits PFL activity, and thus PDHC is likely the dominant 
enzyme for converting pyruvate to acetyl-CoA during our in vitro NO· growth assays 
(290). However, NO· must not completely inactivate PDHC, as acetyl-CoA is an 
essential precursor metabolite for growth on any carbon source. Thus, we postulated 
that partial inhibition of PDHC by NO· might be growth limiting for S. aureus on 
pyruvate, but not hexoses, as a result of an increased need for carbon flux though 
acetyl-CoA to acetate for energy production.  
 In support of this hypothesis, ∆pflAB (encodes PFL) S. aureus was more 
susceptible to the PDHC inhibitor TPBC when grown anaerobically on pyruvate (MIC = 
1.5 µM) than glucose (MIC = 4 µM) (291). Additionally, NO· treatment during growth on 
pyruvate significantly reduced the intracellular concentration of acetyl-CoA and the “flux” 
of pyruvate to acetate in wild-type S. aureus compared to aerobic and anaerobic 
conditions (Figure 2.5A-B). Finally, NO· treatment significantly reduced intracellular ATP 
levels for S. aureus on pyruvate, but did not decrease ATP levels for S. aureus grown 
on glucose (Figure 2.5C). Given the propensity of bacteria to maintain a constant 
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intracellular level of ATP/cell and the increased demand for acetogenic flux in S. aureus 
grown on pyruvate during non-respiratory conditions, these data suggest that partial 
inhibition of PDHC/PFL by NO· inhibits S. aureus growth on pyruvate by limiting ATP 
production and gluconeogenic flux.  
 
Intracellular S. aureus Survival Requires NO·-Resistance. 
 During infection, NO· levels within phagosomes of activated phagocytes surpass 
those known to completely inhibit S. aureus respiration (278, 292). Consistent with this, 
a lactate dehydrogenase deficient mutant of S. aureus (∆ldh1/ldh2/ddh) was 
significantly attenuated for survival in RAW 264.7 macrophages in comparison to wild 
type S. aureus (Figure 2.6A) (the survival kinetics for wild-type S. aureus were the same 
for COL, Newman, and SF8300, data not shown). Furthermore, the survival defect of 
the ∆ldh1/ldh2/ddh mutant was completely abrogated by treating the macrophages with 
the iNOS inhibitor, L-NIL. We validated the efficacy of L-NIL treatment by demonstrating 
reduced levels of extracellular nitrite in macrophages (Figure 2.7A-B).  Given that lactic 
acid fermentation in response to NO· is unique to S. aureus, we compared the survival 
of wild-type S. aureus to S. haemolyticus and S. saprophyticus. Both CNS exhibited 
significantly greater susceptibility to macrophage killing than S. aureus (Figure 2.6B). L-
NIL treatment largely reversed these differences, suggesting S. aureus NO· resistance 
promotes survival during phagocytosis.  
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S. aureus NO· Resistance During Phagocytosis is Glycolysis-Dependent.  
 Given our in vitro data, we hypothesized that S. aureus survival during 
phagocytosis would be glycolysis-dependent. To examine this possibility, we 
constructed S. aureus mutants in several predicted glycolytic (pfkA, encodes 
phosphofructokinase; pyk, encodes pyruvate kinase; and gapA, encodes 
glyceraldehyde-3-phosphate dehydrogenase A) and gluconeogenic (pyc; pckA; and 
gapB, encodes glyceraldehyde-3-phosphate dehydrogenase B) genes in several strain 
backgrounds (Figure 2.1). To confirm the predicted metabolic roles of these genes, we 
grew the mutants aerobically in media with either glucose or casamino acids as the 
primary carbon source. Both ∆pfkA and ∆pyk S. aureus were unable to grow on glucose 
(i.e. encode glycolytic enzymes) while ∆pckA and ∆gapB S. aureus were unable to grow 
on casamino acids (i.e. encode gluconeogenic enzymes)(Figure 2.8A-B). All other 
mutants exhibited either no observable phenotype or very small growths defects (Figure 
2.8C-D). These phenotypes were confirmed using two additional S. aureus strains 
(Newman and SF8300, data not shown). Complementation restored growth of all S. 
aureus COL mutants on their respective carbon sources (Figure 2.8E-F).  
 Next, we examined the survival of the glycolytic (∆pfkA and ∆pyk) and 
gluconeogenic (∆pckA, and ∆gapB) mutants during phagocytosis by RAW 264.7 
macrophages. Both glycolytic mutants (∆pfkA and ∆pyk) exhibited significantly reduced 
survival at 12 and 20 hpi, while the gluconeogenic mutants (∆pckA and ∆gapB) 
displayed no survival defect (Figure 2.9A). Attenuation of the glycolytic mutants was not 
a result of differential bacterial uptake (~75% for all strains) and was completely 
reversed by L-NIL treatment (Figure 2.9B). Furthermore, survival of wild-type S. aureus 
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was significantly improved by the addition of increasing amounts of glucose to the tissue 
culture media (Figure 2.9C). In the absence of NO·, excess glucose had no effect on 
bacterial survival. Furthermore, glucose treatment did not affect macrophage NO· 
production (Figure 2.7). Altogether, these data suggest that S. aureus has access to a 
variety of nutrient sources within macrophages, but host NO· necessitates the specific 
utilization of glycolytic carbon sources as a result of respiration inhibition.  
 
S. aureus  Virulence in Mice is Glycolysis-Dependent. 
 To determine the greater contribution of glycolysis and gluconeogenesis to S. 
aureus pathogenesis, we infected C57BL/6 mice intravenously with wild type, ∆pyk, 
∆pfkA, and ∆pckA S. aureus. Infection with wild type and gluconeogenic-defective 
∆pckA S. aureus produced similar results: both strains colonized and proliferated in the 
kidney and liver (Figure 2.10) and both strains induced ~20% weight loss in infected 
mice by day 5 (data not shown). Organ burdens and weight loss were not significantly 
different between wild type and the ∆pckA mutant. The glycolytic mutants (∆pyk and 
∆pfkA), on the other hand, were significantly attenuated in comparison to wild type and 
were essentially cleared from the kidney and liver by day 2 (Figures 2.10 and 2.11). 
Additionally, ∆pyk S. aureus exhibited a 6-log decrease in tissue burden (day 7) and an 
inability to form an open lesion in a skin and soft tissue infection (SSTI) model of S. 
aureus infection (Figure 2.12).  
 To examine the contribution of host NO· production to the observed attenuation 
of the S. aureus glycolytic mutants, we infected both wild type and iNOS-/- C57BL/6 
mice with wild type, ∆pyk, and ∆pfkA S. aureus intravenously. Loss of iNOS resulted in 
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increased burden of wild type S. aureus in the kidney, but did not affect the burden of 
either glycolytic mutant in either organ (Figure 2.11). The failure of iNOS deletion to 
reverse the attenuation of the glycolytic mutants during sepsis suggests that other 
selective factors maintain the need for bacterial glycolysis even in the absence of host 
NO· production. Staining of both uninfected tissue and S. aureus tissue abscesses 
revealed regions of severe tissue hypoxia, suggesting that low oxygen may also 
necessitate the need for hexose-derived fermentative metabolism independently from 
NO·-mediated respiration inhibition (Figures 2.13 and 2.14).  
 
DISCUSSION 
 Unlike other pathogens, S. aureus is capable of growing during high nitrosative 
stress. S. aureus achieves this unique resistance via the induction of an NO·-resistant 
metabolic state (236). The substrates and central metabolic pathways that support 
these activities were previously poorly defined. Using a variety of defined media 
conditions, we demonstrated that S. aureus resistance to high NO· (i.e. levels sufficient 
to inhibit respiration) is glycolysis-dependent both in vitro and during phagocytosis. We 
determined that non-glycolytic carbon sources fail to support NO· resistant growth due 
to a combination of respiration-dependent catabolism and partial inhibition of 
PDHC/PFL activity. Finally, we showed that glycolysis is required for S. aureus 
pathogenesis in a murine sepsis and SSTI model of infection.  
 Interestingly, several large S. aureus virulence screens have failed to identify 
glycolysis as an essential component of S. aureus virulence (293-295).  This can be 
explained by the fact that the two glycolytic mutants we identified, ∆pyk and ∆pfkA, grow 
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very poorly in the glucose-rich media used to generate the transposon libraries (e.g. BHI 
and TSB, data not shown). By removing glucose as a substrate for growth and 
supplying abundant gluconeogenic substrates, we were able to grow ∆pfkA and ∆pyk S. 
aureus without observable growth phenotypes and identify this metabolic pathway as 
essential for S. aureus pathogenesis. One study previously noted the importance of 
glycolysis to S. aureus virulence, although they utilized an invertebrate model and a 
∆gapA S. aureus mutant (237). We observed no glycolytic defect for this mutant in three 
S. aureus strains (COL, Newman, and SF8300), implying that GapB is reversible and 
can compensate for loss of GapA. This discrepancy could be the result of our ∆gapA 
mutants separately acquiring compensatory mutations, or the fact that the previously 
reported mutant was constructed in a highly mutagenized strain of S. aureus 
(NCTC8325-4) (62, 296). Regardless, experimentation with the ∆pyk and ∆pfkA mutants 
demonstrates that glycolysis is essential to S. aureus virulence.  
 Glycolysis supports S. aureus virulence by promoting growth during innate 
immune activation. Specifically, a subset of glycolytic carbon sources (hexoses) is 
compatible with non-respiratory growth; a selective pressure generated by host NO· 
production and abscess formation (i.e. low oxygen). Hexoses support non-respiratory 
growth of S. aureus because they allow for redox-balanced ATP generation and 
precursor metabolite formation, while avoiding catabolic pathways that are directly 
inhibited by NO·.  Other metabolic substrates may require quinone-dependent (and thus 
respiration-dependent) enzymes (e.g. amino acids and lactate), limit carbon availability 
via excessive fermentation (e.g. mannitol and sorbitol, Figure 2.15), or require NO·-
sensitive enzymes for catabolism (e.g. pyruvate). However, hexose catabolism via 
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glycolysis and hetero-lactic acid fermentation alone cannot fully explain the growth of S. 
aureus during NO· stress, as redox balancing under these conditions requires use of all 
available glucose for lactic-acid production. While EtOH fermentation could alleviate this 
metabolic stress, and does under anaerobic conditions, we do not observe EtOH 
production by S. aureus following NO· exposure (236). These data suggest that 
additional, unidentified, redox-balancing reactions support NO·-resistant growth of S. 
aureus on hexoses.  
 Likewise, non-respiratory growth induced by low oxygen and host NO· production 
is probably not the only selective pressure that necessitates S. aureus glycolytic 
metabolism. For instance, iron restriction, as experienced during infection, has been 
shown to induce expression of S. aureus glycolytic and lactic acid fermentation genes 
as well as restrict growth of S. aureus on gluconeogenic substrates (218, 222). This is a 
result of the high abundance of iron in respiratory and TCA cycle proteins. Despite this, 
respiratory metabolism has been shown to be important for S. aureus virulence, as 
evidenced by the attenuation of terminal oxidase and heme deficient mutants in the 
heart and livers of infected mice (245). This discrepancy can likely be explained by the 
spatiotemporal nature of infection. At certain times, S. aureus will have sufficient oxygen 
and iron to perform respiratory metabolism, but at other times, host iron sequestration, 
low oxygen, and host NO· production will necessitate glycolytic fermentation.  This likely 
explains the lack of virulence restoration when infecting iNOS-/- mice with the ∆pyk and 
∆pfkA mutants. While host NO· production likely necessitates Pyk and PfkA activity 
within activated phagocytes (Figure 2.9B), the iron restricted and hypoxic environment 
of infected tissue also select for high glycolytic flux in S. aureus. Thus, the glycolytic 
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requirement for full S. aureus virulence is multifaceted, making enzymes in this pathway 
attractive candidates for antimicrobial development. 
 Likewise, the concentrations of metabolic substrates available to S. aureus may 
vary according to tissue and stage of infection. A limited supply of gluconeogenic 
substrates and robust availability of glycolytic substrates during the early stages of 
infection fits well with our model of S. aureus metabolic adaptation to tissue invasion 
and innate immunity (Figure 2.16). For instance, glycolytic substrates are essentially 
absent in sweat, the primary carbon source for skin-associated Staphylococci (297, 
298). However, glucose is highly abundant in human serum and certain tissues/organs 
(e.g. the liver) (235, 299).  Furthermore, it is well known that Streptococcus, another 
Gram-positive extracellular pathogen, relies extensively on carbohydrate metabolism to 
support growth and virulence (300). Alternatively, intracellular bacteria (e.g. Listeria, 
Legionella, Mycobacterium, etc.) often rely heavily on gluconeogenic substrates for 
growth (e.g. fatty acids, glycerol, and amino acids), likely due to the 10:1 nature of 
gluconeogenic to glycolytic substrates inside the host cell cytoplasm (301-305). While S. 
aureus lacks many of the predicted glycosidases utilized by Streptococci for the 
catabolism of complex carbohydrates (e.g. mucins), the predominantly extracellular 
nature of S. aureus pathogenesis suggests that this bacterium may primarily be using 
mono- and disaccharides to support growth (the same mono- and disaccharides utilized 
by host cells to support growth).  
 Interestingly, diabetics (a medical condition characterized by defects in total body 
glucose homeostasis) are highly susceptible to S. aureus infection (88, 306, 307). This 
phenomenon is generally attributed to immune dysfunction amongst this patient 
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population, as diabetics exhibit increased susceptibility to many pathogens and have 
documented problems with phagocyte chemotaxis and respiratory burst, despite largely 
being characterized as hyper-inflammatory (308). However, only uncontrolled diabetics 
(i.e. those exhibiting hyperglycemia) exhibit increased infection rates, suggesting that 
increased glucose availability may be a key determinant for S. aureus virulence 
following invasion of sterile tissue (309-311). Furthermore, if these patients are truly 
hyper-inflammatory, then increased glucose availability will promote greater resistance 
of S. aureus to increased host NO· production. This is clear from our observation that S. 
aureus survival during macrophage phagocytosis was improved, in a NO·-dependent 
manner, when serum glucose levels were increased from normal (1g/L) to diabetic (2.5-
4g/L) concentrations. This is especially intriguing given that NO· resistance is a unique 
feature of S. aureus pathogenesis, and infection rates amongst diabetics are 
disproportionately increased for S. aureus in comparison to other pathogens (307).  
 These data suggest that the development of bacterial-specific glycolysis 
inhibitors could be a promising strategy for treating invasive S. aureus infections. This is 
especially important given the increasing drug-resistant nature of many S. aureus 
infections (e.g. MRSA, VRSA, and VISA). However, glycolysis is a highly conserved 
metabolic pathway amongst prokaryotes and eukaryotes, making it especially difficult to 
selectively target S. aureus without inducing detrimental effects on the host. 
Nonetheless, Zoraghi et al. have identified a novel class of antimicrobials that 
selectively inhibit S. aureus Pyk without inhibiting human Pyk or inducing host cell 
toxicity (312, 313). They showed that these novel antimicrobial agents were cytotoxic to 
methicillin-resistant S. aureus (MRSA) and together we demonstrated that the cytotoxic 
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activity of these compounds was dependent on the presence of Pyk (314).  The data 
presented in this manuscript suggest that this drug could be a powerful anti-
Staphylococcal therapeutic, effective for treating both SSTI and sepsis. Furthermore, 
several clinically relevant small colony variants (SCV) of S. aureus, that are associated 
with chronic infection presentations, are deficient in cellular respiration and thus might 
be particularly susceptible to a Pyk inhibitor (315). 
 It is often speculated that the requirement for a given carbon source/central 
metabolic pathway is simply a reflection of the substrates available to pathogens during 
growth in their respective infectious niches. However, we have implicated glycolysis as 
a requirement for S. aureus resistance to innate immunity. Given that NO· resistance is 
a unique feature of S. aureus virulence, further investigation into the glycolytic 
capabilities of the different Staphylococcus species is warranted and may in fact reveal 
a great deal about the disparities that exist in their ability to cause invasive infection. 
 
MATERIALS AND METHODS 
Bacterial Strains and Culture Conditions 
 Staphylococci were cultivated in Brain Heart Infusion media or in chemically 
defined media (CDM) in which primary carbon sources could be modified (316). Strains, 
plasmids, and primers are listed in Table 2.1. Mutants were generated via allelic 
replacement using the E. coli/S. aureus shuttle vectors pBT2ts, pBTK, pBTE, and pBTS 
as previously described (235). Complementation of mutants was carried out by cloning 
a desired gene under its original promoter into the BamHI site of pOS1 or cloning the 
gene into the NdeI site of pOS1-plgt wherein the constitutive lgt promoter drives 
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transcription. Aerobic S. aureus growth curves were performed at 37°C in 96-well plates 
(200 µl/well) using a Tecan Infinite M200 Pro microplate reader with 1 mm orbital 
shaking. Growth was monitored via absorbance at 650 nm at 15-minute intervals. NO· 
donors were suspended in 0.01 N NaOH and added to cultures at an OD650 = 0.15 
(mid-log phase). The NO· donors utilized in this study are DETA/NO (2 and 4 mM) or a 
mixture of NOC-12 and DEANO (10:1 molar ratio). Anaerobic cultures were grown in 
16x150mm tubes containing 5 mls of media with stirring at 37°C in a Coy anaerobic 
chamber.  
 
Growth Rate Analysis 
 Growth rate was calculated at 15-minute intervals using the following equation: 
∆ln(Abs650nm)/∆time(hrs). Aerobic growth rate is the average growth rate during a 2-
hour window of peak logarithmic growth. NO· growth rate is the average growth rate 
during a 4-hour window from 1-5 hrs post-NO· addition. 
 
Enzymatic Determination of Excreted Metabolites 
 Excreted metabolites were harvested from the supernatants of heat inactivated 
(70°C for 5 min.) culture aliquots. Samples were stored at -20°C and thawed on ice prior 
to analysis. L-lactic acid, D-lactic acid, ethanol, formic acid, and acetic acid 
concentrations were measured enzymatically using commercially available reagents (R-
Biopharm AG, Darmstadt, Germany: Roche Yellow Line Kits). Pyruvate levels were 
measured enzymatically (Abs 340 nm) using the following reaction solution: 150 mM 
Tris-HCl (pH 8.5), NADH (333 µg/ml), L-lactate dehydrogenase (approx. 14.5 U).  
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Quantification of Intracellular Acetyl-CoA Levels 
 S. aureus COL cells were grown in 55 mls CDM + Pyruvate (1.1%) in a 125 ml 
flask at 37°C with shaking at 250 rpm (aerobic and NO· treated samples). At an OD660  
= 0.5, added DETA/NO (4 mM final) to one flask and an equal volume of 10 mM sodium 
hydroxide to the other flask. Three (NaOH flask) and fifteen (DETA/NO flask) minutes 
post addition, the S. aureus cells were collected via vacuum filtration, washed with 100 
mls of 4°C sterile saline, transferred into 600 µl of 4°C sterile PBS, and then snap 
frozen using a dry ice/ethanol bath (total time ≤ 5 min.). Additionally, S. aureus COL 
cells were grown in 55 mls CDM + Pyruvate (1.1%) in a 125 ml flask in a Coy anaerobic 
chamber at 37°C with stirring. At OD650 = 0.7, the flask was removed from the 
anaerobic chamber and the cells were harvested according to the procedure outlined 
above for the aerobic and NO· treated samples. The frozen cells were thawed on ice 
and then lysed via bead beating. The supernatants were then treated with perchloric 
acid (0.036 N final) and neutralized using potassium bicarbonate (total protein 
concentrations were measured prior to perchloric acid treatment). We then measured 
acetyl-CoA concentrations in the samples using the PicoProbe Acetyl-CoA Assay Kit 
(BioVision Inc.). Acetyl-CoA concentrations were normalized to total protein.  
 
Acetogenic “Flux” Measurements 
 The flux of pyruvate to acetate during growth of S. aureus was estimated by 
dividing the amount of extracellular pyruvate consumed by the amount of extracellular 
acetate produced over a set period of time and measured according to the enzymatic 
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methods described above. For aerobic and anaerobic samples, this period was from the 
beginning to the end of exponential-phase (as determined by a linear growth curve 
graphed on a log scale). For NO· treated S. aureus, this period was from 1-5 hrs post 
NO· addition (the fermentative window, as determined by sustained lactate production).  
 
ATP Measurement 
 S. aureus cells were grown aerobically in the Tecan M200 Pro (as described 
above) in CDM with either glucose (25mM) or pyruvate (50mM) as the primary carbon 
source. At OD650 nm = 0.15 NO· mix was added to a subset of wells. At 0, 1, 2, 3, 4, 
and 5 hrs post NO· addition the intracellular ATP concentrations were determined using 
the BacTiter-Glo Microbial Cell Viability Assay (Promega). ATP levels were then 
normalized to OD650 values for each time point and then averaged over the following 
time periods: 1-3hrs post-NO· addition for untreated wells (aerobic), 1-5hrs post-NO· 
addition in NO· treated wells.  
 
Phagocytosis Assays 
 RAW 264.7 macrophages were suspended in RPMI 1640 (Gibco, 11875-093) 
supplemented with FBS (10%) and HEPES (25 mM) at a concentration of 1x106 
cells/ml, seeded into the wells of a 48-well plate at 0.5 mls/well, and incubated for 18 
hrs at 37°C. The cells were then activated via incubation in RPMI + LPS (100 ng/ml) + 
IFN-γ (20 ng/ml) for 6 hrs at 37°C, and then spin inoculated in RPMI alone with S. 
aureus (opsonized in HBSS + 10% mouse serum with active complement at 37°C for 30 
min.) at an MOI of 10:1 (S. aureus: RAW 264.7). Following incubation of the RAW cells 
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with S. aureus for 30 min. at 37°C, the cells were washed twice with PBS, and then 
incubated in RPMI + Gentamycin (100 µg/ml) for 1 hour at 37°C. The infected RAW 
cells were then washed twice with PBS, after which certain wells were treated with 
0.01% Triton-X 100 to induce RAW cell lysis for bacterial enumeration (t = 0) while the 
remaining infected RAW cells were incubated in RPMI + gentamycin (12 µg/ml) at 37°C 
for an additional 12 or 20 hrs. Experiments involving glucose titration utilized RPMI 1640 
– Glucose (Gibco, 11879-020) that was supplemented with FBS (10%), HEPES 
(25mM), and tissue culture grade glucose (1,2,3,4 g/L) that was introduced at the time 
of bacterial inoculation. To inhibit iNOS activity, L-NIL (100 nM) treatment was 
introduced simultaneously with activation of the RAW cells with LPS and IFN-γ and 
continued for all incubations following. Nitrite levels of untreated and L-NIL treated 
culture supernatants (heat treated at 70°C for 5 min.) were measured using the Greiss 
reaction.  
 
Murine Infection Models 
 All mutants utilized for animal infections were first transduced and then confirmed 
to still exhibit their respective in vitro growth phenotypes. For virulence assessment via 
sepsis, 6-8 week old female WT and iNOS-/- C57BL/6 mice from Taconic Farms 
(Albany, NY USA) were inoculated via tail vein with 7.5 x 106 CFU of WT S. aureus 
Newman, or isogenic mutants, in 100 µl of PBS. Weight loss was monitored daily for the 
period of infection, with mice exhibiting excessive weight loss being sacrificed as per the 
IACUC-approved protocol. At days 1, 2, and 5 post-infection, kidneys and liver were 
removed from the infected animals, homogenized in 500 µl sterile PBS, and dilution 
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plated on BHI (WT and ∆pckA S. aureus Newman) or TSA without glucose 
supplemented with 0.5% pyruvate (∆pyk and ∆pfkA S. aureus Newman) to enumerate 
CFU. S. aureus strain Newman was utilized for these experiments as weight loss 
exhibited by mice infected intravenously with this strain correlates reliably with bacterial 
burdens in the organs, allowing us to monitor disease progression. For virulence 
assessment in the SSTI model, 6-8 week old female C57BL/6 mice from Jackson Labs 
(Bar Harbor, ME USA) were injected with 1 x 107 CFU WT or ∆pyk S. aureus LAC in 20 
µl of sterile PBS subcutaneously. Abscess size (length x width) was monitored daily. On 
day 7, mice were euthanized and the abscesses were removed, homogenized in 500 µl 
of PBS, and dilution plated on TSA without glucose supplemented with 0.5% pyruvate to 
enumerate CFU. S. aureus strain LAC was utilized for the SSTI model as it belongs to a 
subtype of S. aureus strains (USA300) that are the primary cause of these infections in 
the United States.  
 
Fluorescent Immunohistochemistry 
 Uninfected C57BL/6 mice as well as those inoculated with WT S. aureus i.v. 
(7.5x106 cfu) 2 days prior were injected IP with 60 mg/kg HypoxyprobeTM-1 
(Hypoxyprobe Inc., Burlington, MA, USA) suspended in sterile PBS. After 1hr, liver and 
kidney tissue was collected, fixed in 10% formalin, paraffin embedded, and sectioned 
(10 µm) by the Histopathology Core Facility at UNC. Sections were hematoxylin and 
eosin stained (H&E) by the Histology Core while unstained sections were prepared for 
immunohistochemistry as previously described (47). Briefly, unstained sections were 
de-paraffinized using a series of xylene and ethanol washes and then incubated in hot 
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10 mM sodium-citrate buffer (pH 6) for 20 minutes. Tissues were then blocked in 10% 
donkey serum (Jackson ImmunoResearch, West Grove, PA) and then stained with 
affinity purified anti-HypoxyprobeTM-1 rabbit antisera (PAb2627AP, Hypoxyprobe Inc., 
Burlington, MA, USA) diluted 1:200 in PBS + 2% donkey serum. Staining was detected 
using biotinylated secondary antibodies followed by streptavidin-Dylight-594 conjugates 
(Jackson ImmunoResearch). Stained sections were mounted in ProLong Antifade 
Reagent Gold with DAPI (Invitrogen, Grand Island, NY, USA) and viewed with an 
Olympus BX60 fluorescence microscope. Images were captured using iVision software 
v.4.0.0 (BioVision Technologies, New Minas, Nova Scotia, Canada). 
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Figure 2.1. S. aureus Glycolytic, Gluconeogenic and Fermentative Metabolic 
Pathways. Metabolites are indicated with black dots while metabolic reactions are indicated 
with black lines. For emphasis, the black dots representing several key metabolites 
discussed in the manuscript have been replaced with the names of the metabolites. From 
this group, the metabolites used as primary carbon sources are colored blue (glycolytic) or 
orange (non-glycolytic). Additionally, several reactions have also been colored to indicate 
their glycolytic (blue) or gluconeogenic (orange) direction. Protein names are included next 
to several important metabolic reactions and are colored to indicate their glycolytic (blue), 
gluconeogenic (orange), or miscellaneous (black) function(s). These proteins include: PfkA 
(phosphofructokinase), GapA (glyceraldehyde-3-phosphate dehydrogenase A), GapB 
(glyceraldehyde-3-phosphate dehydrogenase B), Pyk (pyruvate kinase), Ldh1 (L-lactate 
dehydrogenase 1), Ldh2 (L-lactate dehydrogenase 2), Ddh (D-lactate dehydrogenase), 
PDHC (pyruvate dehydrogenase complex), PFL (pyruvate formate lyase), AckA (acetate 
kinase), Pyc (pyruvate carboxylase), PckA (phosphoenolpyruvate carboxykinase). 
Casamino acids enters central metabolism either at pyruvate or through quinone-dependent 
oxidation by the TCA cycle.  
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Figure 2.2. NO· Resistant Growth of S. aureus is Hexose-Dependent. (A) S. aureus COL grown 
at 37°C in CDM +/- NO· Mix with glucose (25 mM), pyruvate (50 mM), or casamino acids (0.5%) as 
the primary carbon source (n = 3, error bars = SEM). NO· mix was added at mid-log and absorbance 
was normalized to time of NO· addition (t0) (n = 3, error bars = SEM) (B) Average growth rates of S. 
aureus COL in CDM + various primary carbon sources (carbon balanced to 25 mM glucose) following 
NO· exposure (NO· mix), normalized to the average mid-log aerobic growth rate in each carbon 
source (n = 3, error bars = SEM). Significance was calculated using a Student's two-sided t-test (*, P 
≤ 0.05, **, P ≤ 0.01)
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Figure 2.3. S. aureus Growth on Most Carbon Sources is Respiration-Dependent. (A) Maximum 
absorbance (650 nm) of S. aureus COL grown at 37°C for 24 hrs anaerobically in CDM +/- potassium 
nitrate (50 mM) with various primary carbon sources (carbon balanced to 25 mM glucose) (n = 3, error 
bars = SEM). (B) Aerobic growth of wild type and menD::ErR S. aureus Newman at 37°C for 32 hrs in 
CDM with glucose (0.5%), pyruvate (1%), or casamino acids (1%) as the primary carbon source (n = 3, 
error bars = pooled std. dev.). 
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Figure 2.4. Anaerobic Growth on Pyruvate Requires Acetogenesis. 
(A) Mid-log production of extracellular metabolites during anaerobic 
growth of S. aureus COL at 37°C in CDM with glucose (0.5%) or 
pyruvate (1%) as the primary carbon source (n = 3, error bars = SEM). 
(B) Anaerobic growth of wild type, ∆pyc, and ∆pckA S. aureus COL at 
37°C in CDM with pyruvate (1%) as the primary carbon source (n = 2, 
error bars = SEM). (C) Anaerobic growth of wild type and ∆ackA S. 
aureus COL at 37°C in CDM with glucose (0.5%) or pyruvate (1%) as 
the primary carbon source (n = 2, error bars = SEM). Statistical 
significance was calculated using a Student’s two-sided t-test (**, P ≤ 
.01).
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Figure 2.5 NO· Exposure Limits Acetogenic Flux of Pyruvate.  
(A) Average intracellular acetyl-CoA levels for S. aureus COL grown at 37°C 
in CDM with pyruvate (1.1%) as the primary carbon source (n = 3, error bars 
= SEM) (B) Average acetogenic “flux” of pyruvate (acetate 
produced/pyruvate consumed) for S. aureus COL grown at 37°C in CDM 
with pyruvate (50 mM) as the primary carbon source (n = 3, error bars = 
SEM) (C) Average intracellular ATP levels (µM/OD650) of S. aureus COL 
grown aerobically +/- NO· Mix in CDM with glucose (25 mM) or pyruvate (50 
mM) as the primary carbon source (n = 3, error bars = SEM). Significance 
was calculated using a Student's two-sided t-test (*, P ≤ 0.05, **, P ≤ 0.01).
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Figure 2.6. Lactate Fermentation Enables S. aureus NO· Resistance During 
Phagocytosis. (A) Percent survival of wild type and ∆ldh1/ldh2/ddh S. aureus COL in 
activated RAW 264.7 macrophages +/- L-NIL (100 nM) at 20hrs post inoculation (MOI = 
10:1, n = 3, error bars = pooled std. dev.). The fold-effect of L-NIL treatment on bacterial 
survival is indicated above the bars. (B) Percent survival of wild type S. aureus COL (SA), 
S. haemolyticus (SH), and S. saprophyticus (SS) in activated RAW 264.7 macrophages +/- 
L-NIL (100nM) at 20hrs post inoculation (MOI = 10:1, 3 ≤ n ≤ 4). Statistical significance was 
assessed using a Student's two-sided t-test (**, P ≤ .01, N.S. = not significant).
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Figure 2.7. NO· Production in RAW 264.7 Cells is Not Affected by Mutations in S. 
aureus Central Metabolism or By Increased Extracellular Glucose. (A) Extracellular 
nitrite (µM) levels for RAW 264.7 macrophages +/- L-NIL at 12 and 20hrs post-infection 
with wild type and central metabolic mutants of S. aureus COL (MOI 10:1) (n = 1). (B) 
Extracellular nitrite levels for RAW 264.7 macrophages +/- L-NIL in RPMI with glucose at 
1 and 4 g/L, 12 hrs hpi with wild type S. aureus (n = 3, error bars = SEM).
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Figure 2.8. Aerobic Growth of Predicted S. aureus Glycolytic and Gluconeogenic Mutants. Growth 
of predicted S. aureus COL central metabolic mutants at 37°C in CDM supplemented with (A and C) 
glucose (25 mM) or (B and D) casamino acids (0.5%) (n = 3, error bars = pooled std. dev.). (E) Growth of 
complemented S. aureus COL glycolytic mutants (∆pyk and ∆pfkA) at 37°C in CDM with glucose (25 mM) 
(n = 1, error bars = std. dev.). (F) Growth of complemented S. aureus COL gluconeogenic mutants 
(∆pckA and ∆gapB) at 37°C in CDM with casamino acids (0.5%) (n = 1, error bars = std. dev.).
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Figure 2.9. S. aureus Requires Glycolysis to Resist NO· During Phagocytosis. 
(A) Percent survival of S. aureus COL central metabolic mutants in activated RAW 
264.7 macrophages at 12 and 20 hpi (3 ≤ n ≤ 6, error bars = pooled std. dev.). (B) 
Percent survival of S. aureus COL glycolytic mutants in activated RAW 264.7 
macrophages +/- 100nM L-NIL at 20 hpi (5 ≤ n ≤ 6, error bars = pooled std. dev.). 
The fold-effect of L-NIL treatment on bacterial survival is indicated above the bars. 
(C) Percent survival of S. aureus COL in activated RAW 264.7 macrophages at 
12hrs +/- L-NIL treatment in RPMI with increasing amounts of glucose (n = 3, error 
bars = pooled std. dev.). Statistical significance was calculated using a Student's 
two-sided t-test (*, P ≤.05, **, P ≤ .01, N.S. = not significant).
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Figure 2.10 Glycolysis is Essential for S. aureus Virulence During Sepsis. C57BL/6 
mice were infected via tail vein injection with 7.5x106 cfu of wild type, ∆pckA, or ∆pyk S. 
aureus Newman. Kidneys (A) and livers (B) were harvested on days 1, 2, and 5 days 
post infection and enumerated for bacteria (8 ≤ n ≤ 12, lines indicate mean organ 
burden, limit of detection was 100 cfu/organ).  
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Figure 2.11. Loss of iNOS Does Not Reverse Attenuation of the S. aureus 
Glycolytic Mutants During Sepsis. Wild type and iNOS-/- C57BL/6 mice were 
infected via tail vein injection with 7.5x106 cfu of WT, ∆pyk, or ∆pfkA S. aureus 
Newman. Kidneys (A) and livers (B) were harvested 24 hrs post-infection and 
enumerated for bacteria (n = 4, lines indicate mean organ burden, limit of detection 
is 100 cfu/organ). 
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Figure 2.12. Glycolysis is Essential for S. aureus Virulence During Skin 
and Soft Tissue Infection. C57BL/6 mice were infected with 1x107 cfu of 
wild type or ∆pyk S. aureus LAC via subcutaneous injection. Infection was 
monitored by measuring (A) lesion size and (B) day 7 abscess burden (5 ≤ n 
≤ 7, error bars  = SEM). Significance was calculated using a Mann Whitney 
test (**, P ≤ .01). 
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Figure 2.13. S. aureus Infected Tissues Display Acute 
Hypoxia. Representative kidney abscesses harvested from 
C57BL/6 mice on day 2 post-infection with 7.5x106 cfu of wild 
type S. aureus Newman were stained with either (A) hematoxylin 
and eosin (H&E) or (B) Hypoxyprobe (pink) and DAPI (blue). 
Tissues were imaged at 20x magnification using an Olympus 
BX60 fluorescence microscope.  
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Figure 2.14. Uninfected Murine Kidneys and Livers Display Areas of Hypoxia. 
The kidneys and liver from an uninfected C57BL/6 mouse were harvested, fixed, paraffin embedded, and 
sliced. Following de-paraffinization and antigen retrieval, tissue slices were blocked in 10% donkey 
serum, then stained with affinity purified α-Hypoxyprobe rabbit antisera, biotinylated goat-α-rabbit 2°, and 
streptavidin-Dylight-594 conjugate (pink). Stained tissue slices were then mounted using Prolong Antifade 
Gold containing DAPI (blue) and imaged at 20x magnification using an Olympus BX60 fluorescence 
microscope.
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Figure 2.15. Excessive Fermentation Limits S. aureus Growth on Hexitols During NO· Stress. 
Production of L-lactate by wild type S. aureus COL grown at 37°C in CDM with mannose (25 mM) or 
mannitol (25 mM) following NO· (NO· mix) addition (n = 3, error bars = SEM). Change in extracellular 
lactate levels was assessed from 0-6 hrs post NO· addition and concentrations were normalized to Abs 
650 nm. Statistical significance was calculated using a Student’s two-sided t-test (*, P ≤ .05). 
 
 
 
Figure 2.16. Model: Tissue Invasion Necessitates S. aureus Glycolytic Metabolism. S. aureus skin 
invasion (1) is mediated by virulence factors and/or host tissue damage and is accompanied by 
decreased oxygen but increased glucose availability. Following tissue seeding, S. aureus is phagocytized 
(2) during which it must employ glycolytic-based fermentation in order to resist the effects of high host 
NO· production. Toxin expression allows for S. aureus escape from the intracellular environment (3). 
Immune activation results in further influx of monocytes, which surround S. aureus forming an abscess (4) 
that further limits both oxygen and glucose availability. S. aureus able to escape this enclosure 
disseminate to the blood stream (5), an environment rich in glucose and heme-bound oxygen. From the 
bloodstream S. aureus invades other sterile tissues including the kidney and liver (6). In these organs, a 
variety of factors necessitate S. aureus glycolysis including tissue hypoxia, host NO· production (7), iron 
limitation, and nutrient availability.  
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TABLE 2.1. Strains, Plasmids, and Primers!
! ! !
Strain Description Reference/Source 
4220 Methicillin Sensitive Restriction Deficient S. aureus W. Shafer 
Newman Methicillin Susceptible Clinical S. aureus Isolate W. Shafer 
COL Methicillin Resistant Clinical S. aureus Isolate W. Shafer 
SF8300 Methicillin Resistant Clinical S. aureus Isolate (59) 
LAC Methicillin Resistant Clinical S. aureus Isolate NARSA 
ATCC 29970 S. haemolyticus human skin isolate ATCC 
ATCC 15305 S. saprophyticus urine isolate ATCC 
AR0355 S. aureus Newman menD::ErR (NWMN_0913) (46) 
AR0407 S. aureus COL ∆ccpA::SpR (SACOL1786) (282) 
AR0455 
S. aureus COL ldh1::ErR/ldh2::KnR/∆ddh::SpR (SACOL0222, 
SACOL2618, SACOL2535) (235) 
AR0744 S. aureus COL ∆pfkA (SACOL1746) (317) 
AR0763 S. aureus COL ∆pyc::ErR (SACOL1123) This study 
AR0766 S. aureus COL ∆pckA::KnR (SACOL1838) This study 
AR1179 S. aureus Newman ∆pckA::KnR (NWMN_1681) This Study 
AR0769 S. aureus COL ∆pyk::ErR (SACOL1745) This study 
AR1180 S. aureus Newman ∆pyk::ErR (NWMN_1592) This Study 
AR0891 S. aureus LAC ∆pyk::ErR (314) 
AR0772 S. aureus COL ∆gapB::KnR (SACOL1735) This study 
AR0777 S. aureus COL ∆gapA (SACOL0838) This study 
AR0905 S. aureus COL ∆ackA::KnR (SACOL1760) 
Spahich 
(Unpublished) 
AR1148 S. aureus COL ∆pfkA + pNV061 This study 
AR1149 S. aureus COL ∆pyk + pNV041 This study 
AR1150 S. aureus COL ∆pckA + pNV056 This study 
AR1151 S. aureus COL ∆gapB + pNV058 This study 
Plasmid Description Reference/Source 
pBT2ts E. coli/S. aureus shuttle vector (318) 
pBTE 1.2kb ermB (ErythromycinR) allele cloned into SmaI of pBT2ts (235) 
pBTK 1.4kb aph-A3 (KanamycinR) allele cloned into SmaI of pBT2ts (235) 
pBTS 1.3kb aad9 (SpectinomycinR) allele cloned into SmaI of pBT2ts (235) 
pNV014 
5' and 3' homology regions of pyc cloned into pBTE to yield 
∆pyc::ErR This study 
pNV018 
5' and 3' homology regions of pckA cloned into pBTK to yield 
∆pckA::KnR This study 
pNV026 
5' and 3' homology regions of pyk cloned into pBTE to yield 
∆pyk::ErR This study 
pNV030 
5' and 3' homology regions of gapB cloned into pBTK to yield 
∆gapB::KnR This study 
pNV032 
5' and 3' homology regions of gapA were amplified via overlap 
extension PCR and cloned into EcoRI of pBT2ts This study 
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pNV034 
5' and 3' homology regions of pfkA were amplified via overlap 
extension PCR and cloned into EcoRI of pBT2ts This study 
pTR61 ldh1::ErR in pBT2ts (ErR in internal NdeI site in ldh1) (236) 
pTR75 ldh2::KnR in pBT2ts (KnR in an engineered SalI site) (236) 
pJF103 
5' and 3' homology regions of ccpA cloned into pBTS to yield 
∆ccpA::SpR (282)  
pNAS24 
5' and 3' homology regions of ackA cloned into pBTK to yield 
∆ackA::KnR 
Spahich 
(Unpublished) 
pNV061 pfkA cloned into the NdeI/BamHI sites of pOS1-plgt This study 
pNV041 pyk cloned into the BamHI site of pOS1-plgt This study 
pNV056 
pckA + 418bp upstream of the start site cloned into the BamHI site 
of pOS1 This study 
pNV058 
gapB + 201bp upstream of the start site cloned into the BamHI site 
of pOS1 This study 
Primer Sequence Use 
pckA-5.1A tggtagaattcCAAGTGTCACATCCTCAGC Deletion 
pckA-5.1B tggtagaattcTGTTTCAGTGTATGTGTCTAC Deletion 
pckA-3.1A gtaggatccGCTGAAAAAGGTAGCTTCAAC Deletion 
pckA-3.1B gtaggatccTAGTATGAAACGTGGTGTGC Deletion 
pfkA-5.1A tggtagaattcTGCAAGAAAGACCTACGACC Deletion 
pfkA-5.1B TCCACCACTAGTTAAAACTGCCAAGGTGAAACAGCTAAGGG Deletion 
pfkA-3.1A CCCTTAGCTGTTTCACCTTGGCAGTTTTAACTAGTGGTGGA Deletion 
pfkA-3.1B tggtagaattcCCAGCAGCAGTTTCACCAG Deletion 
pyk-5.1A tggtagaattcGCAGTTTTAACTAGTGGTGG Deletion 
pyk-5.1B tggtagaattcGCTGGTCCAATTGTACATAC Deletion 
pyk-3.1A gtaggatccACGATTGATGCTGCTCAAGG Deletion 
pyk-3.1B gtaggatccAGAAGGTGTTTGATCTTGAGC Deletion 
gapB-5.1A tggtagaattcGATTATCGTCATGCTGATGG Deletion 
gapB-5.1B tggtagaattcCTTCCAATTCTACCCATACC Deletion 
gapB-3.1A gtaggatccCTGAGCAAATTGGAGCAC Deletion 
gapB-3.1B gtaggatccCGCCTTTAACAATCCAATCG Deletion 
pckA-5.1A tggtagaattcCAAGTGTCACATCCTCAGC Deletion 
pckA-5.1B tggtagaattcTGTTTCAGTGTATGTGTCTAC Deletion 
pckA-3.1A gtaggatccGCTGAAAAAGGTAGCTTCAAC Deletion 
pckA-3.1B gtaggatccTAGTATGAAACGTGGTGTGC Deletion 
gapA-5.1A tggtagaattcCGAACATATGGATATGACTGAACG Deletion 
gapA-5.1B 
GCTAAGTATGCTAATGTACGAACTGCTAAACGACCAATTCTAC
C Deletion 
gapA-3.1A 
GGTAGAATTGGTCGTTTAGCAGTTCGTACATTAGCATACTTAG
C Deletion 
gapA-3.1B tggtagaattcATGGTACTACAGTGATTTTGGC Deletion 
pyc-5.1A ggtagaattcGTAACGGTGGCGTATTTGG Deletion 
pyc-5.1B tggtagaattcGCAATTTCTCCACGGTTAGC Deletion 
pyc-3.1A gtaggatccGTGACACAATAGCGACAGG Deletion 
pyc-3.1B gtaggatccGTTACCAAAACCGGATCAGC Deletion 
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pfkA-lgt tggcacatatgAAGAAAATTGCAGTTTTAACTAGTGG Complementation 
pfkA.1B tggtaggagtccGCTGGTCCAATTGTACATAC Complementation 
pyk.2A tggtaggatccCAAGGTGAAACAGCTAAGGG Complementation 
pyk.1B tggtaggatccCCTTTCCATTGTTGATAAATGG Complementation 
gapB.1A tggtaggatccTTGAAAAGCCGAATTACGGAG Complementation 
gapB.1B tggtaggatccTCCGAAGTCAGAGTTAGGC Complementation 
pckA.1A tggtaggatccTCCTTCTGTAACAGACTCTG Complementation 
pckA.1B tggtaggatccCCCGTTCACACGGGTGG Complementation 
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CHAPTER 3: CARBOHYDRATE TRANSPORTER ACQUISITION PROMOTES 
ENHANCED NON-RESPIRATORY GROWTH AND VIRULENCE OF 
STAPHYLOCOCCUS AUREUS 
 
SUMMARY 
 Staphylococcus aureus exhibits enhanced virulence in humans over other skin 
colonizing Staphylococci. Metabolic adaptation of S. aureus to non-respiratory growth 
conditions encountered during infection has been implicated as contributing to this 
difference. Specifically, S. aureus has been shown to utilize a unique lactate 
dehydrogenase encoded by ldh1 to promote enhanced fermentation of glycolytic 
substrates during nitric oxide exposure. Here, we show that S. aureus has also acquired 
unique carbohydrate transporters that promote uptake of host sugars in an additive 
manner and are disproportionately required during non-respiratory growth (both 
anaerobiosis and nitric oxide induced fermentative growth). We subsequently identify S. 
aureus transporters for 11 carbohydrates and show that at least five genes encode S. 
aureus glucose transporters, including: glcA, glcB, glcC, and glcU. Two glucose 
transporters (GlcA and GlcC) are unique to S. aureus and both contribute 
disproportionately to non-respiratory growth of S. aureus on glucose. Furthermore, 
reduced glucose uptake attenuated S. aureus in a murine model of skin and soft tissue 
infection. These data expand the evidence for metabolic adaptation of S. aureus to 
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invasive infection and provide an alternative mechanism for why diabetics are uniquely 
susceptible to S. aureus disease.   
 
INTRODUCTION 
 Staphylococcus aureus (S. aureus) is a Gram-positive coccus that 
asymptomatically colonizes healthy human skin (75, 319). However, a compromised 
skin barrier or mucus membrane can lead to severe S. aureus infections including: skin 
and soft tissue infections (SSTI’s), bacteremia, osteomyelitis, pneumonia, and toxic 
shock syndrome (320-322). Interestingly, many other species of Staphylococci 
(collectively called coagulase-negative Staphylococci, or CoNS) also colonize the 
human skin (20). However, CoNS cause disease less frequently and with less severity 
than S. aureus. This difference has been extensively studied, and is largely attributed to 
the acquisition of numerous virulence factors by S. aureus, such as: toxins, adhesins, 
and protein A (156, 158, 190). While some of these same individual virulence factors 
may be found in CoNS strains, it is the combined presence of numerous virulence 
factors within S. aureus that is thought to account for the increased incidence, severity, 
and variation of S. aureus disease.  
 Largely absent from this model explaining the increased pathogenic potential of 
S. aureus is the contribution of metabolic adaption. The S. aureus lifecycle can plausibly 
be described as low-level growth on the skin surface with periodic penetration into 
deeper tissue environments marking a phase of enhanced growth and increased 
incidence of transmission. Thus, inflamed skin lesions likely exert a selective pressure 
that partially accounts for the speciation of S. aureus from CoNS. Contributing to the 
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penetration of S. aureus into the deeper sterile layers of skin, and survival within this 
inflamed environment, are all of the traditional virulence factors previously mentioned as 
well as any metabolic adaptations that enhance the growth of S. aureus within this 
environment.  
 Evidence for the contribution of metabolic adaptation to S. aureus growth in 
deeper tissue spaces exists. Biosynthesis of the carotenoid pigment, staphyloxanthin, 
from which the species name “aureus” is derived, protects this bacterium from the toxic 
effects of reactive oxygen species (ROS) produced by activated immune cells (183, 
184). Likewise, S. aureus encodes a unique lactate dehydrogenase (ldh1) that 
promotes non-respiratory growth of S. aureus during exposure to host nitric oxide (NO·) 
(236). Finally, S. aureus possesses unique hemoglobin binding, transport, and 
degradation machinery encoded by the isd locus that promotes iron acquisition in the 
low free-iron environment of host tissue (195, 275). However, there are many additional 
differential aspects of the skin surface and underlying tissue environments that have yet 
to be explored for their potential contribution to metabolic adaptation of S. aureus.  
 Major physiological differences between the skin surface and underlying tissue 
include: oxygen availability, micronutrient availability, carbon sources, nitrogen sources, 
and pH. In general, the skin surface is relatively high in oxygen, ammonium (~20mM), 
urea (~30mM), lactate (~20mM), and certain vitamins (~400mM Nicotinic Acid, 100mM 
Pantothenic Acid, 20mM Riboflavin, and 5mM Thiamine) but low in carbohydrates 
(glucose ~ 0.1mM), peptides, and pH (~5.3) (297, 298). Underlying tissue has lower 
levels of oxygen, lactate (~1mM), urea (~4mM), and vitamins (~50µM Nicotinic Acid, 
2µM Pantothenic Acid, 0.5µM Riboflavin, and 0.1µM Thiamine), but much higher levels 
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of carbohydrates (glucose ~5mM) and peptides as well as a higher pH (~7) (323). 
Overall, these environments are considered stark contrasts in their metabolite richness, 
with the skin environment possessing mostly metabolic waste products (i.e. urea and 
lactic acid) while the underlying skin tissue constitutes a robust consolidation of growth 
supporting substrates (i.e. peptides and carbohydrates).  
 In-line with these observations, we recently demonstrated that glycolysis is 
required for S. aureus SSTI and bloodstream infections(324). These data suggest that 
carbohydrates support growth of this pathogen during tissue invasion. Aside from the 
known difference in carbohydrate abundance between the skin surface and underlying 
tissue, our work, as well as others, demonstrates that a combination of respiration 
inhibitory variables (host nitric oxide production, low tissue oxygen, and low iron levels) 
may represent a selective pressure driving enhanced glycolysis-based fermentation in 
S. aureus (218, 236, 324). However, aside from the ldh1 allele promoting S. aureus 
NO·-resistant growth, there is a lack of molecular evidence supporting this hypothesis. 
Given the high evolutionary conservation of glycolysis amongst all the kingdoms of life, 
metabolic adaption to promote high glycolytic flux would most easily be achieved by the 
acquisition of additional carbohydrate importers (325).  
 Bacterial carbohydrate transporters can generally be divided into those that 
modify the sugar during transport (i.e. phosphotransferase system, or PTS, 
transporters) and those that do not (i.e. 1° and 2° active transporters) (213, 326, 327). 
PTS transport proceeds via a phosphorelay system that transfers the phosphoryl group 
of PEP through a series of carrier proteins (EI and HPr) to a transporter (EII), and then 
on to the sugar as it is imported. PTS sugar transporters are composed of at least three 
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subunits: EIIA, EIIB, and EIIC. The EIIA and EIIB subunits transfer the phosphoryl group 
from HPr to the sugar, while the EIIC subunit acts as a sugar-specific transmembrane 
receptor. Interestingly, the EII subunits may be encoded as individual proteins or as 
mutlisubunit fused proteins. PTS-dependent carbohydrate transport is unique to 
bacteria, and is the predominant form of sugar uptake. Preference for PTS-dependent 
carbohydrate uptake is likely due to ATP-conservation. However, PTS-dependent 
transport is also functionally linked to transcriptional regulation of cellular metabolism 
via carbon catabolite repression, which further contributes to overall metabolic 
efficiency.  
 In this paper, we show that S. aureus exhibits enhanced non-respiratory growth 
compared to CoNS. To partially explain this difference, we demonstrate that 1) 
carbohydrate transport contributes disproportionately to the non-respiratory growth of S. 
aureus and 2) that S. aureus exhibits an expanded list of predicted carbohydrate 
transport proteins in comparison to CoNS. We then confirm the role of several, unique 
and shared, predicted S. aureus transport proteins in the uptake of specific 
carbohydrates. Finally, we demonstrate carbohydrate uptake, and glucose uptake in 
particular, is important for S. aureus virulence in a murine SSTI model.  
 
RESULTS 
S. aureus Exhibits Enhanced Anaerobic Growth Compared to CoNS.   
 S. aureus is uniquely resistant to high levels of the innate immune radical NO· 
(236). S. aureus grows in the presence of high NO· levels by fermenting carbohydrates 
into lactic acid (324). This allows S. aureus to generate both ATP and precursor 
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metabolites in a redox balanced manner that bypasses the need for cellular respiration. 
To test whether the enhanced non-respiratory growth of S. aureus compared to CoNS is 
highly specific to NO·, or whether S. aureus also exhibits enhanced growth behavior 
under other non-respiratory conditions, we compared the anaerobic growth of S. aureus 
strains COL and LAC to S. epidermidis RP62A, S. haemolyticus ATCC 29970, and S. 
saprophyticus ATCC 15305 in rich media. Both strains of S. aureus exhibited enhanced 
growth compared to the CoNS strains, as evidenced by significantly greater growth 
rates and maximum optical densities (Figure 3.1A-B ).  
 Using a small number of substrates (10), we previously demonstrated that non-
respiratory growth of S. aureus is limited to a subset of glycolytic carbohydrates, the 
hexoses (polysaccharides were not tested). Thus, we hypothesized that a differential 
ability to acquire and ferment hexoses, may account for the enhanced non-respiratory 
growth of S. aureus in rich media. To begin testing this hypothesis, we compared the 
anaerobic growth of S. aureus COL to our CoNS strains in a chemically defined medium 
(CDM) with glucose as the primary carbon source. Once again, S. aureus exhibited 
enhanced anaerobic growth compared to the CoNS strains (Figure 3.1C-D). These data 
suggest that unique glycolytic and/or fermentative mechanisms account for the 
enhanced growth of S. aureus under non-respiratory conditions.  
 
S. aureus Encodes an Expanded Repertoire of Predicted Carbohydrate Transporters.  
 One mechanism for the increased growth rate of S. aureus under non-respiratory 
conditions is an increased capacity to ferment lactic acid. While most pathogenic 
Staphylococci encode two lactate dehydrogenases (Ldh and Ddh), S. aureus possesses 
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a third lactate dehydrogenase (Ldh1) that also contributes to redox balancing. This 
molecular redundancy underlies an additive contribution of the lactate dehydrogenases 
to non-respiratory growth (236). Thus, an increased incidence of tissue invasion, and 
subsequent exposure to non-respiratory conditions, has selected for an expanded S. 
aureus fermentative capacity. Likewise, we hypothesize that these selective pressures 
have driven an expanded capacity for S. aureus glycolysis. Given the high conservation 
of the glycolytic pathway amongst all the kingdoms of life, we further speculate that 
enhanced glycolytic flux would most easily be achieved by the acquisition of additional 
carbohydrate importers.  
 To test this hypothesis, we examined the genomes of S. aureus COL and LAC, 
S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. saprophyticus ATCC 15305 
for the presence of carbohydrate importers using the NCBI and UniProt protein 
databases. To diminish the effect of misannotation, we additionally confirmed the 
function of any predicted transporters by ensuring high sequence similarity to sugar 
importers present in the transporter classification database (TCDB), which provides 
functional and phylogenetic classification for membrane transport proteins. In total, we 
identified 29 predicted carbohydrate import proteins in S. aureus, 16 in S. epidermidis, 
20 in S. haemolyticus, and 21 in S. saprophyticus (Figure 3.2 and Table 3.1). Next, we 
assessed conservation of these predicted carbohydrate transport proteins across the 
four Staphylococcus species using sequence similarity comparisons (forward and 
reciprocal BLASTP) combined with genomic context analysis (Metacyc and xBase). 
Ultimately we discovered that S. aureus is predicted to encode both the largest total 
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number (29) and most unique (10) carbohydrate transport proteins of all the 
Staphylococci  (Figure 3.2 and Table 3.1). 
 The list of unique carbohydrate transport proteins predicted for S. aureus, 
includes both (PTS) and non-PTS transport proteins. The two non-PTS transporters, 
MalK and UhpT, are predicted to import maltose and hexose-phosphates, respectively. 
Of the eight unique predicted PTS proteins, three belong to the Glc family 
(SAUSA300_0191: EIIABC, SAUSA300_0236: EIIBC, and SAUSA_0259: EIIA), three 
belong to the Gat family (SAUSA300_0239: EIIA, SAUSA300_0240: EIIB, and 
SAUSA300_0241: EIIC), and two belong to the Asc family (SAUSA300_0330: EIIC, and 
SAUSA300_0332: EIIA). Assuming all of the predicted proteins (including those for 
CoNS strains) are functional, these data suggest that natural selection has promoted 
enhanced uptake of glycolytic substrates into S. aureus compared to CoNS strains. 
Furthermore, the fact that four of the ten unique S. aureus transport proteins are 
predicted to contribute to glucose uptake (the three PTS-Glc family transporters and 
UhpT), suggests that acquisition of this substrate in particular may be especially 
beneficial to this pathogen during infection.  
 
Carbohydrate Uptake in S. aureus is Mostly PTS-dependent and Contributes 
Disproportionately to Non-Respiratory Growth.   
 Since most of the predicted S. aureus transport proteins are PTS proteins 
(21/29), we decided to test the contribution of carbohydrate transport to the anaerobic 
growth of S. aureus using a PTS deficient stain of S. aureus (ptsH-H15A). The H15A 
substitution in PtsH prevents the transfer of the phosphoryl group from EI to PtsH, 
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thereby inhibiting PTS-dependent sugar uptake (326). To confirm the efficacy of this 
mutation and identify PTS-dependent substrates, we compared the aerobic growth of 
WT and ptsH-H15A S. aureus on 16 different carbohydrates. Previous studies 
demonstrated PTS-dependent utilization of at least 7 carbohydrates (lactose, fructose, 
galactose, maltose, sucrose, glucose, and mannitol) by S. aureus (214). In line with 
these observations, we found that loss of PTS-dependent sugar uptake prevented S. 
aureus growth on 10 carbohydrates (mannose, fructose, galactose, mannitol, N-acetyl-
glucosamine, N-acetyl-mannosamine, maltose, sucrose, trehalose, lactose, and 
turansose), reduced growth on two carbohydrates (glucose and maltotriose), but did not 
affect growth on ribose (Table 3.2). These data show that S. aureus carbohydrate 
utilization is largely PTS-dependent.  
 Having confirmed a large reduction in carbohydrate utilization in the PTS-
deficient strain, we next examined the relative contribution of PTS-dependent 
carbohydrate uptake to the aerobic and anaerobic (non-respiratory) growth of S. aureus. 
To do this, we compared the aerobic and anaerobic growth of WT and ptsH-H15A S. 
aureus in TSB.  Although the contribution of PTS-dependent carbohydrate uptake to S. 
aureus growth was statistically significant under both conditions, the impact of PTS 
inhibition was far greater under anaerobic conditions than aerobic (Figure 3.3). 
Compared to WT S. aureus, the COL and LAC ptsH-H15A mutants exhibited a 50% and 
60% reduction in growth rate anaerobically, but only a 13% and 8% reduction in growth 
rate aerobically. These data confirm the enhanced contribution of carbohydrate 
transport to the non-respiratory growth of S. aureus, thereby implicating carbohydrate 
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transporter acquisition as a possible metabolic adaptation to non-respiratory conditions 
experienced by S. aureus during host tissue invasion.  
 
Characterization of Individual S. aureus PTS Transporters.   
 Next, we wanted to identify the sugar specificity of the individual S. aureus PTS 
proteins. Therefore we screened insertion mutants in all of the predicted PTS-protein 
encoding genes (aside from SAUSA300_0758 and fruA) for aerobic growth defects on 
select carbohydrates. Previous studies identified fruA and mtlFA as encoding fructose 
and mannitol importers respectively(215, 216). In support of these observations, we 
found that the mtlF and mtlA mutants were unable to grow on mannitol, while S. aureus 
COL, a natural fruA mutant, exhibited reduced growth on fructose compared to S. 
aureus JE2. Additionally, we identified PTS-transport proteins contributing to the uptake 
of 9 other carbohydrates. Overall, our results link individual PTS-transport proteins to 
the uptake of 11 of the 12 PTS-dependent sugars (Table 3.3). All phenotypes were 
confirmed in a second S. aureus strain background (COL) following transduction, with 
the exception of two insertions we were unable to transduce (SAUSA300_2151 and 
SAUSA300_2576). Of particular note, two of the six mutants with insertions in PTS-
proteins unique to S. aureus (glcA and SAUSA300_0236) exhibited growth defects. The 
glcA mutant displayed a complete loss of growth on N-acetyl-glucosamine (GlcNAc) and 
a partial loss of growth on mannose, while the SAUSA300_0236 mutant displayed a 
complete loss of growth on N-acetyl-mannosamine (ManNAc). Additionally, not a single 
mutant exhibited a growth defect on glucose. These data suggest that glucose uptake 
by S. aureus is genetically redundant.  
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S. aureus Glucose Uptake Activity is Genetically Redundant.  
 To identify the S. aureus glucose transporters, we screened 15 different S. 
aureus mutants for aerobic growth defects on glucose. In total 4 different genes were 
mutated via allelic replacement (glcA, glcB, glcU, and SAUSA300_0236), and then 
combined into all possible double, triple, and quadruple mutants. The deleted genes 
were chosen based on a combination of sequence similarity to known glucose 
transporters as well as high expression levels during aerobic growth on glucose (data 
not shown). Interestingly, we found that only the quadruple S. aureus mutant 
(∆glcA/∆glcB/∆glcU/∆SAUSA300_0236) exhibited a substantial aerobic growth defect 
on glucose (from this point forward we will refer to the quadruple mutant as S. aureus 
∆G4 and the gene SAUSA300_0236, as glcC) (Figure 3.4A-B) Each potential glucose 
transporter was able to independently complement the aerobic growth defect of the S. 
aureus ∆G4 mutant on glucose (Figure 3.4C).  
 To verify that GlcA, GlcB, GlcC, and GlcU are glucose transporters, we 
performed radiolabeled glucose uptake assays using WT, ∆G4, and ∆G4 S. aureus 
containing plasmids constitutively expressing each of the four glucose transporters. The 
∆G4 mutant exhibited a significant glucose uptake defect compared to WT S. aureus 
(45% of WT)(Figure 3.4D). Complementation of the ∆G4 mutant with glcA, glcB, glcC, 
and glcU increased glucose uptake of the ∆G4 mutant to 98%, 110%, 105%, and 56% 
of WT, respectively. We next examined the growth of the S. aureus ∆G4 mutant on 12 
different carbohydrates (GlcNAc and ManNAc were not tested). We found that growth 
attenuation for S. aureus ∆G4 was fairly specific to glucose (significant max 
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absorbance, lag, and growth rate phenotypes) but, as expected, there was a small, but 
significant, growth rate defect on mannose (Table 3.4). Surprisingly, the S. aureus ∆G4 
mutant also displayed significant growth defects on galactose, although these were also 
very small. Lastly, we examined the glucose-dependent expression of the four identified 
transporters. While glcC transcript levels were lower than the other three alleles, none 
of the glucose transporter encoding genes displayed any evidence of glucose-
dependent expression under aerobic conditions (Figure 3.5).  
 Importantly, the S. aureus ∆G4 mutant exhibits residual growth on glucose and 
residual uptake of glucose. These data indicate the presence of an additional glucose 
transporter(s). To rule out the contribution of other PTS-dependent transporters, we 
compared the aerobic growth of WT, ∆G4, ptsH-H15A/∆glcU, and ptsH-H15A/∆glk S. 
aureus COL. Glk, or glucose kinase, is responsible for phosphorylating intracellular 
glucose taken up by non-PTS transporters. Thus, without Glk, intracellular glucose 
cannot be catabolized. Growth of the S. aureus ∆G4 and the ptsH-H15A/∆glcU mutant 
were indistinguishable, whereas the S. aureus ptsH-H15A/∆glk mutant exhibited no 
residual growth on glucose (Figure 3.6). These data indicate that an additional non-
PTS-dependent transporter(s) is responsible for the remaining glucose uptake observed 
for S. aureus ∆G4.  
 
GlcA and GlcC Contribute Disproportionately to the Non-Respiratory Growth of S. 
aureus on Glucose.  
 Our earlier experiments showed that S. aureus displays enhanced non-
respiratory growth on glucose compared to CoNS. To test whether the identified 
! 98 
glucose transporters contribute to this phenotype, we compared the growth of the 
glucose transporter mutants on this substrate under anaerobic and NO·-exposed 
conditions (Figure 3.7). We found that these glucose transporters are disproportionately 
more important for S. aureus growth on glucose during anaerobiosis and prolonged 
high-level NO· exposure than during aerobic growth. Additionally, we found that the two 
unique S. aureus glucose transporters, GlcA and GlcC, contribute more substantially to 
non-respiratory growth of S. aureus on glucose, than the common glucose transporters. 
Also, glcC expression was significantly induced by low oxygen (Figure 3.8).  
 
Growth of S. aureus in Rich Media is Unaffected by Reduced Glucose Uptake.  
 We hypothesized that the acquisition of additional glucose transporters might 
partially explain the enhanced non-respiratory growth phenotypes for S. aureus 
compared to CoNS both on glucose and in rich media. Thus, we compared the growth 
of WT, ∆G4, and the ptsH-H15A/∆glcU S. aureus (COL and LAC) mutants in TSB under 
aerobic and anaerobic conditions. We observed almost no growth defect for the S. 
aureus ∆G4 mutants aerobically or anaerobically in TSB, suggesting that glucose 
transport is nonessential for growth under nutrient rich conditions, perhaps due to the 
presence/uptake of other carbohydrates (Figure 3.9). In line with this hypothesis, we 
observed an additive effect of the ∆glcU and ptsH-H15A mutations, both under aerobic 
and anaerobic conditions (Figures 3.3 and 3.9). These data indicate that carbon is not a 
limiting factor for S. aureus in TSB, and that uptake of other carbohydrates can 
compensate for a reduction in S. aureus glucose uptake.  
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UhpT is Responsible for the Unique Growth of S. aureus on Hexose-Phosphates. 
 There are many carbohydrates that may compensate for reduced glucose uptake 
by S. aureus in TSB. Specifically, the other hexoses (fructose and mannose) also 
support non-respiratory growth of S. aureus, and many polysaccharides are directly 
catabolized into glucose once inside the cell (e.g. maltose, trehalose, sucrose, and 
lactose). However, another potential source of glucose in rich media is glucose-6-
phosphate (G6P). Interestingly, our bioinformatics analysis revealed that S. aureus is 
predicted to encode a unique hexose-phosphate transporter called UhpT. To confirm 
the role of UhpT, we compared the growth of WT and ∆uhpT S. aureus LAC aerobically 
on a variety of carbohydrates. As predicted, ∆uhpT S. aureus LAC exhibited hexose-
phosphate specific growth defects (Table 3.5). Since CoNS are not predicted to encode 
the uhpT allele, we further examined the aerobic growth of 9 CoNS strains on G6P, 
including 3 S. epidermidis and 2 S. saprophyticus clinical isolates. Only two of the 9 
CoNS strains exhibited growth on G6P (Figure 3.10). These data indicate that UhpT is 
responsible for the unique growth of S. aureus on G6P, and may compensate for the 
reduced importance of glucose uptake by S. aureus in rich media.  
 
Carbohydrate Uptake Contributes to S. aureus Virulence.  
 Prior to conducting any animal work, we wanted to characterize the carbohydrate 
transporter mutants for gross virulence defects in vitro. The ptsH-H15A mutation is 
markerless and thus cannot easily be transduced. So we made and verified three 
independent ptsH-H15A mutants in the LAC background. We then separately 
transduced the ∆glcU mutation into each of these three mutants, and verified that each 
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triplicate (our three ptsH-H15A and three ptsH-H15A/∆glcU strains) grew identical under 
aerobic conditions on glucose, casamino acids, and TSB (data not shown). Next, we 
examined all seven mutants (the ∆G4 mutant, 3x ptsH-H15A mutants, and 3x ptsH-
H15A/∆glcU mutants) for defects in pigment production and hemolysis. All mutants were 
positive for both α and β-hemolysis on blood agar, but the ptsH-H15A/∆glcU mutants 
had an observable pigmentation defect following overnight growth in TSB (Figure 3.11). 
These data suggest that the carbohydrate transporter mutants do not possess any 
obvious secondary mutations that could confound the results of animal experiments.  
 Recently, we demonstrated that glycolysis is essential to S. aureus virulence, but 
did not identify what carbohydrates support this requirement. Given that S. aureus is an 
extracellular pathogen, that glucose is the most abundant free carbohydrate in 
mammalian tissue, and that uncontrolled diabetics (i.e. diabetics exhibited increased 
blood glucose levels) are uniquely susceptible to S. aureus infections, we hypothesized 
that glucose is the primary glycolytic substrate utilized by S. aureus during 
infection(307, 311, 323). To test this hypothesis, we infected C57BL/6 mice 
subcutaneously with 1x107 cfu of WT, ∆G4, ptsH-H15A, ptsH-H15A/∆glcU, and ∆glcU 
S. aureus LAC. Importantly, we used independent strains of the ptsH-H15 and ptsH-
H15A/∆glcU S. aureus mutants for the two rounds of mouse infections. We found that 
the ∆G4 S. aureus mutant was significantly attenuated by abscess burden at day 5 
post-infection (~1-log), while the ptsH-H15A mutant, despite losing function of three of 
the four glucose transporters and all other PTS-carbohydrate transporters, was not 
significantly attenuated compared to WT (Figure 3.12A). Combination of the glcU and 
ptsH-H15A mutations resulted in greater attenuation than ∆G4 S. aureus alone (~2-logs 
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compared to WT). Importantly, this difference was not just due to mutation of the glcU 
allele, as the ∆glcU single mutant was also not significantly attenuated in comparison to 
WT. These data suggest that glucose is the primary carbohydrate utilized by S. aureus 
during skin infections, but that other carbohydrates are also present that can contribute 
to growth/survival of S. aureus in this inflamed environment.  
 At a higher dose (1x108 cfu), the ∆G4 mutant showed a different set of infection 
kinetics (Figure 3.12B). At day 7, abscess burdens for ∆G4 S. aureus infected mice 
were not significantly different than that of WT infected mice. However by day 12, when 
the abscess environment is hypoxic, the ∆G4 S. aureus mutant has either been cleared 
from the skin, or is present in numbers significantly lower than WT S. aureus. 
Remarkably, the ∆G4 S. aureus mutant was also far less destructive, even when 
present in comparable numbers to WT S. aureus, as seen from the inability to produce 
open skin lesions throughout the 12 days of infection (Figure 3.12B-C). These data 
suggest the glucose is not just important for S. aureus growth and/or survival, but 
actually contributes to the generation of clinically relevant S. aureus virulence 
phenotypes during skin and soft tissue infections.  
 
DISCUSSION 
 S. aureus belongs to large group of skin colonizing Staphylococci. Compared to 
these other Staphylococci, S. aureus displays markedly enhanced virulence in humans 
(20). Limited evidence suggests this may be partially explained by metabolic adaptation 
of S. aureus to inflamed tissue spaces. For example, we previously showed that S. 
aureus displays enhanced NO· resistant growth resulting from the acquisition of a 
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unique lactate dehydrogenase encoded by ldh1 (236). In the current manuscript we 
provide additional evidence for the metabolic adaptation of S. aureus to invasive 
infection. Specifically, we demonstrate that enhanced non-respiratory growth of S. 
aureus extends beyond NO· exposure to anaerobic conditions and that carbohydrate 
uptake disproportionately contributes to the growth of S. aureus under anaerobic and 
NO· exposed conditions.  We then show that S. aureus is predicted to encode a larger 
number of carbohydrate transporters than other Staphylococci and that at least two 
unique S. aureus carbohydrate transporters (GlcA and GlcC) contribute 
disproportionately to non-respiratory growth. Finally, we demonstrate that S. aureus 
carbohydrate uptake, especially glucose uptake, contributes to the virulence of this 
pathogen in mice. These data indicate that acquisition of unique carbohydrate 
transporters is another mechanism by which S. aureus has metabolically adapted to 
invasive infection.  
 Previous work has shown that non-respiratory growth of S. aureus under both 
anaerobiosis and NO·-exposed conditions requires glycolysis-based heterolactic acid 
fermentation (236, 324). However, the substrates utilized by S. aureus to support these 
growth requirements in vivo have not been identified. Given the high abundance of 
glucose in serum and the observation that diabetics are uniquely susceptible to S. 
aureus infections, we hypothesized that glucose is the primary carbohydrate utilized by 
S. aureus in inflamed tissue spaces (307, 323). Previous work to identify S. aureus 
glucose transporters using single mutations was unsuccessful (216). By combining 
multiple mutations we discovered that S. aureus encodes at least five glucose 
transporters. We identified three PTS-dependent glucose transporters (GlcA, GlcB, and 
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GlcC) as well as one non-PTS-dependent glucose transporter (GlcU) and showed that 
residual glucose uptake is PTS-independent. Interestingly, the glcA and glcC alleles are 
unique to S. aureus and contribute disproportionately to non-respiratory growth of S. 
aureus in vitro. Furthermore, we found that glcC expression was highly induced in 
response to anaerobiosis. Deletion of all four glucose transporters resulted in 
attenuation of S. aureus during murine infection, whereas a loss of uptake for 10 other 
carbohydrates (ptsH-H15A S. aureus) resulted in no observable attenuation. These data 
support our hypothesis that glucose is the primary glycolytic substrate utilized by S. 
aureus in inflamed tissue spaces.  
 The genetic redundancy of S. aureus glucose transport is further suggestive of 
the importance of glucose to S. aureus virulence. Genetic redundancy is generally 
thought to “buffer phenotypes from genomic variations by reducing the phenotypic cost 
of mutation” (328, 329). The functional outcome of this buffering is rapid divergence of 
function amongst gene pairs (330). Importantly, we did find evidence for divergent 
functions amongst the GlcA, GlcB, GlcC, and GlcU transporters. Specifically, GlcA 
contributes to S. aureus growth on mannose and GlcNAc, while GlcC also contributes to 
S. aureus growth on ManNAc and is differentially regulated than the other transporters. 
However, the glcA, glcB, and glcC alleles do not appear to have arisen from gene 
duplication and there is insufficient data to determine the direction of substrate specific 
evolution of these transporters. Instead, the fact that all four genes encode functional 
glucose transporters in two S. aureus clinical strains isolated 41 years apart suggests 
some degree of maintenance, given that duplicate genes undergo mutation rates 
greater than ten times that of the genome as a whole (330). Additionally, the S. aureus 
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GlcA, GlcB, GlcC, and GlcU transporters contributed to non-respiratory growth in an 
additive manner and expression of glcA, glcB, and glcU is roughly equivalent. Thus, we 
hypothesize a unique mechanism by which genetic redundancy may be maintained in 
bacteria: process enhancement via additive behavior (328, 331). In this case, the low 
respiratory conditions present in inflamed tissue spaces could have selected for 
enhanced S. aureus glycolytic flux via the acquisition of multiple transporters with 
redundant glucose transport activity.  
 While consistent with most of our in vitro and in vivo data, this theory considers 
only metabolic pressures and ignores the established importance of glucose to S. 
aureus virulence factor regulation. Specifically, in vitro glucose induces expression of S. 
aureus biofilm related genes (cidA and icaA) and inhibits expression of a master 
virulence regulator (agr/RNAIII), toxins (hla, sec, and tst), and protein A (spa) (220, 256, 
332-334). Our data suggests that in vivo, reduced S. aureus glucose uptake severely 
limits toxin production, as evidenced by decreased lesion formation. Importantly, this 
observation was independent of S. aureus abscess burden, as the ∆G4 S. aureus strain 
exhibited comparable cfu/abscess to WT bacteria during times of differential lesion 
formation. We did not observe a loss of hemolytic activity for ∆G4 S. aureus grown in 
vitro on blood agar plates, but this experiment is not quantitative. Additionally, we found 
that the S. aureus ptsH-H15A/∆glcU mutant exhibited reduced pigment formation. This 
defect may be explained in two ways: 1) slow growth of the mutant in TSB may delay 
sigB activation of the crtOPQMN operon and/or 2) reduced carbohydrate uptake may 
limit the intracellular availability of glucose, a required substrate for staphyloxanthin 
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production (183, 335). Regardless, our data indicate that carbohydrate uptake may also 
contribute to S. aureus infection via regulation of virulence factor production.  
 To contextualize our in vivo findings, one must also consider that respiration, iron 
acquisition, and the TCA cycle have all been shown to contribute to S. aureus virulence 
(Unpublished Observations) (195, 245, 268). Thus, we cannot accurately state that 
inflamed tissue spaces are strictly non-respiratory. However, it is clear from our work 
that S. aureus displays enhanced non-respiratory growth phenotypes and that 
glycolysis-based fermentation is equally required for infection. These seemingly 
paradoxical findings can be reconciled by considering the temporal and spatial aspects 
of infection. For instance, Y. pseudotuberculosis subpopulations within the outer edge of 
spleen microcolonies protect internal bacterial subpopulations from host NO· exposure 
(336). Furthermore, we have shown that NO· production and oxygen availability are 
temporally regulated during S. aureus abscess development (Unpublished 
Observations) (324). Skin abscess iNOS activity is highest 1-7 days post S. aureus 
injection, but the abscesses do not become hypoxic until days 7-12 (Unpublished 
Observations). These data suggest that S. aureus uses carbohydrate-based 
fermentative metabolism to overcome instances of high NO· exposure encountered 
early during infection and instances of hypoxia later on in infection. The observation that 
the ∆G4 S. aureus mutant (high dose) is largely cleared from the abscess during days 
7-12 suggests that low oxygen may be the primary selective force driving maintenance 
of the multiple S. aureus glucose transporters.  
 Regardless of when or why S. aureus glycolytic and glucose transporter deficient 
mutants are attenuated during infection, the fact that they exhibit any attenuation at all 
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emphasizes the importance of glucose to S. aureus disease. In particular, this 
observation may partially explain the unique susceptibility of uncontrolled diabetics (i.e. 
diabetics exhibiting hyperglycemia, or increased blood glucose levels) to S. aureus 
infections (307). Diabetes is an important risk factor for S. aureus disease, with diabetic 
individuals exhibiting increased incidence and severity of S. aureus SSTI’s, bloodstream 
infections, and endocarditis (88, 306, 337-340). If true, the development of novel S. 
aureus glycolysis inhibitors by Kumar et al. may constitute a particularly effective 
treatment for diabetics with S. aureus infections, one that both limits S. aureus growth 
and reduces its destructive capacity during infection (314).  
  
MATERIALS AND METHODS 
Bacterial Strains and Media 
 All Staphylococci were cultivated in BactoTM Tryptic Soy Broth (TSB, BD: 
211825) or in chemically defined media (CDM), wherein the primary carbon source 
could be modified (316). Individual carbohydrates added to CDM were carbon balanced 
to 25mM glucose for all experiments, except the NO· growth assay (see explanation 
below). Casamino acids were added to the CDM at 0.5%. Chloramphenical was added 
to TSB (Cm10) and CDM (Cm2.5) during growth of plasmid containing strains. All 
strains utilized in this study are listed in Table 3.6. All mutant strains, except the PTS 
insertion mutants, were generated via allelic replacement using the E. coli/S. aureus 
shuttle vectors pBT2ts, pBTK, pBTE, pBTS and the new vector pBTT, as previously 
described (235). pBTT was constructed by amplifying the tetK allele from the S. aureus 
COL plasmid pT181 (tet.3A and tet.3b) and then cloning it into the XmaI site of pBT2ts. 
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The PTS-insertion mutants were ordered from the Nebraska Mutant Transposon Library 
(NARSA) and were verified upon arrival by PCR (215). Plasmids and primers used for 
mutant construction, verification, and complementation are listed in Tables 3.7 and 3.8.  
 
Growth Curves 
 Staphylococcus cultures were grown overnight in TSB at 37°C with shaking at 
250 rpm. For aerobic and NO· curves, overnight cultures were washed twice with PBS 
and diluted into TSB or CDM +/- Carbon to an initial OD660nm = 0.04. Diluted cultures 
were then aliquoted into a 96-well plate (200µl/well) and incubated in a Tecan Infinite 
M200 microplate reader set to 37°C with 1mm orbital shaking. Growth was monitored 
via absorbance at 650nm every 15 minutes for 24hrs. For NO· curves, 10mM NOC-12 
(Santa Cruz Biotechnology, 202246) and 1mM DEA NONOate (A.G. Scientific, D-1013) 
were added to the cultures at an OD650nm = 0.15. To extend the fermentative phase of S. 
aureus NO· resistant growth, an additional, identical, dose of NO· donors was added to 
each well 1.5 hours later. To ensure continued substrate availability during such 
prolonged NO· exposure (S. aureus utilizes carbon inefficiently during NO· induced 
fermentation) we used 50mM glucose for these experiments. For anaerobic growth 
curves, the overnight cultures were washed twice with PBS and diluted into 5mls of 
prewarmed (37°C) TSB or CDM +/- Carbon +/- 50mM Potassium Nitrate to an OD660nm 
= 0.08. Cultures were prepared in duplicate in 16x150mm glass tubes containing 1mm 
stir bars. Following dilution, cultures were immediately transferred into a COY anaerobic 
chamber and grown at 37°C with stirring. Growth was monitored hourly via absorbance 
readings at 650nm. 
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Growth Rate and Lag Analysis 
 Growth rates were calculated using the following formula: µ = 
∆ln(Abs650nm)/∆time(hrs). The time intervals used for growth rate analysis are 
experiment specific, and thus provided in the figure legends. Lag time was calculated as 
the time (hrs) until cultures reached an OD650nm = 0.2.  
 
Bioinformatics analysis of Carbohydrate Transporters 
 We searched the NCBI and UniProt gene/protein databases for S. aureus COL, 
S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. saprophyticus ATCC 15305 
for predicted carbohydrate transporters using search terms such as PTS, sugar 
transporter, carbohydrate transporter, etc.. We then used these results to perform 
BLASTP searches against each of the genomes to identify any transporters that were 
not annotated (i.e. missed in the original search). Once a list of putative carbohydrate 
transporters was identified for each Staphylococcus species, we performed BLASTP 
searches against the transporter classification database (TCDB) for each transporter 
candidate to screen for misannotation. Next, we performed forward and reciprocal 
BLASTP searches for each predicted protein against all four Staphylococcus genomes. 
Additionally, we used the ortholog predictor function provided through xBASE 
(http://www.xbase.ac.uk/) and visually inspected/compared the genomic context of each 
gene using MetaCyc (http://metacyc.org/).   
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Real Time Quantitative Reverse Transcriptase PCR. 
 S. aureus COL was grown in 50mls of CDM + Glucose (25mM) or Casamino 
Acids (0.5%) in 250ml flasks at 37°C with shaking at 250rpm. At an OD660 = 0.5, 25mls 
of each culture was added to an equal volume of ice-cold ethanol/acetone (1:1) and 
frozen at -80°C (aerobic cultures). To assess gene expression during NO· exposure, a 
separate set of cultures (CDM + Glucose) was treated with 5mM DETA-NONOate 
(Cayman Chemical, 82120) for 1 hour, then quenched and frozen. Lastly, S. aureus 
COL was grown in 50mls of CDM + Glucose in the anaerobic chamber at 37°C with 
stirring. At OD660 = 0.5, 25mls of culture was removed from the chamber in a 50ml 
conical devoid of oxygen, and then immediately quenched and frozen. RNA was then 
harvested and gene expression analyzed as previously described (282). Transcript 
levels of select genes were normalized to rpoD transcript levels, which deviated very 
little across our experimental conditions. Primers used for qRT-PCR analysis are listed 
in Table 3.7. 
 
Radiolabeled Glucose Uptake Assays 
 S. aureus COL strains were grown in TSB in 50-ml culture volumes to late 
exponential phase (OD660 1-1.2). Cells were centrifuged for 10-min at 5,000-g and then 
immediately resuspended to an OD660 20 in warm PN (37°C). At t0, a mixture of glucose 
and 14C-glucose was added to a 1-ml aliquot of each culture to reach a final 
concentration of 2mM glucose and 100µM 14C-glucose. Cells were incubated in a 37° 
heat block. At 12-min following glucose addition, 150µl of culture was removed and 
immediately diluted into 900µl of PN containing 20mM unlabeled glucose. The diluted 
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cells were pelleted, washed once with 500µl PN (20mM glucose), and then 
resuspended in 150µl PN (20mM glucose). The resuspended cells were added to a 
scintillation vial containing 4-ml EcoScint A scintillation fluid (National Diagnostics). To 
determine the level of radioactivity in each sample, a Beckman LS6500 Multi-Purpose 
Scintillation Counter was used to measure counts per minute (cpm).  
 
Hemolysis Assays 
 To detect hemolysis activity, S. aureus LAC strains (WT, ∆G4, ptsH-H15A #1-3, 
and ptsH-H15A/∆glcU #1-3) were streaked onto blood Agar (Remel, TSA w/ sheep 
blood, R01200) from freezer stocks and incubated at 37°C for 36hrs. Plates were 
subsequently incubated at 4°C for 12hrs and then imaged using a digital microscope.  
 
Virulence Assays.  
 For virulence assessment, 6-8 week old female C57BL/6 mice from Jackson 
Labs (Bar Harbor, ME USA) were anesthetized with avertin (0.08 mg/kg, ACROS 
Organics, 421430100) shaved (on flank), and injected subcutaneously (on flank) with 1 
x 107 CFU of WT, ∆G4, ∆glcU, ptsH-H15A (# 1-2), and ptsH-H15A/∆glcU (#1-2) S. 
aureus LAC in 20 µls of sterile PBS. On day 5, mice were euthanized and the 
abscesses were removed, homogenized in 500 µl of PBS, and dilution plated on TSA to 
enumerate CFU. Additionally, WT (positive control), ptsH-H15A, and ptsH-H15A/∆glcU 
abscesses were plated on CDM Agar + Sucrose in order to screen for reversion of the 
mutants during infection. 
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Figure 3.1. S. aureus Displays Enhanced Anaerobic Growth Compared to CoNS. Anaerobic growth of S. 
aureus (SA) strains COL and LAC, S. epidermidis (SE) RP62A, S. haemolyticus (SH) ATCC 29970, and 
S. saprophyticus (SS) ATCC 15305 in  (A) TSB and  (C) CDM + Glucose (25mM). Corresponding 
average growth rates for TSB and CDM + Glucose are displayed in panels  (B) and  (D), respectively (n = 
3, error bars = pooled SEM). Growth rates were calculated from 2-4 hrs (SA LAC) and 3-5 hrs (SA COL, 
SE, SH, and SS) in TSB, and from 2-8 hrs in CDM + Glucose (25mM). Significance was calculated using 
a Student's two-sided t-test (***, p-value ≤ .001) 
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Figure 1. S. aureus displays enhanced anaerobic growth compared to CoNS. Anaerobic growth of S. aureus (SA) strains COL and 
LAC, S. epidermidis (SE) RP62A, S. haemolyticus (SH) ATCC 29970, and S. saprophyticus (SS) ATCC 15305 in (A) TSB and (C) CDM 
+ Glucose (25mM). Corresponding average growth rates for B and CDM + Glucose are displayed in panels (B) and (D), respectively 
(n = 3, error bars = pooled SEM). Growth rates were calculated from 2-4 hrs (SA LAC) and 3-5 hrs (SA COL, SE, SH, and SS) in TSB, 
and from 2-8 hrs in CDM + Glucose (25mM). Significance was calculated using a Student's two-sided t-test (***, p-value ≤ .001)
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Figure 3.2. Carbohydrate Transport Protein Conservation Amongst the Staphylococci. Venn diagram 
depicting the presence and conservation of putative carbohydrate transport proteins in the genomes of S. 
aureus COL, S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. saprophyticus ATCC 15305.
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Figure 3.3. PTS-Dependent Carbohydrate Uptake Contributes Disproportionately to the Anaerobic 
Growth of S. aureus. Growth of WT and PTS-deficient (ptsH-H15A) S. aureus COL in TSB under (A) aerobic 
and (C) anaerobic conditions (n = 3, error bars = SEM and pooled SEM, respectively).  Average maximum 
growth rates of S. aureus COL and LAC in TSB under (B) aerobic  and (D) anaerobic conditions (n = 3, error 
bars = SEM and pooled SEM, respectively). The growth rate of for PTS-deficient strains is further included in 
the bars as a % value. Significance was calculated using a Student's two-sided t-test (*, p-value ≤ 0.05; **, p-
value ≤ 0.01; ***, p-value ≤ 0.001). 
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Figure 3.4. Identification and Characterization of Four S. aureus Glucose Transporters. Aerobic growth 
of WT and select double, triple, and quadruple S. aureus COL glucose transporter mutants in CDM +/- glucose 
(25mM) with (B) corresponding aerobic growth rates (n = 3, error bars = SEM). (C) Complementation of ∆G4 
S. aureus COL growth in CDM + glucose (25mM) by each individual glucose transporter (n = 1). (D) % 14C-U 
glucose uptake by ∆G4, and ∆G4 complemented S. aureus COL. Uptake of each strain was measured 
following 12min. incubation with radiolabeled substrate, then normalized to WT  (n = 4, error bars = SEM).  
Significance was calculated using a Student's two-sided t-test (*, p-value ≤ 0.05; **, p-value ≤ 0.01; ***, p-value 
≤ 0.001). An asterisk directly above a column indicates significance from WT, while an asterisk above a bar 
indicates significance between mutants. 
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Figure 3.5 Glucose-Dependent Expression of Four S. aureus Glucose Transporters During Aerobic 
Growth. q-RT analysis of glcA, glcB, glcC, and glcU transcript levels under aerobic conditions in CDM + 
Glucose (25mM) or Casamino acids (0.5%). Transcript levels for all genes were normalized to rpoD. (n=3, 
error bars = SEM).  
 
 
 
Figure 3.6. Residual Aerobic Growth of the ΔG4 S. aureus Mutant on Glucose is PTS-Independent. 
Aerobic growth of WT, ΔG4, ptsH-H15A/ΔglcU, and ptsH-H15A/glk::Tn S. aureus LAC in CDM without 
added carbon or with Glucose (25mM) (n = 1). 
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Figure 3.7. Contribution of the Identified Glucose Transporters to the Non-Respiratory Growth of S. 
aureus on Glucose. Anaerobic growth (A) and growth rates (B) of WT and select double, triple, and 
quadruple S. aureus COL glucose transporter mutant in CDM + Glucose (25mM) (n = 3, error bars = pooled 
SEM). NO· exposed growth (C) and growth rates (D) of WT and select double, triple, and quadruple S. aureus 
COL glucose transporter mutant in CDM + Glucose (50mM) (n = 3, error bars = pooled SEM). Significance 
was calculated using a Student's two-sided t-test (**, p-value ≤ 0.01; ***, p-value ≤ 0.001). 
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Figure 3.8. Anaerobic and NO·-Dependent Expression of the S. aureus Glucose Transporters. q-RT 
PCR analysis of glcA, glcB, glcC, and glcU in S. aureus COL grown to mid-log in CDM + Glucose (25mM) 
under aerobic, anaerobic, and NO· exposed (10mM DETA-NONOate for 1hr) conditions. All transcript levels 
were normalized to rpoD (n = 3 for aerobic and anaerobic conditions, n = 2 for NO· treated cells, error bars = 
SEM). Significance was calculated using a Student's two-sided t-test (*, p-value ≤ 0.05). 
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Figure 3.9. Aerobic and Anaerobic Growth of S. aureus ∆G4 and ptsH-H15A/∆glcU in rich media. (A) 
Aerobic growth of WT, ∆G4, and ptsH-H15A/∆glcU S. aureus COL in TSB (n = 3, error bars = SEM). (B) 
Average maximum aerobic growth rates for WT, ∆G4, and ptsH-H15A/∆glcU S. aureus COL and LAC in TSB 
(n = 3, error bars = SEM). (C) Anaerobic growth of WT, ∆G4, and ptsH-H15A/∆glcU S. aureus COL in TSB (n = 
3, error bars = SEM). (D) Average anaerobic growth rate of WT, ∆G4, and ptsH-H15A/∆glcU S. aureus COL 
and LAC in TSB. Growth rates were calculated from 3-5 hrs for COL and 2-4 hrs for LAC (n = 3, error bars = 
SEM). Significance was calculated using a Student's two-sided t-test (*, p-value ≤ 0.05; ***, p-value ≤ 0.001). 
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Figure 3.10. UhpT Allows for the Unique Growth of S. aureus on Glucose-6-
Phosphate. (A) Aerobic growth of WT and ∆uhpT S. aureus COL in CDM +/- 
G6P (25mM) (n = 3, error bars = SEM). Aerobic growth of S. epidermididis (SE), 
S. haemolyticus (SH), and S. saprophyticus (SS) laboratory and clinical strains in 
(B) CDM + Glucose (25mM) and (C) CDM + G6P (25mM) (n = 2, error bars = 
SEM). 
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Figure 3.11. Hemolysis and Pigmentation of the S. aureus Carbohydrate Transporter Mutants. (A) α-hemolysis (B) β-hemolysis 
and (C) pigmentation of the S. aureus LAC carbohydrate transporter mutants. For the ptsH-H15A and ptsH-H15A/∆glcU mutants, the 
numbering indicates independent isolates.  
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Figure 3.12.  S. aureus Glucose Transporter Mutants are Attenuated for 
Virulence in a Murine SSTI Model. (A) Abscess burden on day 5 following 
subcutaneous injection of 1x107 cfu of S. aureus LAC (5 ≤ n ≤ 17, error bars 
= SEM). (B) Abscess burden and (C) lesion size following subcutaneous 
injection of 1x108 cfu of S. aureus LAC (5 ≤ n ≤ 10, error bars = SEM). 
Statistical significance was determined using a Student's two-sided t-test (*, 
p-value = 0.05; ***, p-value = 0.001).
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Table 3.1. Conservation of Predicted Staphylococcus Carbohydrate Transport Proteins. 
S.#epidermidis S.#haemolyticus S.#saprophyticus
USA300 COL RP62A JCSC1435 ATCC#15305
SAUSA300_0191 glcA,*ptsG 4.A.1.1 PTS0Glc Glucose SAUSA300_0191 SACOL0175
SAUSA300_0194 4.A.1.2 PTS0Glc SAUSA300_0194 SACOL0178 SERP1900 SH0741 SSP0594
SAUSA300_0208 malK 3.A.1.1 CUT1 Maltose SAUSA300_0208 SACOL0192
SAUSA300_0216 uhpT 2.A.1.4.1 OPA Hexose0P SAUSA300_0216 SACOL0200
SAUSA300_0236 glcC* 4.A.1.1 PTS0Glc SAUSA300_0236 SACOL0224
SAUSA300_0239 4.A.5.1 PTS0Gat SAUSA300_0239 SACOL0229
SAUSA300_0240 4.A.5.1 PTS0Gat SAUSA300_0240 SACOL0230
SAUSA300_0241 4.A.5.1 PTS0Gat SAUSA300_0241 SACOL0232
SAUSA300_0259 4.A.1.1 PTS0Glc SAUSA300_0259 SACOL0250
SAUSA300_0264 rbsU 2.A.7.5.2 GRP Ribose SAUSA300_0264 SACOL0255 SERP2102
SAUSA300_0314 nanT 2.A.21.3 SSS Sialic*Acid SAUSA300_0314 SACOL0311 SH0283 SSP0376
SAUSA300_0330 4.A.7.1 PTS0Asc SAUSA300_0330 SACOL0400
SAUSA300_0332 4.A.7.1 PTS0Asc SAUSA300_0332 SACOL0402
SAUSA300_0337 glpT 2.A.1.4.3 MFS Glycerol030P SAUSA300_0337 SACOL0407 SERP2060
SAUSA300_0448 4.A.1.2 PTS0Glu Fructose SAUSA300_0448 SACOL0516 SH2538 SSP2282
SAUSA300_0685 fruA 4.A.2.1 PTS0Fru SAUSA300_0685 SERP0359 SH2194 SSP2017
SAUSA300_1191 glpF 1.A.8.2 MIP Glycerol SAUSA300_1191 SACOL1319 SERP0866 SH1614 SSP1461
SAUSA300_1315 crr 4.A.1.1 PTS0Glc SAUSA300_1315 SACOL1457 SERP0998 SH1484 SSP1317
SAUSA300_1672 4.A.1.1 PTS0Glc SAUSA300_1672 SACOL1775 SERP1290 SH1198 SSP1037
SAUSA300_2105 mtlA 4.A.2.1 PTS0Fru Mannitol SAUSA300_2105 SACOL2146 SH0235 SSP0728
SAUSA300_2107 mtlF 4.A.2.1 PTS0Fru Mannitol SAUSA300_2107 SACOL2148 SH0233 SSP0726
SAUSA300_2150 lacE 4.A.3.1 PTS0Lac Lactose SAUSA300_2150 SACOL2181 SERP1790 SH0847
SAUSA300_2151 lacF 4.A.3.1 PTS0Lac Lactose SAUSA300_2151 SACOL2182 SERP1791 SH0846
SAUSA300_2210 glcU 2.A.7.5.1 GRP Glucose SAUSA300_2210 SACOL2246 SERP1838 SH0796 SSP0657
SAUSA300_2270 4.A.1.1 PTS0Glc SAUSA300_2270 SACOL2316 SERP1909 SH0732 SSP0583
SAUSA300_2324 4.A.1.2 PTS0Glc Sucrose SAUSA300_2324 SACOL2376 SERP1968 SH0671 SSP0512
SAUSA300_2449 2.A.1.14 ACS Glucarate SAUSA300_2449 SACOL2521 SERP2069 SH0566 SSP0401
SAUSA300_2476 glcB 4.A.1.1 PTS0Glc Glucose SAUSA300_2476 SACOL2552 SERP2114 SH0521 SSP0336
SAUSA300_2576 4.A.2.1 PTS0Fru SAUSA300_2576 SACOL2663 SERP2260
SERP0025 2.A.1.1 SP SERP0025
SERP0359 fruA 4.A.2.1 PTS0Fru SAUSA300_0685 SERP0359 SH2194 SSP2017
SERP0866 glpF 1.A.8.2 MIP Glycerol SAUSA300_1191 SACOL1319 SERP0866 SH1614 SSP1461
SERP0998 crr 4.A.1.1 PTS0Glc SAUSA300_1315 SACOL1457 SERP0998 SH1484 SSP1317
SERP1290 4.A.1.1 PTS0Glc SAUSA300_1672 SACOL1775 SERP1290 SH1198 SSP1037
SERP1790 lacE 4.A.3.1 PTS0Lac Lactose SAUSA300_2150 SACOL2181 SERP1790 SH0847
SERP1791 lacF 4.A.3.1 PTS0Lac Lactose SAUSA300_2151 SACOL2182 SERP1791 SH0846
SERP1838 glcU 2.A.7.5.1 GRP Glucose SAUSA300_2210 SACOL2246 SERP1838 SH0796 SSP0657
SERP1900 4.A.1.2 PTS0Glc SAUSA300_0194 SACOL0178 SERP1900 SH0741 SSP0594
SERP1909 4.A.1.1 PTS0Glc SAUSA300_2270 SACOL2316 SERP1909 SH0732 SSP0583
SERP1968 4.A.1.2 PTS0Glc Sucrose SAUSA300_2324 SACOL2376 SERP1968 SH0671 SSP0512
SERP2060 glpT 2.A.1.4.3 MFS Glycerol030P SAUSA300_0337 SACOL0407 SERP2060
SERP2069 2.A.1.14 ACS Glucarate SAUSA300_2449 SACOL2521 SERP2069 SH0566 SSP0401
SERP2102 rbsU 2.A.7.5.2 GRP Ribose SAUSA300_0264 SACOL0255 SERP2102
SERP2114 glcB 4.A.1.1 PTS0Glc Glucose SAUSA300_2476 SACOL2552 SERP2114 SH0521 SSP0336
SERP2260 4.A.2.1 PTS0Fru SAUSA300_2576 SACOL2663 SERP2260
Organism Locus Gene#Name TC## Substrate(s)
S.#aureus
S.*aureus*(29)
S.*epidermidis*
(16)
Family
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Table 3.1. Continued… 
 
*"glcC"was"given"this"gene"name"in"the"current"manuscript"
 
S.#epidermidis S.#haemolyticus S.#saprophyticus
USA300 COL RP62A JCSC1435 ATCC#15305
SH0071 2.A.1.1 SP SH0071 SSP0532
SH0188 4.A.3.2 PTS/LAC SH0188 SSP0240
SH0189 4.A.3.2 PTS/LAC SH0189 SSP0238
SH0233 mtlF 4.A.2.1 PTS/Fru Mannitol SAUSA300_2107 SACOL2148 SH0233 SSP0726
SH0235 mtlA 4.A.2.1 PTS/Fru Mannitol SAUSA300_2105 SACOL2146 SH0235 SSP0728
SH0283 nanT 2.A.21.3 SSS SialicBAcidB(ref) SAUSA300_0314 SACOL0311 SH0283 SSP0376
SH0358 4.A.1.1 PTS/Glc Glucose SH0358
SH0521 glcB 4.A.1.1 PTS/Glc Glucose SAUSA300_2476 SACOL2552 SERP2114 SH0521 SSP0336
SH0566 2.A.1.14 ACS Glucarate SAUSA300_2449 SACOL2521 SERP2069 SH0566 SSP0401
SH0671 4.A.1.2 PTS/Glc Sucrose SAUSA300_2324 SACOL2376 SERP1968 SH0671 SSP0512
SH0732 4.A.1.1 PTS/Glc SAUSA300_2270 SACOL2316 SERP1909 SH0732 SSP0583
SH0741 4.A.1.2 PTS/Glc SAUSA300_0194 SACOL0178 SERP1900 SH0741 SSP0594
SH0796 glcU 2.A.7.5.1 GRP Glucose SAUSA300_2210 SACOL2246 SERP1838 SH0796 SSP0657
SH0846 lacF 4.A.3.1 PTS/Lac Lactose SAUSA300_2151 SACOL2182 SERP1791 SH0846
SH0847 lacE 4.A.3.1 PTS/Lac Lactose SAUSA300_2150 SACOL2181 SERP1790 SH0847
SH1198 4.A.1.1 PTS/Glc SAUSA300_1672 SACOL1775 SERP1290 SH1198 SSP1037
SH1484 crr 4.A.1.1 PTS/Glc SAUSA300_1315 SACOL1457 SERP0998 SH1484 SSP1317
SH1614 glpF 1.A.8.2 MIP Glycerol SAUSA300_1191 SACOL1319 SERP0866 SH1614 SSP1461
SH2194 4.A.2.1 PTS/Fru SAUSA300_0685 SERP0359 SH2194 SSP2017
SH2538 4.A.1.2 PTS/Glu FructoseB(ref) SAUSA300_0448 SACOL0516 SH2538 SSP2282
SSP0123 4.A.1.2 PTS/Glc SSP0123
SSP0124 4.A.1.2 PTS/Glc SSP0124
SSP0234* 4.A.1.1 PTS/Glc Glucose SSP0234*
SSP0238 4.A.3.2 PTS/LAC SH0189 SSP0238
SSP0240 4.A.3.2 PTS/LAC SH0188 SSP0240
SSP0241 4.A.3.2 PTS/LAC SSP0241
SSP0336 glcB 4.A.1.1 PTS/Glc Glucose SAUSA300_2476 SACOL2552 SERP2114 SH0521 SSP0336
SSP0376 nanT 2.A.21.3 SSS SialicBAcidB(ref) SAUSA300_0314 SACOL0311 SH0283 SSP0376
SSP0401 2.A.1.14 ACS Glucarate SAUSA300_2449 SACOL2521 SERP2069 SH0566 SSP0401
SSP0512 4.A.1.2 PTS/Glc Sucrose SAUSA300_2324 SACOL2376 SERP1968 SH0671 SSP0512
SSP0532 2.A.1.1 SP Unknown SH0071 SSP0532
SSP0583 4.A.1.1 PTS/Glc SAUSA300_2270 SACOL2316 SERP1909 SH0732 SSP0583
SSP0594 4.A.1.2 PTS/Glc SAUSA300_0194 SACOL0178 SERP1900 SH0741 SSP0594
SSP0657 glcU 2.A.7.5.1 GRP Glucose SAUSA300_2210 SACOL2246 SERP1838 SH0796 SSP0657
SSP0726 mtlF 4.A.2.1 PTS/Fru Mannitol SAUSA300_2107 SACOL2148 SH0233 SSP0726
SSP0728 mtlA 4.A.2.1 PTS/Fru Mannitol SAUSA300_2105 SACOL2146 SH0235 SSP0728
SSP1037 4.A.1.1 PTS/Glc SAUSA300_1672 SACOL1775 SERP1290 SH1198 SSP1037
SSP1317 crr 4.A.1.1 PTS/Glc SAUSA300_1315 SACOL1457 SERP0998 SH1484 SSP1317
SSP1461 glpF 1.A.8.2 MIP Glycerol SAUSA300_1191 SACOL1319 SERP0866 SH1614 SSP1461
SSP2017 fruA 4.A.2.1 PTS/Fru SAUSA300_0685 SERP0359 SH2194 SSP2017
SSP2282 4.A.1.2 PTS/Glu FructoseB(ref) SAUSA300_0448 SACOL0516 SH2538 SSP2282
S.#aureus
S.BhaemolyticusB
(20)
S.BsaprophyticusB
(21)
Organism Locus Gene#Name TC## Family Substrate(s)
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Table 3.2. PTS-Dependent Growth of S. aureus on Select Carbohydrates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT ptsH'H15A WT ptsH'H15A
Glucose +++ ++ +++ ++
Mannose +++ +++
Fructose + +++
Galactose + +
Ascorbate
Mannitol +++ +++
Sorbitol
GlcNAc ++ ++
ManNAc + +
Ribose ++ ++ + ++
Maltose +++ +++
Sucrose +++ +++
Trehalose ++ ++
Lactose ++ ++
Turanose + +
Maltotriose +++ + +++ ++
Sugar COL LAC
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Table 3.3. Contribution of Individual PTS Proteins to S. aureus Growth on Select Carbohydrates. 
Glucose Mannose Fructose Galactose Mannitol GlcNAc ManNAc Maltose Sucrose Trehalose Lactose Maltotriose
None N/A
0191 glcA,+ptsG ABC PTS2Glc PL* CL*
0194 BC PTS2Glc
0236 glcC** BC PTS2Glc CL*
0239 A PTS2Gat
0240 B PTS2Gat
0241 C PTS2Gat
0259 A PTS2Glc
0332 C PTS2Asc
0448 BC PTS2Glc CL* PL*
1315 ABC PTS2Fru PL*
1672 BC PTS2Glc
2105 mtlA BC PTS2Fru CL*
2107 mtlF A PTS2Fru CL*
2150 lacE BC PTS2Lac CL* CL*
2151 lacF A PTS2Lac CL CL
2270 BC PTS2Glc PL* PL*
2324 BC PTS2Glc PL*
2476 glcB ABC PTS2Glc
2576 ABC PTS2Fru PL
PL+=+partial+loss+of+growth
CL+=+complete+loss+of+growth
*+=+phenotype+was+confirmed+with+S.+aureus+COL+transductant
**+=+glcC+was+given+this+gene+name+in+the+current+manuscript
Gene5NameSAUSA3005Tn5
Insertion5Locus
CarbohydrateSubunit(s) Family
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Table 3.4. Sugar-Specific Growth Characteristics of S. aureus COL ∆G4. 
 
 
Table 3.5. Sugar-Specific Growth Characteristics of S. aureus COL ∆uhpT 
 
WT ∆G4 WT ∆G4 WT ∆G4
! 0.24 0.25 N/A N/A 0.28 0.32*
Glucose 1.07 0.63* 9.05 12.61* 0.72 0.44*
G6P 1.10 1.08 8.36 8.75 0.73 0.73
Fructose 0.52 0.46* 14.64 17.26* 0.34 0.42
F6P 1.08 1.07 10.57 11.00 0.65 0.64
Mannose 0.96 1.01 13.66 12.78 0.30 0.43*
Mannitol 1.03 1.06* 9.78 10.27 0.62 0.61
Galactose 0.51 0.42* 16.88 18.24* 0.29 0.26*
Maltose 1.14 1.24* 9.05 9.56 0.65 0.66
Sucrose 1.21 1.25* 10.05 10.63 0.57 0.60
Lactose 1.01 1.04 12.63 12.99 0.54 0.62
Turanose 0.26 0.24 N/A N/A 0.28 0.22
Trehalose 1.18 1.11 13.20 13.99 0.44 0.50
CasaminoFAcids 0.97 0.98 9.44 9.62 0.67 0.69
*FindicatesFsignificantlyFdifferentFthanFWTFusingFaFstudent'sFtwo!sidedFt!testF(p!valueF≤F0.05)
Carbon Max.Abs.(650nm) Lag.(hrs) Max.µ
WT ∆uhpT WT ∆uhpT WT ∆uhpT
! 0.24 0.24 N/A N/A 0.28 0.31*
Glucose 1.07 1.05 9.05 8.21 0.72 0.66
G6P 1.10 0.27* 8.36 N/A 0.73 0.49*
Fructose 0.52 0.5331 14.64 13.50 0.34 0.37*
F6P 1.08 0.22* 10.57 N/A 0.65 0.31*
Mannose 0.96 1.08 13.66 12.18 0.30 0.31
Mannitol 1.03 1.0249 9.78 8.90 0.62 0.62
Galactose 0.51 0.54 16.88 15.69 0.29 0.27
Maltose 1.14 1.123 9.05 8.32 0.65 0.62
Sucrose 1.21 1.20 10.05 9.24 0.57 0.57
Lactose 1.01 1.00 12.63 11.90 0.54 0.57
Turanose 0.26 0.26 N/A N/A 0.28 0.25
Trehalose 1.18 1.27 13.20 11.75 0.44 0.47
CasaminoFAcids 0.97 0.97 9.44 8.75 0.67 0.67
*FindicatesFsignificantlyFdifferentFthanFWTFusingFaFstudent'sFtwo!sidedFt!testF(p!valueF≤F0.05)
Lag'(hrs) Max'µCarbon Max'Abs'(650nm)
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Table 3.6. Strains  
Strain' Genotype' Reference/Source'
S.#aureus#COL$ Methicillin$resistant$S.#aureus$clinical$isolate,$widely$used$as$a$laboratory$strain$ W.$Shafer$
AR1315$ WT$S.#aureus#COL$+$pOS1Cplgt$plasmid$ This$Study$
AR1268$ S.#aureus$COL$∆glcA::KnR# This$Study$
AR1267$ S.#aureus$COL$∆glcB::ErR# This$Study$
AR1269$ S.#aureus$COL$∆glcC::SpR# This$Study$
AR1270$ S.#aureus#COL#∆glcU::ErR# This$Study$
AR1275$ S.#aureus$COL$∆glcA::KnR$(Φ80),$∆glcB::ErR# This$Study$
AR1277$ S.#aureus#COL$∆glcA::KnR$(Φ80),$∆glcC::SpR# This$Study$
AR1278$ S.#aureus#COL$∆glcA::KnR,$∆glcU::ErR$(Φ80)# This$Study$
AR1276$ S.#aureus$COL$∆glcB::ErR$(Φ80),$∆glcC::SpR# This$Study$
AR1279$ S.#aureus#COL$∆glcC::SpR,$∆glcU::ErR$(Φ80)$ This$Study$
AR1280$ S.#aureus$COL$∆glcA::KnR$(Φ80),$∆glcB::ErR$(Φ80),$∆glcC::SpR# This$Study$
AR1281$ S.#aureus$COL$∆glcA::KnR$(Φ80),$∆glcB::ErR,$∆glcU::ErR# This$Study$
AR1283$ S.#aureus#COL#∆glcA::KnR$(Φ80),$∆glcC::SpR,$∆glcU::ErR$(Φ80)# This$Study$
AR1282$ S.#aureus#COL$∆glcB::ErR$(Φ80),$∆glcC::SpR,$∆glcU::ErR# This$Study$
AR1284$ S.#aureus$COL$∆G4:$∆glcA::Kn
R$(Φ80),$∆glcB::ErR$(Φ80),$
∆glcC::SpR,$∆glcU::ErR)# This$Study$
AR1501$ S.#aureus$∆G4$+$pMG027# This$Study$
AR1502$ S.#aureus$∆G4$+$pMG028# This$Study$
AR1503$ S.#aureus$∆G4$+$pMG029# This$Study$
AR1504$ S.#aureus$∆G4$+$pMG030# This$Study$
AR1316$ S.#aureus$COL$ptsHCH15A$ This$Study$
AR1328$ S.#aureus$COL$COL0175::Tn$(Φ11$NE172)# This$Study$
AR1329$ S.#aureus$COL$COL0178::Tn$(Φ11$NE112)# This$Study$
AR1330$ S.#aureus$COL$COL0224::Tn$(Φ11$NE450)# This$Study$
AR1331$ S.#aureus$COL$COL0229::Tn$(Φ11$NE1421)# This$Study$
AR1332$ S.#aureus$COL$COL0230::Tn$(Φ11$NE1620)$ This$Study$
AR1333$ S.#aureus$COL$COL0250::Tn$(Φ11$NE1584)# This$Study$
AR1334$ S.#aureus$COL$COL0516::Tn$(Φ11$NE1490)# This$Study$
AR1335$ S.#aureus$COL$COL1457::Tn$(Φ11$NE1944)# This$Study$
AR1336$ S.#aureus$COL$COL1775::Tn$(Φ11$NE1457)# This$Study$
AR1337$ S.#aureus$COL$COL1917::Tn$(Φ11$NE634)# This$Study$
AR1338$ S.#aureus$COL$COL2146::Tn$(Φ11$NE929)# This$Study$
AR1339$ S.#aureus$COL$COL2148::Tn$(Φ11$NE1737)# This$Study$
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AR1340$ S.#aureus$COL$COL2182::Tn$(Φ11$NE61)# This$Study$
AR1341$ S.#aureus$COL$COL2316::Tn$(Φ11$NE648)# This$Study$
AR1342$ S.#aureus#COL$COL2376::Tn$(Φ11$NE767)# This$Study$
AR1343$ S.#aureus#COL$COL2552::Tn$(Φ11$NE39)# This$Study$
S.#aureus$LAC$ Methicillin$resistant$S.#aureus$clinical$isolate,$widely$used$as$a$laboratory$strain$ This$Study$
AR1432$ S.#aureus#LAC$∆glcU::TcR$(Φ11)# This$Study$
AR1297$ S.#aureus$LAC$∆G4:$∆glcA::Kn
R$(Φ11),$∆glcB::ErR$(Φ11),$
∆glcC::SpR$(Φ11),$∆glcU::TcR$(Φ11)# This$Study$
AR1318$ S.#aureus#LAC$ptsHCH15AC1$ This$Study$
AR1319$ S.#aureus#LAC$ptsHCH15AC2$ This$Study$
AR1320$ S.#aureus#LAC$ptsHCH15AC3$ This$Study$
AR1321$ S.#aureus#LAC$ptsHCH15AC1,$glk::Tn$(Φ11$NE759)# This$Study$
AR1323$ S.#aureus#LAC$ptsHCH15AC1,$∆glcU::TcR$(Φ11)$ This$Study$
AR1325$ S.#aureus#LAC$ptsHCH15AC2,$∆glcU::TcR$(Φ11)$ This$Study$
AR1326$ S.#aureus#LAC$ptsHCH15AC3,$∆glcU::TcR$(Φ11)$ This$Study$
S.#aureus$JE2# Methicillin$resistant$S.#aureus#laboratory$strain$ $(215)$
NE39$ SAUSA300_2476::Tn$ $(215)$
NE61$ SAUSA300_2150::Tn$ $(215)$
NE112$ SAUSA300_0194::Tn$ $(215)$
NE172$ SAUSA300_0191::Tn$ $(215)$
NE450$ SAUSA300_0236::Tn$ $(215)$
NE634$ SAUSA300_1809::Tn$ $(215)$
NE648$ SAUSA300_2270::Tn$ $(215)$
NE767$ SAUSA300_2324::Tn$ $(215)$
NE929$ SAUSA300_2105::Tn$ $(215)$
NE992$ SAUSA300_0241::Tn$ $(215)$
NE1282$ SAUSA300_0332::Tn$ $(215)$
NE1290$ SAUSA300_2576::Tn$ $(215)$
NE1421$ SAUSA300_0239::Tn$ $(215)$
NE1457$ SAUSA300_1672::Tn$ $(215)$
NE1490$ SAUSA300_0448::Tn$ $(215)$
NE1584$ SAUSA300_0259::Tn$ $(215)$
NE1620$ SAUSA300_0240::Tn$ $(215)$
NE1737$ SAUSA300_2107::Tn$ $(215)$
NE1927$ SAUSA300_2151::Tn$ $(215)$
NE1944$ SAUSA300_1315::Tn$ $(215)$
S.#epidermidis$RP62A# Methicillin$resistant$S.#epidermidis$laboratory$strain,$ATCC$35984# ATCC$
S.#epidermidis#ATCC$12228# S.#epidermidis$laboratory$strain# ATCC$
T6531$ S.#epidermidis$clinical$isolate$ $(236)$
W6903$ S.#epidermidis$clinical$isolate$ $$(236)$
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W6293$ S.#epidermidis$clinical$isolate$ $$(236)$
S.#haemolyticus#ATCC$29970# S.#haemolyticus$laboratory$strain# ATCC$
S.#saprophyticus$ATCC$15305# S.#saprophyticus$laboratory$strain# ATCC$
CIL3$ S.#saprophyticus$clinical$isolate# $$(236)$
CIL4$ S.#saprophyticus$clinical$isolate# $$(236)$
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   Table 3.7. Plasmids 
 
Plasmid( Description( Reference(
pBT2ts' E.#coli/S.#aureus#shuttle'vector# (318)'
pBTE' 1.2'kb'ermB'allele'cloned'into'SmaI'of'pBT2ts' (235)'
pBTK' 1.4'kb'aphCA3'allele'clones'into'SmaI'of'pBT2ts' (235)'
pBTS' 1.3'kb'aad9'allele'cloned'into'SmaI'of'pBT2ts' (235)'
pBTT*' 1.7'kb'tetK'allele'cloned'into'XmaI'of'pBT2ts' This'study'
pOS1Cplgt' S.#aureus'complementation'vector'driven'by'the'lgt'promoter# (341)'
pMG027' glcB'cloned'into'the'NdeI'site'of'pOS1Cplgt'via'Gibson'assembly# This'study'
pMG028' glcA'cloned'into'the'NdeI'site'of'pOS1Cplgt'via'Gibson'assembly# This'study'
pMG029' glcC'cloned'into'the'NdeI'site'of'pOS1Cplgt'via'Gibson'assembly# This'study'
pMG030' glcU'cloned'into'the'NdeI'site'of'pOS1Cplgt'via'Gibson'assembly# This'study'
pNV62' 5''and'3''regions'of'glcB'cloned'into'EcoRI'and'BamHI'sites'of'pBTE'to'yield'∆glcB::ErR' This'study'
pNV63' 5''and'3''regions'of'glcA'cloned'into'EcoRI'and'BamHI'sites'of'pBTK'to'yield'∆glcA::KnR' This'study'
pNV64' 5''and'3''regions'of'glcC'cloned'into'EcoRI'and'BamHI'sites'of'pBTS'to'yield'∆glcC::SpR' This'study'
pNV65' 5''and'3''regions'of'glcU'cloned'into'EcoRI'and'BamHI'sites'of'pBTE'to'yield'∆glcU::ErR' This'study'
pNV66' 5''and'3''regions'of'glcU'cloned'into'EcoRI'and'BamHI'sites'of'pBTT*'to'yield'∆glcU::TcR' This'study'
pNV68' ptsH'(43C>A,'44A>C,'45C>A)'was'amplified'by'overlap'extension'PCR'and'cloned'into'EcoRI'site'of'pBT2ts' This'study'
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Table 3.8. Primers 
 
Primers' Sequence' Use'
tet.1A&& CACTACCCGGGCGCCAGTCGATTTAACGGAC& Construction&of&pBTT&
tet.1B& CACTACCCGGGGTTAATACGTGTGCTCTGCGAGG& Construction&of&pBTT&
glcA65.1A& tgcttgaattcGATAATCCCGTATCTGGTCTTGG& Construction&of&pNV63&
glcA65.1B& tgcttgaattcTTACCAATACGTTGCAATTGACCG& Construction&of&pNV63&
glcA63.1A& taggtggatccCGCCTATTATCGTGACACAAGG& Construction&of&pNV63&
glcA63.1B& taggtggatccATAGGCTGCTTCGCTTGATGC& Construction&of&pNV63&
glcB65.1A& tgcttgaattcGCAGATGTAGGTACAGCAACAG& Construction&of&pNV62&
glcB65.1B& tgcttgaattcTACCAGCTGCTGGTAAAATCGC& Construction&of&pNV62&
glcB63.1A& taggtggatccCAAGATGCTGATCCAGGTAAGC& Construction&of&pNV62&
glcB63.1B& taggtggatccATGACACACGCTACACTGATCG& Construction&of&pNV62&
glcC65.1A& taggtggatccCAAAGCGTTCAATCACGTGATCG& Construction&of&pNV64&
glcC65.1B& taggtggatccGACTTGCCGAACTGCTGTGC& Construction&of&pNV64&
glcC63.1A& tgcttgaattcCAGCAAGGCACTGGTGTGC& Construction&of&pNV64&
glcC63.1B& tgcttgaattcCGTATGCAACATGGAAATTCTCTGG& Construction&of&pNV64&
glcU65.1A& tagctgaattcCGATGCGATTGAATCACCTGG& Construction&of&pNV65&and&pNV66&
glcU65.1B& tagctgaattcCACTTCCCCAGAATAAAGCAGG& Construction&of&pNV65&and&pNV66&
glcU63.1A& tagctggatccAAGATCGTCGTCAGATGACGG& Construction&of&pNV65&and&pNV66&
glcU63.1B& tagctggatccTTATGGCTGATATAGGTGGTGC& Construction&of&pNV65&and&pNV66&
ptsH6H15A65.1A& ctaggatccGATCGTGATTGATCCACCTAGC& Construction&of&pNV68&
ptsH6H15A65.1B& GGTCTAGCTGCAATACCAGTC& Construction&of&pNV68&
ptsH6H15A63.1A& GACTGGTATTGCAGCTAGACC& Construction&of&pNV68&
ptsH6H15A63.1B& ctaggatccAAGCTCTGCGTGAACACCATC& Construction&of&pNV68&
glcB6lgt.1a& atacaattgaggtgaacatATGTTTAAGAAATTGTTTGGAC& Construction&of&pMG027&
glcB6lgt.1b& tttggatcctcgagcatatgTTATTTGACTGTCATAATTAGCTTAC& Construction&of&pMG027&
glcA6lgt.1a& atacaattgaggtgaacatATGAGGAAGAAACTTTTCG& Construction&of&pMG028&
glcA6lgt.1b& tttggatcctcgagcatatgTTATTTAGCTTCAAATAATTGATC& Construction&of&pMG028&
glcC6lgt.1a& atacaattgaggtgaacatATGAAATCTTTATTTGAAAAAGC& Construction&of&pMG029&
glcA6lgt.1b& tttggatcctcgagcatatgTTAATCCCCGAGCAATTC& Construction&of&pMG029&
glcU6lgt.1a& atacaattgaggtgaacatATGCAATTTCTTGATTTCTTAATC& Construction&of&pMG030&
glcU6lgt.1b& tttggatcctcgagcatatgCTATTTCAAATTACCTAGAATTATAGC& Construction&of&pMG030&
rpoD_RT.1A& AACTGAATCCAAGTGATCTTAGTG& qRT6PCR&
rpoD_RT.1B& TCATCACCTTGTTCAATACGTTTG& qRT6PCR&
glcA6RT.1A& CTGTTGCGATTTTACCAGCAGC& qRT6PCR&
glcA6RT.1B& GATACCACCAGCACCTGTC& qRT6PCR&
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glcB.1A& TTGCGATTTTACCAGCAGCTGG& qRT6PCR&
glcB6RT.1B& ACAACTTGTCCTGCTGCTTCC& qRT6PCR&
glcC6RT.2A& GGTCATCTTTGCAATTGGTGTCG& qRT6PCR&
glcC6RT.2B& ATCTTTTGCCAATGTGCCCGTG& qRT6PCR&
glcU6RT.1A& TTCGTCGGCGGTGGACC& qRT6PCR&
glcU6RT.1B& CAAACGCCCATAATGCACCAG& qRT6PCR&
NE396R& ATGTGCTGGTTCTTTCGCTGC& Confirmation&of&Tn&insertion&
NE616F& ATACAGTGTAACGATGATGCATGG& Confirmation&of&Tn&insertion&
NE616R& AAGATTTCGCTGTCGTTCCTGC& Confirmation&of&Tn&insertion&
NE1126F& CTGAGCATGATGTGAAAGTTGCG& Confirmation&of&Tn&insertion&
NE1126R& ATTGACTGTACCAGGTCCAACC& Confirmation&of&Tn&insertion&
NE1726F& GGTGGCGTACAAACTGTCGC& Confirmation&of&Tn&insertion&
NE1726R& GAAACGCTTACCAGCGAAGAAACC& Confirmation&of&Tn&insertion&
NE4506F& CCAAACACCGTTAAAGCATACCC& Confirmation&of&Tn&insertion&
NE4506R& CGGTCATAATACCTGTGATAATCC& Confirmation&of&Tn&insertion&
NE6346F& CTATTGGTGCTGGTGTTGTTATTGC& Confirmation&of&Tn&insertion&
NE6346R& ACCCCCACTAACGATAGGTAC& Confirmation&of&Tn&insertion&
NE6486F& ACAATGGCCACATACGTTTGGC& Confirmation&of&Tn&insertion&
NE6486R& CATACACCGATATAGCCTGAAGC& Confirmation&of&Tn&insertion&
NE7676F& CGGAAGTCAAAGCACAATCTGC& Confirmation&of&Tn&insertion&
NE7676R& CGTATGCGCTCATTAGCGATGG& Confirmation&of&Tn&insertion&
NE9296F& GAGGTGTAAACATGTCACAAACTG& Confirmation&of&Tn&insertion&
NE9296R& GTGGACCCATAATCATTGCACC& Confirmation&of&Tn&insertion&
NE9926F& CCAGCAGCACAAGCGATGG& Confirmation&of&Tn&insertion&
NE9926R& CATCGGTGCTGTCCAATCTGC& Confirmation&of&Tn&insertion&
NE12826F& CATTGGGACAGTTAAGCGAATGC& Confirmation&of&Tn&insertion&
NE12826R& CATTGTTCGGTCTTGCATGTGC& Confirmation&of&Tn&insertion&
NE12906F& ACTTGGATGATGATTCAGTGAACC& Confirmation&of&Tn&insertion&
NE12906R& ATGACACCGTCAGCTTCTTCG& Confirmation&of&Tn&insertion&
NE14216F& AGGGAAAATGGATGGGACAGC& Confirmation&of&Tn&insertion&
NE14216R& TTCTGTCTGTTGATCAAGTGTTCC& Confirmation&of&Tn&insertion&
NE14576F& AACGTCTAGTTCCAATTATGACTGC& Confirmation&of&Tn&insertion&
NE14576R& GTATGATACATTGCTAACGCAGCC& Confirmation&of&Tn&insertion&
NE14906F& ATTAATGTGATTGCGAGTACGGC& Confirmation&of&Tn&insertion&
NE14906R& AAGCGCTACGGGTCCAACG& Confirmation&of&Tn&insertion&
NE15846F& ATGCAACGTATGATACGAAGTGC& Confirmation&of&Tn&insertion&
NE15846R& GATTGCTAAGCCTTCACCTACC& Confirmation&of&Tn&insertion&
NE16206F& AAATTGGAGCAGATTCTACGAACG& Confirmation&of&Tn&insertion&
NE16206R& GACCCACGTTACATATCAATTCCG& Confirmation&of&Tn&insertion&
NE17376F& TCAAGCAATGAAAGATCGTGAGC& Confirmation&of&Tn&insertion&
NE17376R& CCAGCACCAAAGTGAACTGC& Confirmation&of&Tn&insertion&
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NE19276F& TAACAGCAGCTCAAGCTGGAG& Confirmation&of&Tn&insertion&
NE19276R& AATAAATCCATCACGGATGGCTC& Confirmation&of&Tn&insertion&
NE19446F& CACAGTTCAATTAGACGGTGAAGG& Confirmation&of&Tn&insertion&
NE19446R& GTCAAATATCTCTTCTGCTAGACG& Confirmation&of&Tn&insertion&
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CHAPTER 4: REX REGULON EXPANSION CONTRIBUTES TO ENHANCED 
STAPHYLOCOCCUS AUREUS FERMENTATIVE GROWTH 
 
SUMMARY 
 Staphylococcus aureus is a Gram-positive skin colonizing bacteria capable of 
causing severe infections in humans. Recent evidence suggests that metabolic 
adaptation has contributed to the enhanced virulence observed for S. aureus over other 
skin colonizing Staphylococci. Specifically, S. aureus encodes a unique Rex-regulated 
lactate dehydrogenase (ldh1) that contributes to enhanced growth under non-respiratory 
conditions encountered in vivo. Here, we demonstrate that additional Rex-regulated 
factors contribute to the non-respiraotry growth of S. aureus and that the size of the S. 
aureus Rex regulon is larger than that predicted for other Staphylococci. We then 
characterize two S. aureus Rex-regulated factors including: a novel FNT-family lactate 
channel encoded by SACOL0301 (lchA) and a potential α-aminobutyric acid 
fermentative pathway encoded by SACOL1478-76. Our data provides further evidence 
for the metabolic adaptation of S. aureus to infection, and suggests that non-respiratory 
growth conditions are a significant selective pressure generated by inflamed host tissue.  
 
INTRODUCTION 
 S. aureus is a skin colonizing bacterium capable of causing severe, and often 
deadly, human infections. The extreme invasiveness and virulence of S. aureus disease 
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distinguishes it from other less pathogenic skin colonizing Staphylococci (i.e., 
coagulase-negative Staphylococci or CoNS) (20). In general, CoNS infections are 
device-related, occur primarily in immune-compromised patients, and are typically 
caused by only a handful of species (S. epidermidis, S. haemolyticus, S. saprophyticus). 
The primary CoNS virulence trait is robust biofilm formation, which promotes resistance 
to immune clearance as well as recalcitrance to antibiotic treatment (153, 342). S. 
aureus on the other hand, is a leading cause of skin and soft tissue infections (SSTI’s), 
bacteremia, endocarditis, and osteomyelitis and uses a robust arsenal of unique toxins 
and adhesins to cause disease in both healthy and immune-compromised individuals 
(88, 156, 158, 190, 343-345). Several decades of research have shown the importance 
of these unique virulence factors in promoting S. aureus disease. Less well understood 
are the metabolic differences between S. aureus and CoNS and how they contribute to 
the differing pathogenic potential of the Staphylococci. 
 Given the increased frequency of tissue invasion, we hypothesize that S. aureus 
has undergone metabolic adaptations that promote growth in inflamed tissue spaces. 
Such spaces are generally low in iron, low in oxygen, and have high levels of reactive 
oxygen and nitrogen species (ROS and RNS) (287, 324, 346-348). A common 
phenotypic effect of these conditions is inhibition of bacterial respiration. Oxygen is the 
preferred terminal electron acceptor of S. aureus and is reduced via the combined 
activities of two terminal oxidases, CydAB and QoxABCD (245). In the absence of 
alternative electron acceptors (e.g., nitrate), low oxygen restricts S. aureus substrate 
oxidation via respiration-dependent enzymes (e.g., Mqo, SdhCAB, Lqo, GlpD, etc.) and 
induces glycolytic flux (219, 324). Likewise, low iron restricts S. aureus respiration and 
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TCA cycle activity while inducing glycolysis (218, 222). This is because iron is 
abundantly utilized by S. aureus terminal oxidases (CydAB and QoxABCD) and several 
TCA cycle enzymes (SdhA, CitB, and CitG) (245, 275). Interestingly, the high iron 
content of these enzymes also makes them susceptible to inhibition by host nitric oxide 
(NO·) (280, 324). NO· is a membrane permeable radical gas produced by activated 
phagocytes that reacts directly with heme-bound iron and indirectly with thiols via the 
production of RNS. S. aureus is uniquely resistant to high levels of NO· exposure, 
despite that fact that high NO· inhibits S. aureus respiration(236). 
 Evidence for species-specific metabolic adaptation of S. aureus to inflamed 
tissue spaces is limited. S. aureus encodes a unique human-hemoglobin specific 
transport/catabolic system (the isd system) that promotes iron acquisition during 
infection (195, 275). Additionally, S. aureus encodes a variety of unique hemolytic toxins 
(190). Thus, S. aureus may be better able to acquire host iron and consequently 
respire, during infection, in comparison to the less pathogenic Staphylococci. However, 
S. aureus also encodes a unique lactate dehydrogenase (Ldh1) and unique glucose 
transporters (GlcA and GlcC) that promote enhanced growth of S. aureus under non-
respiratory conditions (e.g., high NO· exposure and low oxygen) (Unpublished 
Observations) (236). These factors contribute to S. aureus fermentative growth in an 
additive manner, acting alongside factors shared amongst Staphylococcus strains: two 
lactate dehydrogenases (Ldh2 and Ddh) and three glucose transporters (GlcB, GlcU, 
and UhpT). All of these unique factors (e.g., the isd system, ldh1, glcA, and glcC) have 
been shown to contribute to S. aureus virulence in animal models of infection. 
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 S. aureus utilizes two transcriptional regulators, SrrAB and Rex, to sense and 
respond to respiration inhibition. SrrAB is a two component regulatory system that 
activates gene expression in response to low respiratory flux (SrrAB is thought sense 
the redox status of the quinone pool) (246). SrrAB activates expression of the S. aureus 
terminal oxidases (CydAB and QoxABCD), the anaerobic nitrate reductase (narGH), 
several heme biosynthetic enzymes (hemABCX), pyruvate formate lyase (pflAB), an 
iron-sulfur cluster repair protein (scdA), and a NO· detoxification enzyme (hmp). 
Inactivation of SrrAB results in attenuated growth of S. aureus under low respiratory 
conditions and decreased virulence in murine models of sepsis (172). Rex is a 
repressor whose affinity for DNA is inversely controlled by the cellular NAD+/NADH ratio 
(NAD+ promotes Rex-DNA interactions while NADH causes Rex to lose affinity for DNA) 
(253). Electromobility shift assays and proteomics analysis show that Rex regulates two 
lactate dehydrogenases (ddh and ldh1), pyruvate formate lyase (pflAB), srrAB, a 
putative ethanol dehydrogenase (adhE), several nitrate respiration genes (narGH, nirR, 
and nirC), as well as other genes of unknown function. The contribution of Rex to S. 
aureus growth under low respiratory conditions and S. aureus virulence in animal 
models of infection has not been tested. 
 In this manuscript, we demonstrate that derepression of the Rex regulon is 
required for the non-respiratory growth of S. aureus. Furthermore, we show that S. 
aureus is predicted to encode an expanded Rex regulon in comparison to less 
pathogenic Staphylococci. We then characterize two unique S. aureus Rex-regulated 
factors (SACOL0301 and SACOL1478) and demonstrate that they contribute to the 
non-respiratory growth of S. aureus. Our results suggest that the high frequency of S. 
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aureus infection has selected for an increased fermentative capacity in this pathogen, 
thus providing additional support for the hypothesis that metabolic adaptation 
contributed to the speciation of S. aureus from the other Staphylococci. 
 
RESULTS 
Rex Regulon Derepression is Required for the Non-Respiratory Growth of S. aureus on 
Carbohydrates. 
 To directly test the contribution of Rex regulon to non-respiratory growth of S. 
aureus, we cloned the rex gene into the multicopy expression plasmid pOS1-plgt, which 
allows for constitutive rex expression under the lgt promoter. We then compared the 
aerobic, anaerobic, and NO· resistant growth of WT S. aureus cells carrying the rex-
overexpression plasmid (pRex) to those carrying an empty pOS1-plgt vector. We 
performed our growth assays in chemically defined media (CDM) supplemented with 
glucose, as we have previously shown that non-respiratory growth of S. aureus is 
carbohydrate dependent and that at least one Rex-regulated factor (ldh1) contributes to 
growth under these conditions. We utilized NO· donor levels sufficient to inhibit S. 
aureus respiration for several hours. We found that Rex overexpression significantly 
inhibited growth of S. aureus under non-respiratory conditions but did not affect growth 
under aerobic conditions (Figure 4.1). Specifically, the growth rate for WT S. aureus + 
pRex was 96%, 17.9% and 19.4% that of the empty vector control under aerobic, 
anaerobic, and NO·-exposed conditions, respectively. These data demonstrate that 
Rex-derepression is required for non-respiratory growth of S. aureus on carbohydrates. 
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 Rex regulates three factors known to contribute to growth of S. aureus during 
non-respiratory conditions: ldh1, ddh, srrAB (Unpublished Observations) (236, 246, 
253). To examine whether additional Rex-regulated factors contribute to the non-
respiratory growth of S. aureus, we grew WT and ∆ldh1∆ddh∆srrAB S. aureus under 
aerobic, anaerobic, and NO· exposed conditions and then compared the percent growth 
rate to that of the Rex-overexpressing strain. The ∆ldh1∆ddh∆srrAB S. aureus mutant 
displayed no aerobic growth defects, but had a significantly reduced growth rate 
anaerobically (80.5%) and following NO· exposure (32%) (Figure 4.1). Importantly, the 
percent growth rate defect was always larger for the rex-overexpressing strain than for 
the ∆ldh1∆ddh∆srrAB mutant, suggesting that additional Rex-regulated factors 
contribute to the non-respiratory growth of S. aureus on carbohydrates. 
 
S. aureus Encodes an Expanded Rex Regulon. 
 S. aureus exhibits enhanced non-respiratory growth compared to less pathogenic 
Staphylococci. This can partially be explained by the acquisition of a unique Rex-
regulated lactate dehydrogenase (ldh1) by S. aureus (236). To identify additional Rex-
regulated factors contributing to the enhanced non-respiratory growth of S. aureus over 
that of the other Staphylococci, we compared the predicted Rex regulons of 9 
Staphylococcus species, including: S. aureus (COL and Mu50), S. epidermidis (RP62A 
and ATCC 12228), S. haemolyticus JCSC1435, S. saprophyticus ATCC 15305, S. 
carnosus TM300, S. pseudintermedius (HKU10-03 and ED99), S. lugdunensis (HKU09-
01 and N920143), S. warneri SG1, and S. pasteuri SP1. S. aureus exhibited the largest 
number of putatively Rex-regulated genes (48), while S. pasteuri exhibited the lowest 
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(27). Importantly, Pagels et al. have characterized the effect of different mismatches in 
the conserved Rex-binding sequence on the ability of S. aureus Rex to bind the DNA 
(253). Using this information, and removing genes whose putative Rex-binding site fell 
within the coding sequence of another gene, we curated the predicted Rex regulons for 
S. aureus COL, S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. 
saprophyticus ATCC15305. Furthermore, we added genes that are predicted to be 
within putative operons of Rex-regulators genes. This resulted in a total of 38, 28, 20, 
and 12 predicted Rex-regulated genes for S. aureus COL, S. epidermidis RP62A, S. 
haemolyticus JCSC1435, and S. saprophyticus ATCC15305, respectively (Figure 4.2 
and Table 4.1). These data suggest that S. aureus encodes an expanded Rex regulon 
compared to CoNS. 
 To assess the conservation of the predicted Rex regulons, we performed protein 
sequence similarity analysis and genome context analysis for each entry from the 
curated lists of S. aureus COL, S. epidermidis RP62A, S. haemolyticus JCSC1436, and 
S. saprophyticus ATCC 15305 against the genomes and protein databases for 9 
Staphylococcus species and the closely related bacteria, Macrococcus caseolyticus (M. 
caseolyticus). When we compared the predicted Rex regulons for S. aureus, S. 
epidermidis, S. haemolyticus, and S. saprophyticus to just each other, we found that 
each genome encoded 16, 8, 3, and 6 unique/uniquely Rex-regulated genes, 
respectively (Figure 4.2). When we searched for these genes in the other Staphylococci 
and M. caseolyticus, we found that S. aureus, S. epidermidis, S. haemolyticus, and S. 
saprophyticus encoded 10, 6, 2, and 6 unique/uniquely Rex-regulated genes, 
respectively (Table 4.1).  
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The Rex-Regulated S. aureus Gene SACOL0301 Encodes a Lactate Export Channel.  
 S. aureus is known to ferment carbohydrates into lactic acid under non-
respiratory conditions and to export lactate into the surrounding media to very high 
concentrations (235, 349, 350). Export of lactate by S. aureus should reduce 
stoichiometric inhibition of the lactate dehydrogenases, allowing greater redox balancing 
under anaerobic and NO· exposed conditions. S. aureus is predicted to encode three 
proteins that may contribute to lactate transport. Two of these genes (SACOL2363 and 
SACOL0093) share high sequence similarity with known lactate permeases, and one of 
them, SACOL2363, is predicted to be Rex-regulated. The third allele, SACOL0301, is 
predicted to encode a homolog of FocA (short for formate channel A) which belongs to 
the formate nitrite transporter family (FNT) (351). FocA has only been shown to 
transport formate in whole cells, but in reconstituted planar membranes FocA transports 
a variety of other small anions in addition to formate (e.g., lactate, chloride, 
hypophosphite, etc.) (352). SACOL0301 is predicted to be Rex-regulated and is absent 
in the S. epidermidis and S. haemolyticus genomes. We hypothesize that at least one of 
these predicted transporters contributes to S. aureus lactate export and growth under 
non-respiratory conditions. 
 To test this, we first compared the expression of all three genes in WT S. aureus 
COL grown aerobically and anaerobically on glucose. We found that SACOL2363 and 
SACOL0301, the two genes predicted to be Rex-regulated, were both significantly 
induced under anaerobic conditions, while expression of SACOL0093 was unchanged 
(Figure 4.3). To confirm that induction of SACOL2363 and SACOL0301 under 
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anaerobic conditions was Rex-dependent, and to further confirm that SACOL0093 is not 
Rex-regulated, we compared the aerobic expression of all three genes in WT and ∆rex 
S. aureus COL. Both SACOL2363 and SACOL0301 were significantly induced in the 
∆rex mutant, while SACOL0093 expression remained unchanged (Figure 4.3). These 
data confirm that SACOL2363 and SACOL0301 are Rex-regulated and show that two of 
the three predicted lactate transport protein encoding genes are highly expressed under 
growth conditions that require S. aureus lactic acid fermentation. 
 Next, we assessed the contribution of the predicted lactate transporters to the 
growth of S. aureus under a variety of respiratory and non-respiratory conditions using 
WT, ∆SACOL0301, ∆SACOL2363∆SACOL0093 (∆COL-2), and 
∆SACOL0301∆SACOL2363∆SACOL0093 (∆COL-3) S. aureus COL. We found that 
none of the mutants exhibited observable aerobic growth defects in media with either 
glucose or L-lactate as the primary carbon source (Figure 4.4). However, when grown 
on glucose under non-respiratory conditions, both ∆SACOL0301 and ∆COL-3 exhibited 
significantly reduced growth rates compared to WT S. aureus (Figure 4.5A-C). The fact 
that no phenotype was observed for ∆COL-2 and the growth rates of ∆SACOL0301 and 
∆COL-3 were not significantly different suggests that SACOL0301 is the only gene that 
contributes to the non-respiratory growth of S. aureus. Importantly, all strains exhibited 
roughly identical cfu/Abs650nm during mid-exponential phase. Additionally, the anaerobic 
growth of ∆SACOL0301 could be restored to that of WT S. aureus via plasmid 
complementation or nitrate addition (Figure 4.6). 
 Finally, we compared the extracellular levels of L-lactate, D-Lactate, EtOH, and 
formate produced by ∆SACOL0301 and ∆COL-2 during anaerobic growth on glucose 
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(values were normalized to those found for WT S. aureus). We found that the double 
mutant had comparable levels of extracellular metabolites to WT, but that ∆SACOL0301 
exhibited significantly reduced extracellular L and D-Lactate (~50% of WT) and 
significantly elevated levels of formate and EtOH (~200% of WT) (Figure 4.5D). These 
data are consistent with SACOL0301 encoding a Rex-regulated lactate export channel, 
as reduced lactate export will restrict lactate production due to stoichiometric inhibition 
of ldh1 and ddh and thus redirect carbon flow into an alternative fermentative metabolic 
pathway (i.e. ethanol production). 
 
SACOL0301 is a novel member of the FNT-family. 
 Sequence homology of SACOL0301 places it in the FNT family, whose members 
form homopentameric channels, similar in structure to aquaporins, that allow the 
passage of small monoanionic substrates (351, 353). There are three known members 
of the FNT family and each is named for the substrate that it transports: FocA transports 
formate, NirC transports nitrite, and HSC transports hydrosulfide. SACOL0301 
transports lactate, and is thus a novel member of the FNT-family. As such we have 
named SACOL0301, lchA, for lactate channel A. Protein sequence alignment 
(ClustalW2) of LchA with the five characterized members of the FNT-family shows 
conservation of both channel restriction sites (F88/F214/ and L92/L102) as well as the 
T104 and H221 residues important for closing the channel in the absence of high 
concentrations of anionic substrate (Figure 4.7) (353-357). Interestingly, LchA has a 
uniquely long N-terminus that is similar to that of NirC and HSC, albeit longer (Figure 
4.7 and 4.8). Phylogenetic analysis of the FNT protein sequences using a neighbor 
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joining method employing 4 separate distance matrix models all displayed LchA as 
intermediately related to HSC/NirC and the three FocA sequences (Figure 4.9), 
supporting the assignment of LchA as a novel member of the FNT family. 
 
LchA does not contribute to virulence of S. aureus in a murine sepsis model. 
 Lactate production is known to contribute to S. aureus virulence in murine 
models of infection (236). Thus, we infected C57BL/6 mice with 5x107 cfu of WT or 
∆lchA S. aureus Newman via tail vein injection and then compared weight loss and 
organ burdens (kidneys, liver, lung, and heart) for these mice. We utilized S. aureus 
Newman for the infection because it generates reproducible murine weight loss that 
corresponds to bacterial tissue burden. This allows us to easily and safely monitor 
disease progression. Prior to infection, we verified that the ∆lchA Newman strain 
exhibited similar growth phenotypes to the S. aureus COL ∆lchA mutant (data not 
shown). We found that both weight loss and organ burdens (day 6 post infection) of the 
∆lchA-infected mice were not significantly different from that of WT S. aureus infected 
mice (Figure 4.10). While these data may suggest that lactate export does not 
contribute to virulence of S. aureus during infection, the residual lactate export we 
observed for the ∆lchA mutant in vitro suggests that genetic redundancy may 
compensate for the loss of lchA during infection. 
 
S. aureus produces a variety of fermentative end products during anaerobic growth.  
 Lactate fermentation alone cannot support the non-respiratory growth of S. 
aureus on carbohydrates. This is because lactate fermentation produces one molecule 
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of NAD+ per pyruvate while glycolysis generates two NADH molecules per glucose (one 
molecule of glucose generates two pyruvate via glycolysis). Thus all available carbon 
must be utilized for lactate production (a metabolic waste product) in order for the cell to 
run glycolysis in a redox-balanced manner. This paradox may partially be explained by 
S. aureus EtOH fermentation, which allows for the regeneration of 2x NAD+/pyruvate. S. 
aureus has been shown to produce ethanol from glucose under anaerobic conditions 
and is predicted to encode two Rex-regulated alcohol dehydrogenases capable of 
participating in EtOH fermentation (219, 236). However, the toxicity of EtOH limits 
production of this fermentative end product. Thus, we hypothesize that S. aureus 
possesses additional, undescribed, fermentative reactions that promote the non-
respiratory growth of S. aureus on carbohydrates. 
 To identify novel S. aureus fermentative end products, we performed GC/LC-
mass spectrometry based metabolomics on the intracellular metabolite pool of WT S. 
aureus COL grown aerobically and anaerobically on glucose (25mM). We identified 272 
total metabolites. 122 metabolites increased (range: 1.004-1607-fold) and 150 
metabolites decreased (range: 1.05-1951-fold) in the anaerobic sample compared to the 
aerobic metabolite pool (Table 4.2). Importantly, 9 of the top 20 metabolites that 
increased in abundance during anaerobic growth were putative fermentative end 
products. Three of these fermentative end products (lactate, α-aminobutyric acid, and α-
hydroxyglutaric acid) were also in the top four most abundant intracellular metabolites 
during anaerobic growth, suggesting that their production is both specific to and robust 
during anaerobic growth. These data suggest that S. aureus produces unique 
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fermentative end products during non-respiratory growth, and that production of these 
compounds may support enhanced redox-balancing activity. 
 
The Rex-regulated S. aureus operon SACOL1478-1476 likely encodes a unique α-
aminobutyric acid fermentation pathway.  
 S. aureus encodes two putative alanine dehydrogenases, one of which is 
predicted to be Rex-regulated (SACOL1478). Several species of bacteria are known to 
ferment alanine from carbohydrates(358). Thus, we postulated that alanine fermentation 
might promote redox balancing during the non-respiratory growth of S. aureus on 
carbohydrates (alanine is produced from pyruvate). However, intracellular alanine levels 
were only slightly elevated during the anaerobic growth of S. aureus on glucose (Table 
4.2). Interestingly, the structure of α-aminobutyric acid (AABA, the 3rd most abundant 
and 2nd most induced metabolite during anaerobic growth) is very similar to that of 
alanine (Figure 4.11). Additionally, SACOL1478, the putative Rex-regulated alanine 
dehydrogenase, is in an operon with genes encoding enzymes similar to those found in 
a metabolic pathway that was engineered in E. coli to catalyze the fermentation of 
threonine into AABA (359). These genes, SACOL1477 and SACOL1476, are predicted 
to encode a threonine dehydratase and an amino acid permease, respectively. Thus, 
we hypothesized that SACOL1478 actually encodes a Rex-regulated AABA 
dehydrogenase and that this operon encodes a fermentative pathway that converts 
extracellular threonine into AABA (Figure 4.15). 
 To begin testing this hypothesis we first confirmed that SACOL1478 was Rex-
regulated using qRT-PCR. We found that SACOL1478 was significantly induced by 
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deletion of S. aureus rex (~10-fold induction over WT S. aureus) and by anaerobic 
growth (~100-fold induction over aerobic growth) (Figure 4.12). Furthermore, we found 
that expression of SACOL1477 (the putative threonine dehydratase predicted to be in 
an operon with SACOL1478) was identical to that of SACOL1478 under all conditions 
tested. Next, we examined the contribution of SACOL1478 to the aerobic and anaerobic 
growth of S. aureus COL on glucose and in TSB. We found that a ∆SACOL1478 mutant 
displayed no significant aerobic or anaerobic growth defects on glucose, but did display 
a significantly reduced growth rate anaerobically in TSB (Figure 4.13). We postulated 
that a low level of fermentable substrate (e.g. threonine) in our chemically defined 
media (CDM) might explain this difference. Thus, we compared the anaerobic growth of 
WT and ∆SACOL1478 S. aureus COL in CDM + glucose with and without additional 
threonine (0.25%). Threonine addition significantly improved the anaerobic growth of 
WT S. aureus but significantly inhibited the anaerobic growth of the ∆SACOL1478 
mutant (Figure 4.13A-B). 
 To more directly characterize the activity of SACOL1478, we examined the 
extracellular profile of amine containing compounds via HPLC following growth of S. 
aureus under several conditions. This allows visualization of amino acid production and 
consumption, as well as AABA production by S. aureus. Importantly, we found that WT 
S. aureus produces AABA but only under anaerobic growth conditions. Additionally, we 
found that AABA production was dependent on SACOL1478 (Figure 4.14). 
Supplementation of the CDM + glucose with additional threonine (2x) increased the 
concentration of extracellular AABA. Interestingly, the alanine peak was also affected in 
the same manner as the AABA peak. Together, these data are consistent with 
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SACOL1478 encoding an AABA dehydrogenase that supports NAD+ regeneration 
during anaerobic growth of S. aureus on carbohydrates. 
 
DISCUSSION 
 S. aureus is a highly dangerous human pathogen that exhibits enhanced 
virulence compared to other Staphylococci. We have previously shown that S. aureus 
exhibits an increased capacity for growth under non-respiratory conditions, in 
comparison to less pathogenic Staphylococci, due to the acquisition of several unique 
metabolic factors (e.g., ldh1, glcA, and glcC) (Unpublished Observations) (236). These 
factors promote enhanced glycolytic flux and fermentation. Thus, we hypothesize that 
an increased frequency of tissue invasion and subsequent exposure to host 
inflammation, has led to the metabolic adaption of S. aureus to low respiratory 
conditions. In the current manuscript, we expand on this hypothesis by demonstrating 
that 1) non-respiratory growth of S. aureus on carbohydrates requires Rex regulon 
derepression, 2) S. aureus is predicted to encode an expanded Rex regulon, and 3) 
characterizing one rare and one unique S. aureus Rex-regulated protein. 
 Comparison of the predicted S. aureus Rex regulon with those of three CoNS 
species revealed that S. aureus is predicted to encode both the most (38) and most 
unique (16) Rex-regulated factors. When we examined the genomes of additional 
Staphylococci, and the closely related M. caseolyticus, for the presence of the Rex-
regulated factors identified in our initial four Staphylococci (S. aureus, S. epidermidis, S. 
haemolyticus, and S. saprophyticus), we found that S. aureus was still predicted to 
encode the largest number of unique/uniquely Rex-regulated factors (10). Amongst 
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these factors are an essential two-component regulatory system (walKR) involved in 
regulating the composition of the cell-wall, a hypothetical protein encoded by 
SACOL0166, srrAB, a leukocidin (lukAB), and an alcohol dehydrogenase predicted to 
be involved in alcohol fermentation (adh1) (246, 360). Interestingly, LukAB exhibits a 
cellular tropism for killing phagocytic cells, which, via robust oxygen consumption and 
NO· production, play a large role in generating the low respiratory conditions present in 
inflamed host tissues (361). Additionally, two Rex-regulated factors (ldh1 and ddh) have 
been previously shown to be important for S. aureus survival during phagocytosis, 
suggesting that Rex-derepression in response to innate immune cell activation may 
indeed represent one mechanism for the activation of lukAB expression (324). However, 
additional work must be done to confirm that lukAB is actually Rex-regulated. 
 One S. aureus allele we confirmed to be Rex-regulated was SACOL0301. 
Protein sequence comparison identified this allele as a homolog of the FNT family 
protein, FocA. FNT-family proteins are structurally similar to aquaporin family proteins, 
forming homopentameric channels that allow the passage of small monoanionic 
substrates across the membrane(351). Although known to exhibit broad substrate 
specificity in vitro, FNT family members are named for the substrate they primarily 
transport in vivo (e.g. nirC encodes a nitrite channel). This led to the hypothesis that the 
substrate specificity of FNT family proteins is determined mostly by the intracellular 
concentration of potential transportable substrates. Thus, genetic linkage with small 
anionic producing/utilizing metabolic enzymes is a common feature of the characterized 
FNT transporter encoding genes(351). For instance, hsc is found in an operon with a 
sulfite reductase (arsABC), nirC is encoded in an operon with a nitrite reductase 
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(nirBD), while focA can be found either in an operon with pyruvate formate lyase (pflAB) 
or formate dehydrogenase (fdhAB). Importantly, the activity of these coregulated 
enzymes either supports cellular respiration or else generates PMF. Identification of 
lchA breaks this paradigm in several ways. First, lactate is a fermentative end product 
and is not degraded extracellularly to produce PMF. Secondly, lchA does not appear to 
be encoded within an operon. Instead, coregulation of lchA, ldh1, and ddh by Rex, 
provides a genetic linkage between this channel and its substrate producing enzymes. 
 The second S. aureus allele we confirmed to be Rex-regulated was SACOL1478. 
This allele is annotated as an alanine dehydrogenase and is predicted to be in an 
operon with a threonine dehydratase (SACOL1477) and an amino acid permease 
(SACOL1476). However, our results provide preliminary evidence that SACOL1478 
encodes an AABA dehydrogenase and that the SACOL1478-1476 operon encodes a 
pathway for the fermentation of extracellular threonine into AABA (Figure 4.15). 
Specifically, using metabolomics we found that S. aureus produced robust 
concentrations of intracellular AABA, but not alanine, when grown anaerobically in CDM 
+ glucose. We then observed that threonine supplementation enhanced the anaerobic 
growth of S. aureus in CDM + glucose in a SACOL1478-dependent manner. Finally, 
using HPLC we found that anaerobic production of AABA by S. aureus was dependent 
on both threonine and SACOL1478. However, we also found that the size of the alanine 
peak in our HPLC analysis was also dependent on threonine and SACOL1478. Since 
alanine is a component of our CDM, it is difficult to tell whether SACOL1478 and 
threonine supplementation contribute to alanine production during anaerobiosis or 
whether alanine consumption is simply prevented in the presence of SACOL1478 and 
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threonine. Ultimately, additional genetic and biochemical characterization of this operon 
is needed to demonstrate the true function of proteins encoded by SACOL1478-1476. If 
further analysis supports our proposed function for this operon (i.e. fermentation of 
threonine into AABA), this would be, to the best of our knowledge, the first 
demonstration that S. aureus can use amino acids as fermentative substrates and the 
first demonstrated instance of a naturally occurring pathway for the fermentation of 
threonine into AABA. 
 Interestingly, our metabolomics data also demonstrated the robust production of 
at least two other fermentative end products by S. aureus grown anaerobically in CDM + 
glucose, including: α-hydroxyglutaric acid and α-hydroxyisocaproic acid. Previous 
research has demonstrated that the anaerobes Pseudomonas aerogenes and 
Clostridium difficile can convert glutamic acid into α-hydroxyglutaric acid and leucine 
into 2-hydroxyisocaproic acid, respectively (362-364). Both reactions have been shown 
or are proposed to use NADH-dependent alcohol dehydrogenases, thus promoting 
redox balancing during non-respiratory growth via the fermentation of amino acids.  S. 
aureus is predicted to encode two Rex-regulated alcohol dehydrogenases 
(SACOL0135/adhE and SACOL0660/adh1/adhP). Both enzymes share high sequence 
homology to acetaldehyde dehydrogenases/ethanol dehydrogenases, suggesting they 
likely participate in EtOH fermentation (219). However these enzymes have not been 
biochemically characterized. Furthermore, an alcohol dehydrogenase isolated from two 
strains of Clostridium beijerinckii was shown to exhibit activity with both primary and 
secondary alcohols, suggesting that adh1 and adhE could possibly react with multiple 
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substrates (365). How these reactions fit into S. aureus non-respiratory metabolism 
requires additional experimentation. 
 Although preliminary in many respects, the identification of unique/rare Rex-
regulated factors in the S. aureus genome that contribute to the non-respiratory growth 
of this pathogen is consistent with our hypothesis that S. aureus has metabolically 
adapted to the low respiratory conditions present during infection. This observation 
informs both our understanding of how human pathogens can arise from commensal 
bacteria (i.e., the speciation of S. aureus from less/non-pathogenic Staphylococci) and 
the metabolisms that support pathogenesis of extracellular bacteria. Specifically, these 
observations highlight the importance of low respiratory environments as a selective 
pressure inherent to the course of S. aureus infections, which helps to explain the 
isolation of respiration-deficient clinical variants of S. aureus. 
 
MATERIALS AND METHODS 
Bacterial Strains and Media 
 All Staphylococci were cultivated in BactoTM Tryptic Soy Broth (TSB, BD: 
211825) or in chemically defined media (CDM), wherein the primary carbon source 
could be modified (316). Chloramphenicol was added to cultures for the maintenance of 
plasmids at a concentration of 10 µg/ml for overnights (TSB) and 2.5 µg/ml for all 
experimental growth conditions (TSB and CDM). All strains, plasmids, and primers 
utilized in this study are listed in (Table 4.3). All non-transduced mutants were 
generated via allelic replacement using the E. coli/S. aureus shuttle vectors pBT2ts, 
pBTK, pBTE, and pBTS as previously described (235). AR1404 (S. aureus Newman 
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∆lchA::SpR) was generated via transduction using Φ80 lysates from AR0805 (S. aureus 
COL ∆lchA::SpR). AR1313 (S. aureus COL ∆rex::KmR) was generated via transduction 
using Φ80 lysates from AR0352 (S. aureus COL ∆rex::KmR) (282). AR1418 (S. aureus 
COL ldh1::ErRddh::SpR∆srrAB::KmR) was generated via transduction using Φ80 lysates 
from AR1417 (S. aureus ∆srrAB::KmR) and AR0456 (S. aureus ldh1::ErRddh::SpR).  
 
Growth Curves 
 Staphylococcus cultures were grown overnight in TSB at 37°C with shaking at 
250rpm. For aerobic and NO· curves, overnight cultures were washed twice with PBS 
and diluted into TSB or CDM +/- Carbon +/- Cm2.5 to an initial OD660nm = 0.04. Diluted 
cultures were then aliquoted into a 96-well plate (200µl/well) and incubated in a Tecan 
Infinite M200 microplate reader set to 37°C with 1mm orbital shaking. Growth was 
monitored via absorbance at OD650nm every 15 minutes for 24hrs (a 30 sec linear 
shaking period was included prior to every read). For NO· curves, a mixture of NO· 
donors (10mM NOC-12 and 1mM DEA NONOate) was added at an initial time point 
corresponding to an OD650nm = 0.15 (t0). To extend the fermentative phase, additional 
NOC-12/DEA NONOate was added (5mM:0.5mM) two hours (t2) and four hours (t4) 
after the initial dose. To ensure continued substrate availability during such prolonged 
NO· exposure (S. aureus utilizes carbon inefficiently during NO· induced fermentation) 
we used 50mM glucose for these experiments. For anaerobic growth curves, the 
overnight cultures were washed twice with PBS and diluted into 5mls of prewarmed 
(37°C) TSB or CDM +/- Carbon +/- 50mM Potassium Nitrate to an OD660nm = 0.08. 
Cultures were prepared in duplicate in 16x150mm glass tubes containing 1mm stir bars. 
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Following dilution, cultures were immediately transferred into a COY anaerobic chamber 
and grown at 37°C with stirring. Growth was monitored hourly via absorbance readings 
at 650nm. 
 
Growth Rate Analysis 
 Growth rates were calculated using the following formula: µ = 
∆ln(Abs650nm)/∆time(hrs). The time intervals used for growth rate analysis are specific 
to each experiment and are therefore provided in the figure legends. 
 
Rex Regulon Prediction: 
 Using the Geneious software package, we performed genome searches of S. 
aureus (COL and Mu50), S. epidermidis (RP62A and ATCC 12228), S. haemolyticus 
JCSC1435, S. saprophyticus ATCC 15305, S. carnosus TM300, S. pseudintermedius 
(HKU10-03 and ED99), S. lugdunensis (HKU09-01 and N920143), S. warneri SG1, and 
S. pasteuri SP1 for Rex-binding sites located within 350bp upstream of predicted ORFs 
using the conserved Rex binding sequence (TGTGAn6TCACA, allowing single 
mismatches). We then curated the predicted Rex regulons for S. aureus COL, S. 
epidermidis RP62A, S. haemolyticus JCSC1435, and S. saprophyticus ATCC 15305 by 
excluding ORFs whose putative upstream Rex-binding site fell within the coding region 
of another predicted gene. Additionally, we excluded genes whose putative Rex-binding 
site(s) included mutations shown to result in a loss of binding (253). Conservation 
analysis was assessed for each entry in the curated Rex regulons by forward and 
reciprocal BLASTP searches (BLOSUM62, expect value of 10, identity and e-value 
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cutoffs of 50% and 1e-50, respectively) and visual inspection of genome context using 
MetaCyc (http://metacyc.org/) against the genome/protein databases of 9 
Staphylococcus species and M. caseolyticus. 
 
Real Time Quantitative Reverse Transcriptase PCR. 
 S. aureus COL strains were grown in 50mls of CDM + Glucose (25mM) in 250ml 
flasks at 37°C with shaking at 250rpm. At an OD660 = 0.5, 25mls of each culture was 
added to an equal volume of ice-cold ethanol/acetone (1:1) and frozen at -80°C (aerobic 
cultures). To assess gene expression during NO· exposure, a separate set of cultures 
(CDM + Glucose) was treated with 5mM DETA-NONOate (Cayman Chemical, 82120) 
for 1 hour, then quenched and frozen. Lastly, S. aureus COL was grown in 50mls of 
CDM + Glucose in the anaerobic chamber at 37°C with stirring. At OD660 = 0.5, 25mls of 
culture was removed from the chamber in a 50ml conical devoid of oxygen, and then 
immediately quenched and frozen. RNA was then harvested and gene expression 
analyzed as previously described (282). Transcript levels of select genes were 
normalized to rpoD transcript levels, which deviated very little across our experimental 
conditions. Primers used for qRT-PCR analysis are listed in Table 4.3. 
 
Enzymatic Quantification of Extracellular Metabolites: 
 250 µl culture aliquots were harvested from anaerobic cultures (0.45 ≤ Abs 
OD65nm ≤ 0.65) and immediately heat inactivated at 70°C for 5 minutes. The samples 
were then pelleted, and the supernatants transferred to clean microfuge tubes. 
Supernatants were stored at -20°C and thawed on ice prior to analysis. L-lactic acid, D-
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lactic acid, ethanol, and formic acid were measured enzymatically using commercially 
available reagents (R-Biopharm AG, Darmstadt, Germany: Roche Yellow Line Kits). 
Metabolite levels for each sample were then normalized to the density of the culture 
from which they were harvested (i.e., Abs OD650), and mutant metabolite levels were 
then normalized to WT metabolite levels by experiment. 
 
HPLC Analysis: 
 Derivatized supernatants from S. aureus cells propagated aerobically or 
anaerobically overnight in CDM + glucose (25mM) +/- 250uM threonine were analyzed 
via HPLC using the AccQ-Tag™ Amino Acid Analysis system (Waters, Milford MA) as 
per manufacturer instructions. 100 µl of derivatized sample was injected using a 
Waters™ 717plus Autosampler into an Applied Biosystems 140B solvent delivery 
system and separated on a Waters AccQ-Tag™ 3.9x150 mm column. Separation was 
achieved using manufacturer specifics. Derivatized amines were detected via a Hewlett 
Packard 1046A programmable fluorescent detector (Ex = 250 nm, Em = 395 nm). 
Values were analyzed with a Peaksimple Chromatography Data System (SRI, Torrance, 
CA). 
 
GC/LC-Mass Spectrometry Metabolomics: 
 For aerobic samples, overnight cultures of S. aureus COL were washed twice 
with sterile PBS, diluted 1:100 into 50mls of CDM + glucose (25mM) in a 250mls flasks, 
and incubated at 37°C with shaking at 250rpm until Abs OD65nm = 0.5. For anaerobic 
samples, overnight cultures of S. aureus COL were washed twice with sterile PBS, 
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brought into the anaerobic chamber, diluted 1:100 into 50mls of CDM + glucose (25mM) 
in a 250mls flask  (degassed in chamber overnight), and incubated at 37°C with stirring 
until Abs OD650nm = 0.65 (different spectrophotometer, matches with the OD650 = 0.5 for 
the aerobic spec). Once the desired Abs was reached, cultures were filtered, washed 
with 100mls of 4°C 0.6% NaCl, quenched in 750 µls of 60% EtOH, quickly frozen using 
a dry ice and EtOH bath, and then stored at -80°C. The time required to harvest, wash, 
quench, and freeze samples was ≤ 3 minutes. Once three samples were collected for 
each condition, all samples were thawed on ice, transferred to lysing matrix-B tubes 
(MP Biomedicals cat # 116911050), and lysed at 4°C using a bead beater (3x 30 sec. 
lysing periods with 5 minute ice incubations in between). Samples were then pelleted 
and 500µl of each supernatant was transferred to a fresh tube (supernatants from each 
condition were combined to yield 1.5 mls). Supernatants were then lyophilized in 200µl 
aliquots using a speed-vacuum set at room temperature until the total sample volume 
for each condition was 200 µl. GC/LC mass spectrometry analyses were performed by 
RTI international (Research Triangle Park, NC). 
 
Virulence Assays. 
 For virulence assessment, 6-8 week old female C57BL/6 mice from Jackson 
Labs (Bar Harbor, ME USA) were injected intravenously (tail vein) with 5 x 107 CFU of 
WT and ∆lchA (Φ80) S. aureus Newman. Weight loss of infected mice was monitored 
daily. On day 6 post-infection the mice were sacrificed and organs (kidneys, liver, lungs, 
and heart) were harvested, homogenized, and plated on TSA agar for serial dilution for 
the enumeration of bacteria.  
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Figure 4.1. Rex Derepression is Required for the Non-Respiratory Growth of S. aureus on 
Carbohydrates. Aerobic (A), anaerobic (B), and NO· exposed (C) growth of WT, ∆ldh1∆ddh∆srrAB, WT 
+ empty vector, and WT + pRex in CDM + glucose (25mM anaerobic curve, 50mM NO· curve) +/- Cm2.5 
(n = 3, error bars = SEM). NO· donors (10:1, NOC-12:DEANO) were added at t0 (11mM), t2 (5.5mM), 
and t4 (5.5mM). (D) Corresponding growth rates for aerobic (t2.5-t6), anaerobic (t4-t14), and NO· (t1-t5) 
growth curves (n = 3, error bars = SEM). Significance was determined using a Student’s two-sided t-test 
(n.s., not significant; *, p-value ≤ 0.05; **, p-value ≤ 0.01, ***, p-value ≤ 0.001).  
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Figure 4.2. Size and Conservation of the Predicted Rex Regulons of Several 
Staphylococci. S. aureus COL, S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. 
saprophyticus ATCC 15305.  
 
 
 
 
Figure 4.3. qRT-PCR Expression of Three Potential S. aureus Lactate Transporters. RNA 
was harvested during mid-exponential growth of WT and ∆rex S. aureus COL in CDM + glucose 
(25mM) or L-lactate (50mM). Aerobic cultures incubated at 37°C with shaking at 250rpm. 
Anaerobic cultures were incubated at 37°C in a Coy anaerobic chamber with stirring. Transcript 
abundance was normalized to that of rpoD (n = 3, error bars = SEM). Statistical significance was 
determined using a Student’s two-sided t-test (*, p-value ≤ 0.05).  
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Figure 4.4. Contribution of the Three Predicted Lactate Transporters 
to S. aureus Aerobic Growth.  Aerobic growth of WT, ∆COL-2 
(∆SACOL2363∆SACOL0093), ∆lchA (∆SACOL0301), and ∆COL-3 
(∆SACOL0301∆SACOL2363∆SACOL0093) S. aureus COL in CDM + 
glucose (25mM) (A) or L-lactate (50mM) (B) (n = 3, error bars = SEM). (C) 
Corresponding growth rates for glucose (t4-t7) and L-lactate (t5-t9) grown 
cells (n = 3, error bars = SEM).   
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Figure 4.5. SACOL0301 Contributes to the Non-Respiratory Growth of S. aureus. Anaerobic (A) and 
NO· exposed (B) growth of WT, ∆COL-2 (∆SACOL2363∆SACOL0093), ∆lchA (∆SACOL0301), and 
∆COL-3 (∆SACOL0301∆SACOL2363∆SACOL0093) S. aureus COL in CDM + glucose (25mM for 
anaerobic curve, 50mM for NO· curve) (n = 3, error bars = SEM). NO· donors (10:1, NOC-12:DEANO) 
were added at t0 (11mM), t2 (5.5mM), and t4 (5.5mM). (C) Corresponding growth rates for anaerobic 
grown (t5-t10) and NO· exposed (t1.5-t4) S. aureus (n = 3, error bars = SEM). (D) Extracellular metabolite 
levels (% WT) for anaerobically grown ∆COL-2 (∆SACOL2363∆SACOL0093) and ∆lchA S. aureus COL 
in CDM + glucose (25mM) at mid-log (n = 3, error bars = SEM). Statistical significance was determined 
using a Student’s two-sided t-test (C) and a paired Student’s two-sided t-test (D) (n.s., not significant; *, p-
value ≤ 0.05; **, p-value ≤ 0.01; ***, p-value ≤ 0.001; an asterisk directly above a bar indicates 
significance from WT).   
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Figure 4.6. Complementation of the Anaerobic ∆SACOL0301 S. aureus Growth 
Defect. (A) Anaerobic growth of WT and ∆lchA S. aureus COL in CDM + glucose 
(25mM) + nitrate (50mM). Blue line indicates maximum absorbance detectable by 
spectrophotometer (n = 3, error bars = SEM). (B) Anaerobic growth of WT + pOS1 
(empty vector), ∆lchA + pOS1 (empty vector), and ∆lchA + pNV50 (pOS1-lchA) in CDM 
+ glucose (25mM) + Cm2.5 (n = 2, error bars = SEM).  
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Figure 4.7. Protein Sequence Alignment of LchA with Characterized FNT-Family 
Proteins. ClustalW2 alignment of LchA with E. coli NirC, C. difficile HSC, S. typhimurium 
FocA, E. coli FocA, and V. cholerae FocA. The colored boxes highlight conserved 
residues of the selectivity filter (green = cytoplasmic slit, purple = constriction ring, and 
red = closure mechanism).   
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Figure 4.8. 3D Structural Comparison of FNT Monomers. 3D structures of the characterized FNT monomers (E. coli NirC, C. difficile HSC, and 
E. coli FocA) as well as the predicted (Phyre2) structure of the S. aureus LchA monomer as seen from the side (i.e. perpendicular to the 
membrane) (A) and the bottom (i.e. from the intracellular side through the membrane) (B). The N-terminus section of each protein (i.e. all amino 
acids prior to the start of the first transmembrane α-helix) is shown in blue.  
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Figure 4.9. Phylogenetic Analysis of FNT Family Members. The protein sequences of each 
characterized FNT family member (E. coli NirC, C. difficile HSC, S. typhimurium FocA, E. coli FocA, and 
V. cholerae FocA) were aligned with S. aureus LchA using ClustalW2 and then analyzed using a 
bootstrapped Neighbor Joining method employing the Kimura formula (1000 iterations).  
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Figure 4.10. SACOL0301 Does Not Contribute to S. aureus Virulence During 
Murine Sepsis. C57BL/C mice were infected with 5x107 cfu of WT or ∆lchA S. 
aureus Newman via tail vein injection. Weight loss (A) was monitored daily while 
organ burdens (B) were determined on day 6 post infection (n = 8, error bars = 
SEM).  
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Figure'4.11.'Molecular'Structures'of'Alanine'and'AABA.'
'
'
'
'
'
'
'
'
'
Figure 4.12. qRT-PCR Expression Analysis of SACOL1478 and SACOL1477. RNA was harvested 
during mid-exponential growth of WT and ∆rex S. aureus COL in CDM + glucose (25mM) either 
aerobically or in an anaerobic chamber. Transcript abundance was normalized to rpoD (n = 1).  
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Figure 4.13. SACOL1478 Contributes to the Anaerobic Growth of S. aureus COL. (A) Anaerobic 
growth of WT and ∆SACOL1478 S. aureus COL in CDM + glucose (25mM) +/- threonine (0.5%) with 
corresponding growth rates (t4-t14) shown in (B) (n = 3, error bars = SEM). (C) Anaerobic growth of WT 
and ∆SACOL1478 S. aureus COL in TSB with corresponding growth rates (t3-t5) shown in (D) Blue line 
indicates maximum absorbance detectable by spectrophotometer (n = 3, error bars = SEM). Statistical 
significance was determined using a Student’s two-sided t-test (n.s., not significant, **, p-value ≤ 0.01).  
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Figure 4.14. SACOL1478 Contributes to the Anaerobic Production of AABA by S. aureus. 
Amine containing substrates present in S. aureus supernatants were harvested, derivatized, and 
then visualized by HPLC. Supernatants were harvested from WT S. aureus grown aerobically 
and anaerobically in CDM + glucose (25mM) +/- threonine (2x) and from ∆SACOL1478 grown 
anaerobically in CDM + glucose (25mM). Figures are representative.   
 
 
 
Figure 4.15. Proposed AABA Fermentation Pathway. SACOL1476 is predicted to encode 
an amino acid permease, SACOL1477 is predicted to encode a threonine dehydratase (also 
known as a threonine deaminase or threonine ammonia-lyase), and SACOL1478 is predicted 
to encode an alanine dehydrogenase. We hypothesize that SACOL1476 imports threonine, 
SACOL1477 converts threonine into 2-oxobutanoate and ammonia, and SACOL1478 oxidizes 
2-oxobutantoate into α-aminobutyric acid using NADH.   
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         Table 4.1. Rex Regulon Conservation Amongst Several Staphylococci 
 
S.#aureus S.#epidermidisS.#haemolyticusS.#saprophyticus S.#carnosusS.#pseudintermediusS.#lugdunensis S.#warneri S.#pasteuri M.caseolyticus
COL RP62A JCSC1435 ATCC#15305 TM300 HKU10I03 HKU09I01 SG1 SP1 JCSC5402
SACOL0019 )yycF)(walR,)vicR) 685 SACOL0019 SERP2534 SH0017 SSP0021 Sca2456 SPSINT2432 SLGD02565 A284_00095 STP1_1380 MCCL0021
SACOL0020 yycG N/A SACOL0020 SERP2533 SH0018 SSP0022 Sca2455 SPSINT2431 SLGD02566 A284_00100 STP1_1379 MCCL0022
SACOL0021 yycH N/A SACOL0021 SERP2532 SH0019 SSP0023 Sca2454 SPSINT2430 SLGD02567 A284_00105 STP1_1378 MCCL0023
SACOL0022 yycI N/A SACOL0022 SERP2531 SH0020 SSP0024 Sca2453 SPSINT2429 SLGD02568 A284_00110 STP1_1737 MCCL0024
SACOL0135 adhE alcohol)dehydrogenase 639 SACOL0135 SERP0389
SACOL0166 None unknown 658 SACOL0166 SERP0463 SH0617 SSP2192 SPSINT2386 SLGD02044 A284_02265 STP1_0936
SACOL0204 pflB pyruvate)formate)lyase 696 SACOL0204 SERP2366 Sca2017 SPSINT2094 SLGD00171 A284_00780 STP1_1246 MCCL0434
SACOL0205 pflA pyruvate)formate)lyase N/A SACOL0205 SERP2365 Sca2016 SPSINT2093 SLGD00172 A284_00785 STP1_1245 MCCL_0433
SACOL0222 ldh1 L6lactate)dehydrogenase 6169,)6227 SACOL0222 SH0525 Sca1369 SPSINT1529 MCCL_0163
SACOL0301 lchA lactate)channel 651 SACOL0301 SSP0590 Sca1814 SPSINT2419
SACOL0660 adh1/adhP alcohol)dehydrogenase 6306 SACOL0660 SERP0257 SSP0237 Sca2372 SLDG02225
SACOL1478 ald1 alanine)dehydrogenase 638 SACOL1478 SPSINT2419 SLGD02329
SACOL1477 ilvA1 threonine)dehydratase N/A SACOL1477 SPSINT2418 SLGD02330
SACOL1476 None amino)acid)permease N/A SACOL1476 SPSINT2417 SLGD02331
SACOL1535 srrA respiratory)responsive)regulator 6103 SACOL1535 SERP1055 SH1424 SSP1260 Sca1118 SPSINT1187 SLGD01420 A284_06250 STP1_0072 MCCL1138
SACOL1534 srrB respiratory)responsive)regulator N/A SACOL1534 SERP1054 SH1425 SSP1261 Sca1117 SPSINT1186 SLGD01421 A284_06255 STP1_0071 MCCL1137
SACOL2006 lukA Leukocidin 666 SACOL2006
SACOL2004 lukB Leukocidin N/A SACOL2004
SACOL2363 None 6124 SACOL2363 SERP1957 SH0691 SSP0537 Sca1867 SPSINT2037 SLGD00672 A284_02675 STP1_0857 *MCCL0162
SACOL2364 None 6210 SACOL2364 SERP1958 SH0690 SSP0536 Sca_1868 SLGD00671 A284_02670 STP1_0858
SACOL2395 narG 6107 SACOL2395 SERP1987 SH0654 Sca1894 SPSINT2068 SLGD00597 A284_02455 STP1_0901 MCCL0136
SACOL2394 narH N/A SACOL2394 SERP1986 SH0655 Sca1893 SPSINT2067 SLGD00598 A284_02460 STP1_0900 MCCL0137
SACOL2393 narJ N/A SACOL2393 SERP1985 SH0656 Sca1892 SPSINT2066 SLGD00599 A284_02465 STP1_0899 MCCL01138
SACOL2392 narI N/A SACOL2392 SERP1984 SH0657 Sca1891 SPSINT2065 SLGD00560 A284_02470 STP1_0898 MCCL0139
SACOL2391 nreA N/A SACOL2391 SERP1983 SH0658 Sca1890 SPSINT2064 SLGD00561/2 A284_02475 STP1_0897 MCCL0140
SACOL2390 nreB N/A SACOL2390 SERP1982 SH0659 Sca1889 SPSINT2063 SLGD00563 STP1_0896 MCCL0141
SACOL2389 nreC N/A SACOL2389 SERP1981 SH0660 Sca1888 SPSINT2062 SLGD00564 A284_02490 STP1_0895 MCCL0142
SACOL2399 nirR 664 SACOL2399 SERP1992 SH0650 Sca1899 SPSINT2075 SLGD00593 A284_02430 STP1_0905 MCCL1342
SACOL2398 nirB nitrite)reductase)(large)subunit_ N/A SACOL2398 SERP1990 SH0651 Sca1897 SPSINT2073 SLGD00594 A284_02435 STP1_0904 MCCL1340
SACOL2397 nirD nitrite)reductase)small)subunit N/A SACOL2397 SERP_1989 SH0652 Sca1896 SPSINT2072 SLGD00595 A284_02440 STP1_0903 MCCL1339
SACOL2396 None uroporphyrinogen)methylase)III N/A SACOL2396 SERP_1988 SH0653 Sca1895 SPSINT2071 SLGD00596 A284_02845 STP1_0902 MCCL1338
SACOL2491 None 6128 SACOL2491 SERP2051 SH0583 SSP0417 Sca2209 SPSINT2085 SLGD00514 A284_02095 STP1_0972
SACOL2534 frp 6185 SACOL2534 SERP2086 SH0546 SSP0379 Sca1976 SPSINT2185 SLGD00477 A284_01885 STP1_1016 MCCL1443
SACOL2535 ddh D6lactate)dehydrogenase 6102 SACOL2535 SERP2087 SH0545 Sca2121 SPSINT0522 SLGD00476 A284_01880 STP1_1017 MCCL_0071
SACOL2657 arcA arginine)deiminase 679 SACOL2657 SERP2250 SH0367 Sca2085 SPSINT2396 SLGD00317 A284_00615 STP1_1278
SACOL2656 arcB2 ornithine)carbomoyltransferase N/A SACOL2656 SERP2249 SPSINT2397 A284_00610 STP1_1279
SACOL2655 arcD arg/orn)aniporter N/A SACOL2655 SERP2247 SH0368 Sca2084 SPSINT2398 A284_00605 STP1_1280
SACOL2654 arcC2 carbamate)kinase N/A SACOL2654 SPSINT2399 A284_00600 STP1_1280
SERP0389 None adhE 639 SACOL0135 SERP0389
SERP1987 narG 6129 SACOL2395 SERP1987 SH0654 Sca1894 SPSINT2068 SLGD00597 A284_02455 STP1_0901 MCCL0136
SERP1986 narH N/A SACOL2394 SERP1986 SH0655 Sca1893 SPSINT2067 SLGD00598 A284_02460 STP1_0900 MCCL0137
SERP1985 narJ N/A SACOL2393 SERP1985 SH0656 Sca1892 SPSINT2066 SLGD00599 A284_02465 STP1_0899 MCCL01138
SERP1984 narI N/A SACOL2392 SERP1984 SH0657 Sca1891 SPSINT2065 SLGD00560 A284_02470 STP1_0898 MCCL0139
SERP1983 nreA N/A SACOL2391 SERP1983 SH0658 Sca1890 SPSINT2064 SLGD00561/2 A284_02475 STP1_0897 MCCL0140
SERP1982 nreB N/A SACOL2390 SERP1982 SH0659 Sca1889 SPSINT2063 SLGD00563 STP1_0896 MCCL0141
SERP1981 nreC N/A SACOL2389 SERP1981 SH0660 Sca1888 SPSINT2062 SLGD00564 A284_02490 STP1_0895 MCCL0142
SERP_1990 nirB nitrite)reductase)(large)subunit_ 6144 SACOL2398 SERP1990 SH0651 Sca1897 SPSINT2073 SLGD00594 A284_02435 STP1_0904 MCCL1340
SERP_1989 nirD nitrite)reductase)small)subunit N/A SACOL2397 SERP_1989 SH0652 Sca1896 SPSINT2072 SLGD00595 A284_02440 STP1_0903 MCCL1339
SERP_1988 None uroporphyrinogen)methylase)III N/A SACOL2396 SERP_1988 SH0653 Sca1895 SPSINT2071 SLGD00596 A284_02845 STP1_0902 MCCL1338
SERP_2031 None AA6ABC)Transporter 6359 SACOL2453 SERP2031 SH0606 Sca1934 SLGD00544 A284_02220 STP1_0945 MCCL1461
SERP_2030 None AA6ABC)Transporter N/A SACOL2452 SERP_2030 SH0607 Sca1933 SLGD00545 A284_02225 STP1_0944 MCCL1462
SERP_2029 None AA6ABC)Transporter N/A SACOL2451 SERP_2029 SH0608 Sca1932 SLGD00546 A284_02230 STP1_0943 MCCL1463
SERP_2028 None AA6ABC)Transporter N/A SACOL2450 SERP_2028 SH0609 Sca1931 SLGD00547 A284_02235 STP1_0942 MCCL1464
SERP_2032 None Sorbitol)Dehydrogenase 6148 SERP2032 SH0605 SSP1612 Sca2335 SLGD00543 A284_11700 STP1_1419 MCCL1801
SERP_2051 None Unknown 690 SACOL2491 SERP2051 SH0583 SSP0417 Sca2209 SPSINT2085 SLGD00514 A284_02095 STP1_0972
SERP_2086 frp 6164 SACOL2534 SERP2086 SH0546 SSP0379 Sca1976 SPSINT2185 SLGD00477 A284_01885 STP1_1016 MCCL1443
SERP_2087 ddh D6Lactate)Dehydrogenase 682 SACOL2535 SERP2087 SH0545 Sca2121 SPSINT0522 SLGD00476 A284_01880 STP1_1017 MCCL_0071
SERP_2096 pfoR perfringolysin)regulator)O 6113 SACOL2546 SERP2096 SH0537 Sca1981 SPSINT2087 SLGD00468 A284_01845 STP1_1344
SERP_2094 sdhB serine)dehydratase N/A SACOL2545 SERP_2094 SH0538 SSP1545 Sca1980 SPSINT2088 SLGD00469 A284_01850 MCCL0809
SERP_2093 sdhA serine)dehydratase N/A SACOL2544 SERP_2093 SH0539 SSP1544 Sca1979 SPSINT2089 SLGD00470 A284_01855 MCCL0810
SERP_2111 None Thioredoxin 6202 SACOL2550 SERP2111 SH0524 SSP0340 Sca0828 SPSINT2023 SLGD00457 A284_01790 STP1_1034 MCCL0063
SERP_2112 None Putative)dehydrogenase 636 SERP2112 SH0522 SPSINT2343 SLGD00455 A284_01780 STP1_1036 MCCL1471
SERP_2366 pflB Pyruvate)Formate)Lyase 673 SACOL0204 SERP2366 Sca2017 SPSINT2094 SLGD00171 A284_00780 STP1_1246 MCCL0434
SERP_2365 pflA Pyruvate)Formate)Lyase N/A SACOL0205 SERP2365 Sca2016 SPSINT2093 SLGD00172 A284_00785 STP1_1245 MCCL_0433
SERP_2381 None NADH/flavin)Oxidoreductase 636 SERP2381 SLGD00224 MCCL1670
SERP_2380 None Drug)Transporter N/A SERP2380 SLGD00223
ROPFunction
S.)epidermidis)
(28)
Locus Gene#NameOrganism
S.)aureus))))))))))))
(38)
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         Table 4.1. Continued… 
 
 
 
S.#aureus S.#epidermidisS.#haemolyticusS.#saprophyticus S.#carnosusS.#pseudintermediusS.#lugdunensis S.#warneri S.#pasteuri M.caseolyticus
COL RP62A JCSC1435 ATCC#15305 TM300 HKU10I03 HKU09I01 SG1 SP1 JCSC5402
SH_0057 None Hypothetical 3149 SACOL0040 SERP2501 SH0057 SSP0034
SH_0258 argF OrnithineDCarbamoylDTransferase 331 SACOL1181 SERP2351 SH0258 SSP0232 Sca2251 SPSINT2397 A284_00610 STP1_1153
SH_0259 None carbamateDkinase N/A SACOL1182 SERP2352 SH0259 Sca2252 SPSINT2399 A284_00610
SH_0357 None Hypothetical 3109 SACOL1183 SERP2353 SH0357 Sca2253/55 A284_01025 STP1_1197
SH_0367 arcA arginineDdeiminase 379 SACOL2657 SERP2250 SH0367 Sca2085 SPSINT2396 SLGD00317 A284_00615 STP1_1278
SH_0368 arcD Arg/OrnDaniporter N/A SACOL2655 SERP2247 SH0368 Sca2084 SPSINT2398 A284_00605 STP1_1280
SH_0522 None PutativeDdehydrogenase 336 SERP2112 SH0522 SPSINT2343 SLGD00455 A284_01780 STP1_1036 MCCL1471
SH_0523 None ThioesteraseDContaining 3181 SACOL2551 SH0523 SSP0339 SLGD00456 A284_01785 STP1_1035
SH_0537 pfoR perfringolysinDregulatorDO 3113 SERP2096 SACOL2546 SH0537 Sca1981 SPSINT2087 SLGD00468 A284_01845 STP1_1344
SH_0538 sdhB serineDdehydratase N/A SACOL2545 SERP_2094 SH0538 SSP1545 Sca1980 SPSINT2088 SLGD00469 A284_01850 MCCL0809
SH_0539 sdhA serineDdehydratase N/A SACOL2544 SERP_2093 SH0539 SSP1544 Sca1979 SPSINT2089 SLGD00470 A284_01855 MCCL0810
SH_0545 ddh D3LactateDDehydrogenase 3136 SACOL2535 SERP2087 SH0545 Sca2121 SPSINT0522 SLGD00476 A284_01880 STP1_1017 MCCL_0071
SH_0546 frp 3182 SACOL2534 SERP2086 SH0546 SSP0379 Sca1976 SPSINT2185 SLGD00477 A284_01885 STP1_1016 MCCL1443
SH_0583 None Unknown 386 SACOL2491 SERP2051 SH0583 SSP0417 Sca2209 SPSINT2085 SLGD00514 A284_02095 STP1_0972
SH_0650 nirR SACOL2399 SERP1992 SH0650 Sca1899 SPSINT2075 SLGD00593 A284_02430 STP1_0905 MCCL1342
SH_0651 nirB nitriteDreductaseD(largeDsubunit_ 3144 SACOL2398 SERP1990 SH0651 Sca1897 SPSINT2073 SLGD00594 A284_02435 STP1_0904 MCCL1340
SH_0652 nirD nitriteDreductaseDsmallDsubunit N/A SACOL2397 SERP_1989 SH0652 Sca1896 SPSINT2072 SLGD00595 A284_02440 STP1_0903 MCCL1339
SH_0653 None uroporphyrinogenDmethylaseDIII N/A SACOL2396 SERP_1988 SH0653 Sca1895 SPSINT2071 SLGD00596 A284_02845 STP1_0902 MCCL1338
SH_0690 None Unknown 3232,D3258 SACOL2364 SERP1958 SH0690 SSP0536 Sca_1868 SLGD_00671 A284_02670 STP1_0858
SH_0691 lctp2 Permease 3133,D3160 SACOL2363 SERP1957 SH0691 SSP0537 Sca1867 SPSINT2037 SLGD00672 A284_02675 STP1_0857 *MCCL0162
SSP_0417 None Unknown 3106 SACOL2491 SERP2051 SH0583 SSP0417 Sca2209 SPSINT2085 SLGD00514 A284_02095 STP1_0972
SSP_0536 None 3238 SACOL2364 SERP1958 SH0690 SSP0536 Sca_1868 SLGD_00671 A284_02670 STP1_0858
SSP_0537 lctp2 375 SACOL2363 SERP1957 SH0691 SSP0537 Sca1867 SPSINT2037 SLGD00672 A284_02675 STP1_0857 *MCCL0162
SSP_0590 focA lactateDchannel 370 SACOL0301 SSP0590 Sca1814 SPSINT2419
SSP_0591 None AminoDAcidDPermease 3375 SACOL2309 SERP1902 SH0739 SSP0591 Sca1812 SPSINT1979 SLGD00712 A284_02945 STP1_0800 MCCL0079
SSP_1001 ldh1 LactateDDehydrogenase 354/3112 SH0525 SSP1001 Sca1369 SPSINT1529 MCCL0163
SSP_1427 None PhosphonateDABCDtransporter 337 SACOL0128 SERP2286 SH0318 SSP1427 SLGD00528 A284_01055 STP1_1186
SSP_1428 None Hypothetical 3233 SACOL0129 SERP2287 SSP1428 SLGD00529 A284_01055 MCCL0438
SSP_1728 hmp flavohaemoprotein 398 SH1899 SSP1728 Sca0683 SPSINT0769 SLGD01812 STP1_2121 A284_08515
SSP_1729 None chitinase 3163 SACOL1071 SERP0647 SH1900 SSP1729 Sca0682 SPSINT0768 SLGD01813 A284_08520 STP1_2120
SSP_1934 None Hypothetical 3179 SSP1934
SSP_1933 None Hypothetical N/A SSP1933 Sca1525
GeneDandDROPDPresent
GeneDPresentDInDOperon,DOperonDROP
GeneDPresentDbutDROPDAbsent
GeneDAbsent
S.DsaprophyticusD
(12)
S.DhaemolyticusD
(20)
ROPFunctionLocus Gene#NameOrganism
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Table 4.2. Intracellular Metabolite Pools of WT S. aureus COL Grown Aerobically and 
Anaerobically in CDM + Glucose as Determined by GC/LC-MS.  
 
Metabolite Aerobic Anaerobic Fold/Change
S"Formylglutathione 238 382328 1607.749418
2"aminobutyric=acid 762530 420887017 551.9612566
2"Hydroxyglutaric=acid 392407 188947237 481.508139
2"Hydroxyisocaproic=acid 31830 9670260 303.8126748
DG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) 506 112517 222.4875204
Allyl=isothiocyanate 1766 376270 213.0804309
3,4"Dihydroxyphenylglycol=O"sulfate 308 46128 149.6043216
Glucose 4522780 648804447 143.4525772
Tyrosine 1100865 91783624 83.37409582
UMP 327938 24687957 75.28242584
Propane"1,2"diol 270242 17334241 64.14339778
Phosphoenolpyruvic=acid 2066 122409 59.25994836
á"Phenyllactic=acid 33731 1773953 52.59055285
Hydroxyacetic=acid 1587713 77350943 48.71846005
Lactate 38475506 1826306091 47.46672042
N"a"Acetyl"L"arginine 27600 1099573 39.83912065
LysoPC(18:2(9Z,12Z)) 15124 592491 39.1743559
2"Hydroxy"3"methylbutyric=acid 93349 3315299 35.51494034
trans"2"Hydroxycinnamic=acid 18460 608876 32.98423731
2"Aminoacrylic=acid 1313 38992 29.70694931
Iminoaspartic=acid 1533 39836 25.9919266
trans"1,2"Dihydrobenzene"1,2"diol 3173 69704 21.9649345
S"Nitrosoglutathione 2731 58629 21.4704017
TG(8:0/8:0/8:0) 9823 209729 21.3512004
AMP 770993 15013572 19.47303327
3"amino"2"piperidone 137292 2432210 17.7155628
Xylose 808083 14256972 17.64295679
Ribitol 93501 1525527 16.3156727
Glutamic=acid 1962292 31210020 15.90488071
Ribose=5"phosphate= 13041 195808 15.01519915
7,8"Dihydropteroic=acid 5324 79155 14.86755138
Uracil 92867 1181474 12.72226286
Gluticol 88494 1098962 12.41854587
Ribose,=phosphate 8369 84731 10.12466317
Pyrrolidonecarboxylic=acid 653990 5703637 8.721291897
Asparagine 45955 339480 7.387279147
Isoleucine 9794018 70260321 7.173799345
Glyceraldehyde=3"phosphate 11943 85630 7.170221946
Cotinine 6510 45513 6.991548073
p"Synephrine 6340 43850 6.916452735
Alloisoleucine 946110 6198580 6.551646583
3"Phosphoglyceric=acid 25050 157026 6.26840285
Vinylacetylglycine 36208 216778 5.987021621
5"Hydroxyindoleacetic=acid 28772 160757 5.587191088
Homoserine 930516 5152761 5.537531577
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Table 4.2. Continued… 
 
Metabolite Aerobic Anaerobic Fold/Change
4"(2"Aminophenyl)"2,4"dioxobutanoic8acid 5949 31191 5.243115023
Dihydroandrosterone 81743 378493 4.6302573
Ribonic8γ"lactone 37484 169127 4.512001827
Gamma"Glutamylcysteine 13063 58102 4.447904531
L"prolyl"L"proline 31370 139359 4.442415249
Glutamine 1344148 5954278 4.429777023
Malic8acid 634874 2765480 4.35595066
Threo"3"Phenylserine 12603 53267 4.226398036
5b"Pregnanediol 112226 451123 4.01976125
2"Aminomuconic8acid 66894 265051 3.96227174
Citrulline 107203 417274 3.892370353
Bisnorcholic8acid 39874 147488 3.698855671
Sphinganine 14514 53355 3.676146136
N"Acetylglutamine 496854 1779567 3.581672664
4"Aminophenol 56087 195833 3.491598728
Acetylcysteine 21288 73494 3.45234016
N"Acetyl"L"phenylalanine 17496 57169 3.267636784
Galactitol 9375 29160 3.11037454
Arabinose 10139 31504 3.107241183
2"Methylbutyrylglycine 11926 36842 3.089280319
Arabitol 73392 202740 2.762427359
N"Glycyl"L"Proline 13651 37346 2.735706221
Adenosine83',5'"diphosphate 36603 100076 2.734063507
3,4"Dehydro"DL"proline 37000 93695 2.532313163
Proline 403703 1015431 2.515291394
Deoxyadenosine 10467 24619 2.352120785
3"Indolepropionic8acid 72995 169598 2.323415424
Glyceric8acid 119437 269655 2.257715832
Thymine 348254 764180 2.194315455
2"Furoylglycine 178688 377722 2.113862488
6"Phosphogluconic8acid 68569 143176 2.088050588
Guanosine 31839 64066 2.012169397
17"Hydroxylinolenic8acid 70508 140901 1.998365186
N'"Formylkynurenine 29425 55225 1.876782978
Linolelaidic8acid 239471 445273 1.859404774
Chenodeoxycholic8acid8sulfate 58257 107466 1.84469198
3"Oxooctadecanoic8acid 241014 441355 1.831243227
Cytosine 36827 67284 1.827018455
4,8"Dimethylnonanoyl8carnitine 96963 175270 1.807596151
4"Aminobutyraldehyde 5125932 9168962 1.788740615
7,10"Hexadecadienoic8acid 63510 113215 1.782639953
Allolithocholic8acid 131544 234187 1.780292301
trans"4"Decenoic8acid 26619 46978 1.764803896
5"Aminopentanoic8acid 13467866 22724984 1.687348547
13"L"Hydroperoxylinoleic8acid 110363 185591 1.681648653
18"Hydroxycortisol 15284 25375 1.66019229
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Metabolite Aerobic Anaerobic Fold/Change
Alanine 45187598 72669937 1.608183228
N23Succinyl3L3ornithine 181367 291015 1.604562817
p3chlorophenylalanine 5196366 8183525 1.574855417
Phosphoserine 228813 357820 1.563812122
ProstaglandinBE2 399564 573846 1.436181705
23Hydroxyestradiol333methylBether 73826 105082 1.423379991
PyroglutamicBacidB 794308 1107120 1.393817814
Fumarate 3043509 4240921 1.39343143
Adenine 476859 650671 1.364493222
HeptadecanoicBacid 70081876 95361336 1.360713232
L3beta3aspartyl3L3alanine 105940 142362 1.34379747
OctanoicBacid 51824 68897 1.329441069
BenzoquinoneaceticBacid 619201 799092 1.290520932
13Piperideine323carboxylicBacid 38266 47716 1.246969243
PyrophosphateB(4:1) 343856 421659 1.226266228
Uridine 49956 61005 1.221180488
Glycerol 11497007 13897307 1.208776047
23Oxo343methylthiobutanoicBacid 4391677 5283957 1.203175285
L3gamma3glutamyl3L3leucine 133254 158444 1.189041016
123KetodeoxycholicBacid 30776921 36448564 1.184282321
HexanoicBacid 179880 212330 1.180399868
DeoxycholicBacid 1223170 1433791 1.172193175
LPA(0:0/18:2(9Z,12Z)) 53866 60806 1.12883953
33Methylhistidine 157561 174998 1.110673227
MonoethylBphthalate 35014 38687 1.10488521
Allocystathionine 104865 114063 1.087716639
BenzoicBacid 306871 333197 1.085786232
Hypoxanthine 48446 52292 1.079387562
Desmosine 128444 135120 1.05197285
HexadecanoicBacid 9061518 9476116 1.045753675
2,43DiaminobutyricBacid 765050 768331 1.004288831
Hydantoin353propionicBacid 44718 42636 0.953437567
Phenol 195951 182589 0.931807804
3,B4Bdehydroproline 1887105 1720745 0.911843852
LysoPC(16:0) 581765 520808 0.895221869
PregnenoloneBsulfate 188766 167545 0.887582274
33HydroxyhippuricBacid 49676 42888 0.863350776
7a,12a3Dihydroxy333oxo343cholenoicBacid 466206 400322 0.858681551
FructoseB1,63bisphosphate 325379 261454 0.803535018
23Monostearin 591667 472227 0.798130475
Threose 12775 10188 0.797501357
NicotinamideB 263997 210266 0.796472088
OctadecanoicBacid 8734888 6843992 0.783523718
53DodecenoicBacid 76731 58561 0.763200732
UreidosuccinicBacid 280902 213367 0.759576779
33hydroxybutanoicBacid 88018 66832 0.759295758
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Table 4.2. Continued… 
 
Metabolite Aerobic Anaerobic Fold/Change
Lysine 1669067 1218637 0.730130706
Arginine 291508 208332 0.714670629
Valine 26987992 19172979 0.710426298
N9Formyl9L9methionine 47601 33570 0.705234186
79KetodeoxycholicCacid 728729 480687 0.659623336
DodecanedioicCacid 94271 62037 0.658073032
69deoxy9mannose 156410 102046 0.652426737
DodecanoicCacid 90501 57988 0.640743009
Cystathionine 49706 31052 0.624710913
Succinate 1680163 1014494 0.603807038
39methyl929pentenedioicCacid 36098 21506 0.595776003
Cysteine 2996917 1768324 0.590047709
N9Acetyl9L9asparticCacid 196544 113696 0.578476101
SulfolithocholicCacid 45325 25366 0.559647988
OleicCacid 160636 80791 0.502943431
19Methylnicotinamide 501082 246417 0.491769196
19stearoyl9rac9glycerol 4809085 2110494 0.438855571
m9AminobenzoicCacid 180010 67532 0.375158042
N,N9Dimethylglycine 1559223 539136 0.345772465
AsparticCacid 50264717 17289329 0.343965502
Allantoin 62079 20249 0.326187304
Sucrose 6850 2234 0.326077769
89Hydroxyguanosine 183910 58120 0.316021676
Ornithine 156887 48816 0.311150567
GuanidinosuccinicCacid 116270 35684 0.306906813
5'9Methylthioadenosine 3244752 958463 0.295388866
PhosphateC(3:1) 64153321 18584219 0.289684436
Benzene 73576 19716 0.267972909
Palmitin 2065891 545197 0.263903931
39methyl929oxovalerate 71707 18822 0.262482809
39Methoxytyramine 164493 43174 0.26246898
19Ethyl929pyrrolidinecarboxylicCacid 281344 72517 0.257750466
39Methylindole 527613 132498 0.251126994
GluconicCacid,Cphosphate 151263 36244 0.2396053
AminoadipicCacid 108589 24933 0.229606662
Phenylalanine 18117563 4153007 0.229225493
MannitolC19phosphate 109477 24678 0.2254161
5,69Dihydroxyindole929carboxylicCacid 387838 84096 0.216833544
Pyruvate 1227328 265587 0.216394476
Matitol 123390 26088 0.211430422
PyridoxalC5'9phosphate 183720 37688 0.205137357
39Methoxy949HydroxyphenylglycolCsulfate 7245475 1394121 0.192412689
N9Acetylcystathionine 23983519 4486941 0.187084369
N9formyl9glycine 1282851 229573 0.178954939
Cystine 199577 32504 0.162862374
cis959Tetradecenoylcarnitine 161775 23700 0.146501451
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Metabolite Aerobic Anaerobic Fold/Change
Indole'7'carboxaldehyde 8635 1154 0.133660014
Deoxyuridine 85637 11315 0.132128995
L'beta'aspartyl'L'leucine 971594 120413 0.123933642
4'FumarylacetoaceticCacid 37403 4564 0.122014708
3'DeoxyarabinohexonicCacid 213586 26056 0.121992368
TetradecanoicCacid 1250097 150980 0.120774445
2'oxoglutaricCacid 283338 30739 0.108489219
5'Methoxytryptophol 36475 3911 0.107218095
PipecolinicCacid 20065 2147 0.107025293
RetinoicCacid 85128 9082 0.10669221
Guanine 706473 74222 0.105060062
1'hydroxycyclohexene 2739886 275414 0.100520104
Histidine 519340 51292 0.098764082
CystathionineCsulfoxide 77660 6955 0.089557918
UreidopropionicCacid 1649924 143891 0.087210567
P'CoumaricCacid 351113 27851 0.079321835
Leucine 16718221 1321058 0.079019062
Homocysteine 300564 23536 0.078307398
3'Dehydroxycarnitine 150143 10749 0.071592035
Succinyladenosine 115484 7789 0.067443959
Glycine 130936777 8747636 0.066808089
Glyceraldehyde 55625 3409 0.061281889
Serine 33438639 1849066 0.0552973
3'Hydroxyquinine 76467 4138 0.054116262
GluconicCacid 336945 18055 0.053585837
Carnitine 974192 52147 0.053528516
N'Acetylmethionine 15779578 828418 0.052499361
NicotinicCacid 147200 7344 0.049891404
Glutamylalanine 1043523 51572 0.049421222
CN'acetyl'N'glycine 30530 1345 0.044061864
Adenosine 631001 26942 0.042696802
Urea 298681 10812 0.036199154
L'phenylalanyl'L'proline 206111 7377 0.035792772
HydrocinnamicCacid 16336 583 0.035668742
GlutaconicCacid 104515 3626 0.034693002
OroticCacid 218347 7432 0.034037582
N'AcetylneuraminicCacid 234351 7720 0.032941144
OxalicCacid 35703930 1145376 0.032079844
Threonine 13034537 415136 0.03184891
UrocanicCacid 181421 5652 0.031155986
Spermidine 993674 27601 0.027776436
Tryptophan 4000508 101798 0.025446279
PhenyllacticCacid 1312266 33392 0.025446026
GlutaraldehydeC 125089 3154 0.025211162
3'Methoxytyrosine 58768 1456 0.024773781
IndoleacrylicCacid 1645157 40692 0.024734128
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Metabolite Aerobic Anaerobic Fold/Change
Arachidic(acid 126497 2955 0.023362331
Hydroxypropionic(acid 574317 13097 0.022803643
Rhamnose 401786 8948 0.022271324
4>(2>Amino>3>hydroxyphenyl)>2,4>dioxobutanoic(acid 975800 20639 0.021151137
2,3>Diaminopropionic(acid 251596 5283 0.020997047
Nonanoic(acid 73179 1484 0.020280209
2,3>Dihydroxyvaleric(acid 81982 1623 0.019799744
2>hydroxybutanoic(acid 92198 1613 0.017493082
Taurocyamine 133910 2298 0.017157573
Citric(acid 3916494 57994 0.014807693
3>Hydroxyanthranilic(acid 36963 496 0.013412893
Deoxycytidine 80728 1007 0.012479151
Glycerol,(2>phposphate 226048 2425 0.010728597
m>Coumaric(acid 174434 1824 0.010458444
Demethylphylloquinone 234765 2401 0.010227941
Linolic(acid 274818 2704 0.009840994
Hydroxyisocaproic(acid 9626662 91347 0.009488938
3>Hydroxyphenylacetic(acid 114853 1078 0.009387314
Xylulose 30504 283 0.009286052
Argininosuccinic(acid 156576 1314 0.008391564
Uridine(5'>diphosphate 31790 240 0.007533969
Methylcysteine 5790726 42490 0.007337666
5>Thymidylic(acid 383575 2699 0.007036715
2>Phenylethanol(glucuronide 159112 1101 0.006917759
m>Chlorobenzoic(acid 72124 491 0.006803452
Gamma>Aminobutyric(acid 5078517 34421 0.006777763
Homocystine 360299 2387 0.006625177
Galactonic(acid 65557 403 0.006150306
Vanillactic(acid 34749 206 0.005916952
Isocoproporphyrin 330249 1843 0.005581771
Orotidine 22181 123 0.005551046
Inosine 11508 64 0.005531373
Isovalerylglutamic(acid 147949 705 0.004765852
Propionylcarnitine 334283 1565 0.004681945
d>Erythrotetrofuranose 2398560 10643 0.004437233
2,3,4>Trihydroxybutyric(acid 402335 1734 0.004309137
d>Glucose,(phosphate 511230 1515 0.002962515
Aminomalonic(acid 7542440 20115 0.002666948
Kynurenic(acid 822975 1986 0.002412906
Methionine 4558097 10304 0.002260686
Butyrylcarnitine 282629 549 0.001941991
Taurine 800673 410 0.000512645
Glucosamine 39754 0 0
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Table 4.3. Strains, Plasmids, and Primers 
 
Strain' Description' Reference'
S.#aureus#COL$
Methicillin$resistant$S.#aureus$clinical$isolate,$widely$used$as$a$laboratory$
strain$ W.$Shafer$
AR1315$ WT$S.#aureus#COL$+$pOS1Cplgt$plasmid$ Chapter$3$
AR1408$ WT$S.#aureus$COL$+$pNV55$(pOS1CplgtCrex)$ This$Study$
AR1418$ S.#aureus$COL$ldh1::ErR,$ddh::SpR,$∆srrAB::KmR$(Φ80)$ This$Study$
AR0805$ S.#aureus#COL$∆lchA::SpR,$lchA$=$SACOL0301$ This$Study$
AR0655$
S.#aureus#COL$∆SACOL2363::SpR,$∆SACOL0093::SpR.$Referred$to$as$∆COLC
2$in$text.# This$Study$
AR1372$
S.#aureus$COL$∆lchA::SpR,$∆SACOL2363::SpR,$∆SACOL0093::SpR.$Referred$
to$as$∆COLC3$in$text.# This$Study$
AR1397$ S.#aureus$COL$∆lchA::SpR$+$pOS1# This$Study$
AR1398$ S.#aureus$COL$∆lchA::SpR$+$pNV50$(pOS1ClchA)# This$Study$
AR0781$ S.#aureus$COL$∆SACOL1478# This$Study$
AR1313$ S.#aureus$COL$∆rex::KmR$(Φ80)$ This$Study$
S.#aureus$Newman#
Methicillin$susceptible#S.#aureus$clinical$isolate,$widely$used$as$a$
laboratory$strain$ (366)$
AR1404$ S.#aureus$Newman$∆lchA::SpR$(Φ80)# This$Study$
Plasmid' Description' Reference'
pBT2ts$ E.#coli/S.#aureus#shuttle$vector# (318)$
pBTE$ 1.2$kb$ermB$allele$cloned$into$SmaI$of$pBT2ts$ (235)$
pBTK$ 1.4$kb$aphCA3$allele$clones$into$SmaI$of$pBT2ts$ (235)$
pBTS$ 1.3$kb$aad9$allele$cloned$into$SmaI$of$pBT2ts$ (235)$
pNAS18$ 5'$and$3'$homology$regions$of$SACOL0301$cloned$into$the$EcoRI$and$
BamHI$sites$of$pBTS$to$yield$∆lchA::SpR$
This$Study$
pJS18$ 5'$and$3'$homology$regions$of$SACOL0093$cloned$into$the$EcoRI$and$
BamHI$sites$of$pBTS$to$yield$∆SACOL0093::SpR$using$infusion$
This$Study$
! 179 
pJS19$ 5'$and$3'$homology$regions$of$SACOL2363$cloned$into$the$EcoRI$and$
BamHI$sites$of$pBTS$to$yield$∆SACOL2363::SpR$using$infusion$
This$Study$
pNV35$ 5'$and$3'$homology$regions$of$SACOL1478$were$amplified$separately,$
fused$via$overlap$extension$PCR,$and$cloned$into$the$EcoRI$site$of$pBT2ts$
This$Study$
pOS1$ S.#aureus#complementation$vector# (367)$
pNV50$ lchA$cloned$into$the$EcoRI$site$of$pOS1$ This$Study$
pOS1Cplgt$ S.#aureus$complementation$vector$driven$by$the$lgt$promoter# (341)$
pNV55$(pRex)$ rex#cloned$into$the$NdeI$site$of$pOS1Cplgt$ This$Study$
Primers' Sequence' Use'
COL$0301Cu$1.A$EcoRI$ gatcgaattcTGCTTGGCCATACAGCGGGT$ Construction$of$pNAS18$
COL$0301Cu$1.B$EcoRI$ gatcgaattcGGGTAGGCAGTGAGCA$ Construction$of$pNAS18$
COL$0301Cd$1.A$BamHI$ gatcggatccACAATGCGTTAGTCGATGCCT$ Construction$of$pNAS18$
COL$0301Cd$1.B$BamHI$ gatcggatccAGTGTGTGGAAAATGACAGCCA$ Construction$of$pNAS18$
00935'.1A$ cagtgcagcggaattcAGTATAAGGCTATCTTTTGCC$ Construction$of$pJS18$
00935'.1B$ taccgagctcgaattcTAATCGCACCTGCTGATACAC$ Construction$of$pJS18$
00933'.1A$ tacttgctggggatccTTACAATTTCAGCTATCC$ Construction$of$pJS18$
00933'.1B$ cgactctagaggatccCAAAGAAGATGGCAACAAACC$ Construction$of$pJS18$
lctpC5'.1A$ TGGAACGACATGTGTATAACC$ Construction$of$pNV40$
lctpC5'.1B$ ACCAATCGCACCAAAAGCACC$ Construction$of$pNV40$
lctpC3'.1A$ TAAAGCAGGTAATGTCTTCCC$ Construction$of$pNV40$
lctpC3'.1B$ CTACAATCAACTGTGCCATCC$ Construction$of$pNV40$
ald1C5.1A$ tggtagaattcATGAAGCGGATGATGTTATAGG$ Construction$of$pNV35$
ald1C5.1B$ ggtcatgtgatgaagctaatccGCAAGCTACACGTCCTTCAC$ Construction$of$pNV35$
ald1C3.1A$ tgtaaggacgtgtagcttgcGGATTAGCTTCATCACATGACC$ Construction$of$pNV35$
ald1C3.1B$ tggtagaattcGTTGGTAATGCGCCTGCACC$ Construction$of$pNV35$
focAC1.A$ tggtagaattcTGCCTAGTAATGATTGACCCATCG$ Construction$of$pNV50$
focAC1.B$ ctgtagaattcAGGCATCGACTAACGCATTGTTC$ Construction$of$pNV50$
rexC2.A(NdeI)$ tgcatcatatgCACGAAGGAGGAAATAGCGAATG$ Construction$of$pNV55$
rexC1.B(NdeI)$ ctgtacatatgGACATACTTAGTCCCAGACTG$ Construction$of$pNV55$
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rpoD_RT.1A$ AACTGAATCCAAGTGATCTTAGTG$ qRTCPCR$of$rpoD$
rpoD_RT.1B$ TCATCACCTTGTTCAATACGTTTG$ qRTCPCR$of$rpoD$
SACOL0301_RT.1A$ GGACGACTGGGTAAATAACG$ qRTCPCR$of$lchA$
SACOL0301_RT.1B$ TAAATCCTGCCATCATCGCG$ qRTCPCR$of$lchA$
lctp1_RT.1A$ CATTATGCAGCATTGACAAC$ qRTCPCR$of$SACOL0093$
00935'.1B$ TACCGAGCTCGAATTCTAATCGCACCTGCTGATACAC$ qRTCPCR$of$SACOL0093$
lctP2_RT.1A$ TTTCTTCCAAGGTATCATTCC$ qRTCPCR$of$SACOL2363$
lctP2_RT.1B$ AAATGCGTTGAATGCAAATCC$ qRTCPCR$of$SACOL2363$
ald1CRT.1A$ GTGAAGGACGTGTAGCTTGC$ qRTCPCR$of$SACOL1478$
ald1CRT.1B$ TCGTGAGTTACGATCTTAGCG$ qRTCPCR$of$SACOL1478$
ilvA1CRT.1A$ CCATTTATTCGTCGAACACCTC$ qRTCPCR$of$SACOL1477$
ilvA1CRT.1B$ GCAGATGCTGCGATAATGCC$ qRTCPCR$of$SACOL1477$
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CHAPTER 5: DISCUSSION 
 
SUMMARY OF RESULTS 
 Staphylococcus aureus (S. aureus) is endemic and epidemic to many US 
hospitals. In fact, S. aureus is currently the second leading health-care associated 
infection in the US, causing an estimated ~ 77,000 hospital infections annually (368-
371). S. aureus also frequently infects individuals in the community who have not had 
recent healthcare contact (321). Both hospital and community-associated (HA and CA) 
S. aureus infections place a large burden on the US healthcare system, costing well 
over a billion dollars annually (372). The predominant S. aureus clinical presentation is 
skin and soft tissue infections (SSTIs), accounting for ~50% of all S. aureus 
hospitalizations (373). The frequency of S. aureus SSTIs is increasing and is thought to 
be strongly associated with the ability of this organism to colonize human skin (373). 
However, this cannot fully account for the frequency of S. aureus SSTIs, as several 
other Staphylococcus species also colonize human skin but cause SSTIs far less 
frequently. Research into this discrepancy has revealed that S. aureus encodes many 
unique virulence factors (especially toxins) that promote enhanced tissue invasion and 
destruction. Additional evidence also suggests that S. aureus has metabolically adapted 
to inflamed tissue spaces, and thus may be better able to grow during infection than 
other skin colonizing Staphylococci.  
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Evidence for species-specific metabolic adaptation of S. aureus to inflamed host tissue 
comes from characterization of two unique metabolic factors (the isd system and ldh1) 
in the S. aureus genome. The isd system is a human hemoglobin-specific uptake and 
catabolic system that promotes iron acquisition during infection (195, 275). Due to the 
prevalence of both iron and heme in the S. aureus respiratory chain, the isd system is 
suspected to promote enhanced respiratory activity of S. aureus during infection. The 
ldh1 allele, on the other hand, promotes enhanced non-respiratory growth of S. aureus 
via enhanced lactate fermentation (236). Expression of ldh1 is induced in response to 
respiration inhibition along with another, shared lactate dehydrogenase encoded by the 
ddh allele. These lactate dehydrogenases (Ldh1 and Ddh) contribute to lactate 
production in an additive manner, along with third lactate dehydrogenase (Ldh2) that is 
also both shared by other Staphylococci and constitutively expressed (236, 282). Thus, 
while lactate fermentation is not an exclusive to S. aureus, this pathogen displays an 
enhanced overall capacity to produce lactate in comparison to less pathogenic 
Staphylococci (236). Importantly, both the isd system and lactate fermentation have 
been shown to contribute to S. aureus virulence in murine models of infection, 
suggesting that S. aureus performs both respiratory and non-respiratory metabolism 
during infection (195, 236).   
 Studies to identify host mechanisms driving selection for enhanced S. aureus 
lactate fermentation during infection revealed that host nitric oxide (NO·) production is 
involved (172, 236). NO· is a membrane permeable radical gas produced by activated 
phagocytes that readily binds iron. Due to its high reactivity with iron, NO· exposure 
inhibits S. aureus respiration. Importantly, S. aureus is uniquely resistant to high-level 
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NO· exposure, displaying growth in the presence of NO· levels that are both 
bacteriostatic and bactericidal to other pathogens, including other skin colonizing 
Staphylococci (Unpublished Observations) (236). Loss of ldh1 attenuates the growth of 
S. aureus in the presence of NO· in vitro and affects the virulence of S. aureus in vivo in 
a NO·-dependent manner (236). Interestingly, expression of ldh1 in other Staphylococci 
does not confer NO· resistance, suggesting that additional differences between the 
Staphylococci exist that explain the enhanced non-respiratory growth of S. aureus 
following high-level NO· exposure (unpublished data). The overarching goal of my 
thesis work was therefore to characterize the metabolism of S. aureus in the presence 
of NO· for the purposes of identifying additional mechanisms by which S. aureus may 
have metabolically adapted to this host immune radical.  
 The data presented in Chapter 2 shows that S. aureus resistance to NO· 
exposure is glycolysis-dependent. Specifically, we found that only a subset of glycolytic 
substrates (hexoses) support S. aureus NO· resistant growth in vitro and then 
demonstrate that this is because catabolism of these substrates is 1) respiration-
independent, 2) not susceptible to direct NO· inhibition and 3) produces ATP in a redox 
balanced manner. We then generated two glycolytic (∆pyk and ∆pfkA) and two 
gluconeogenic (∆pckA and ∆gapB) S. aureus mutants and examined them for survival 
defects during phagocytosis by macrophages. We found that gluconeogenesis was 
dispensable and glycolysis was required for S. aureus survival. Attenuation of the 
glycolytic mutants was completely reversed by inhibition of macrophage NO· 
production. Additionally, glucose supplementation promoted enhanced survival of wild-
type (WT) S. aureus in a NO·-dependent manner. Next, we examined the virulence of 
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these mutants in mice. Similar to the macrophages, we found gluconeogenesis was 
dispensable for S. aureus virulence, while glycolysis was required. However, in this 
case, inhibition of host nitric oxide production did not restore virulence of the S. aureus 
glycolytic mutants. Finally, we demonstrated that S. aureus tissue abscesses are 
hypoxic (i.e. low in oxygen). These data suggest S. aureus utilizes glycolysis to resist 
NO· exposure both in vitro and in vivo, but that other factors (e.g., low oxygen) also 
necessitate S. aureus glycolysis during infection.  
 Data presented in Chapter 3 shows that 1) enhanced non-respiratory growth of 
S. aureus is not specific to NO· exposure and 2) acquisition of unique carbohydrate 
transporters is another mechanism by which S. aureus has metabolically adapted to 
infection. First, we demonstrated that S. aureus exhibits enhanced anaerobic growth 
compared to less pathogenic Staphylococci. We then generated lists of predicted 
carbohydrate transport proteins for 4 Staphylococcus species (S. aureus, S. 
epidermidis, S. haemolyticus, and S. saprophyticus) and then compared the number 
and uniqueness of each putative carbohydrate transporter. We found that S. aureus 
was predicted to encode the most (29) and most unique (10) carbohydrate transporters. 
Since most of these transporters were predicted to be phosphotransferase system 
(PTS) proteins, we generated a PTS deficient strain of S. aureus (pts-H15A) and then 
examined it for loss of growth on various carbohydrates. The ptsH-H15A mutant 
exhibited a complete loss of growth on 11 carbohydrates and reduced growth on 2 
carbohydrates (including Glucose). We then utilized this mutant to demonstrate that 
non-respiratory growth of S. aureus disproportionately requires carbohydrate uptake.  
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 Due to its abundance in host tissue, we suspected that glucose might be the 
primary carbohydrate utilized by S. aureus during infection. Thus, we identified and 
characterized four S. aureus glucose transporters (GlcA, GlcB, GlcC, and GlcU), two of 
which (GlcA and GlcC) are unique to S. aureus. We discovered that expression of glcC 
was induced by non-respiratory conditions and that GlcA and GlcC disproportionately 
contribute to the non-respiratory growth of S. aureus on glucose, suggesting that low 
respiratory conditions (e.g., low oxygen, NO·, and low iron) encountered during infection 
may have selected for the acquisition of these alleles. To test the contribution of 
carbohydrate transport in general, and glucose transport specifically, to S. aureus 
virulence, we infected mice subcutaneously with the ptsH-H15A mutant (deficient for 
GlcA, GlcB, and GlcC activity), a quadruple glucose transporter mutant (∆G4), and a 
combined ptsH-15A/glcU mutant. We found that the ∆G4 but not the ptsH-H15A mutant 
was significantly attenuated for survival in this model, while the ptsH-H15A/∆glcU 
mutant was even more severely attenuated than the ∆G4 mutant alone. These data 
demonstrate that uptake of glycolytic substrates (especially glucose) is a critical feature 
of S. aureus virulence, and suggests that exposure to low-respiratory conditions during 
infection has selected for enhanced carbohydrate uptake/glycolytic flux by S. aureus.  
 The focus of Chapter 4 is the NADH responsive regulator Rex. As previously 
mentioned, expression of ldh1 and ddh is induced in response to respiration inhibition. 
This occurs via a build-up of intracellular NADH, which binds to Rex and causes it to 
lose affinity for DNA. Both ldh1 and ddh have conserved Rex binding sites in their 
promoter regions and are repressed by Rex under aerobic conditions. Importantly Rex 
has never been shown to directly contribute to the non-respiratory growth of S. aureus, 
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despite the fact that is predicted to regulate a wide variety of genes important for 
fermentative metabolism. Using a Rex-overproducing strain of S. aureus, we 
demonstrate that Rex-regulon derepression is required for the anaerobic and NO· 
resistant growth of S. aureus. We then demonstrate that this cannot entirely be 
explained by the repression of several Rex-regulated factors (e.g. ldh1, ddh, and srrAB) 
previously demonstrated to contribute to the non-respiratory growth of S. aureus. We 
thus hypothesized that in addition to ldh1 S. aureus may also possess other unique, or 
uniquely Rex-regulated factors that contribute to the enhanced non-respiratory growth 
of S. aureus in comparison to other Staphylococci. Using the conserved Rex-binding 
sequence, we scanned the genomes of several Staphylococci (S. aureus, S. 
epidermidis, S. haemolyticus, and S. saprophyticus) and discovered that similar to the 
carbohydrate transporters, S. aureus is predicted to encode the most (38) and most 
unique (16) Rex-regulated factors. 
 Next, we fully characterized one rare S. aureus allele (SACOL0301), and partially 
characterized one unique S. aureus allele (SACOL1478), that were predicted to be Rex-
regulated. We determined that SACOL0301 was in fact Rex-regulated and found that 
deletion of SACOL0301 resulted in attenuated growth of S. aureus on glucose under 
non-respiratory conditions. Sequence analysis revealed that SACOL0301 was 
homologous to FocA, a formate channel belonging to the format nitrate transporter 
family. Importantly, FNT family transporters exhibit broad substrate specificity for small 
anionic substrates (351, 352). Thus, we hypothesized that SACOL0301 may encode a 
lactate export channel. Indeed, we found that the ∆SACOL0301 exhibited reduced 
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export of lactate under anaerobic conditions, and thus renamed this allele lchA, for 
lactate channel A.  
 Our characterization of SACOL1478 was more preliminary. First, we confirmed 
that SACOL1478 is Rex-regulated and then showed that a ∆SACOL1478 S. aureus 
mutant displays an anaerobic growth defect. SACOL1478 is predicted to be an alanine 
dehydrogenase, however metabolomics analysis of anaerobically grown S. aureus 
showed that alanine was not a major fermentative end product. Instead, we observed 
that a structurally related molecule, α-aminobutyric acid (AABA), was highly abundant. 
Thus we hypothesized that SACOL1478 might encode an AABA dehydrogenase. Using 
HPLC we demonstrated that the ∆SACOL1478 S. aureus mutant did not produce AABA 
under anaerobic conditions and identified threonine as a putative substrate for AABA 
production. These data suggest that increased exposure to low-respiratory conditions 
during infection has selected for an enhanced capacity to perform fermentative 
metabolism by S. aureus over other Staphylococci, and defined Rex-regulon expansion 
as one mechanism by which this has occurred.  
 Overall, the data presented in this thesis demonstrate that S. aureus has 
undergone significant metabolic adaptation to promote enhanced glycolysis and 
fermentative activity in comparison to other human skin colonizing Staphylococci. We 
have shown that this has primarily been achieved via the acquisition of unique (e.g., 
glcA, glcC, SACOL1478-1476, ldh1, etc.) and rare (lchA) alleles and have identified 
several host factors (tissue oxygen gradients, NO· production, and iron chelation) as 
potential selective pressures driving the maintenance of these alleles within the S. 
aureus genome. Given these data, we hypothesize that the acquisition of novel 
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virulence factors by S. aureus (e.g. toxins, etc.) led to an increased frequency of tissue 
invasion, which subsequently resulted in the metabolic adaptation of this pathogen to 
inflamed tissue spaces.  
 
IMPORTANCE 
Development of Novel Anti-S. aureus Therapeutics.  
 Widespread drug resistance is a significant problem in treating S. aureus 
infections. The most clinically significant drug resistance associated with S. aureus 
strains is methicillin resistance (45). Methicillin is a penicillin derivative belonging to the 
β-lactam antibiotics that was introduced in 1960. That same year, the first MRSA strains 
were isolated from patients. Since 1960, MRSA prevalence has increased and is still 
increasing in recent times (122, 370, 374). The percentage of S. aureus strains that are 
methicillin resistant varies by country, but has been documented to be greater than 50% 
in several countries, including the United States (119, 370, 375). Importantly, methicillin 
resistance amongst S. aureus strains is associated with worse clinical outcomes and 
increased healthcare costs (376, 377). Thus, the development of novel therapeutics for 
the treatment of MRSA infections is considered a high priority for continued clinical 
management of S. aureus disease worldwide. The work presented in this thesis 
identifies carbohydrate uptake, glycolysis, and fermentation as pertinent targets for the 
development of novel anti-Staphylococcal therapeutics.  
 The most promising target is currently the S. aureus central metabolic enzyme 
pyruvate kinase (Pyk). We demonstrated in Chapter 1, that S. aureus ∆pyk is 
completely attenuated in two separate models of murine infections. Concurrent with this 
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work, a separate group of researchers identified S. aureus pyruvate kinase (Pyk) as a 
highly connected ‘hub protein’ with structural features that distinguish it from the human 
pyruvate kinase (312, 378, 379). Members of this research group subsequently 
screened a library of chemical compounds for those that could bind the unique regions 
of S. aureus Pyk and inhibit its activity (314). Optimization efforts for several identified 
chemicals resulted in the production of a series of substituted bis-indole molecules 
exhibiting a low IC50 and high selectivity for S. aureus Pyk. These compounds were 
shown to be bactericidal to methicillin resistant S. aureus (MRSA) strains at 
concentrations that were non-toxic to human cell lines. The most promising candidate 
(10d) has an IC50 for S. aureus Pyk of 2 nM and a MIC of 0.3 µg/ml. A recent 
collaboration between our groups allowed us to examine 10d for off-target effects by 
exposing growing ∆pyk S. aureus cells to the compound (314). We found that 10d was 
bacteriostatic to the ∆pyk S. aureus mutant, but was no longer bactericidal. Thus, while 
the drug does appear to have off target effects, a very important feature (i.e., its 
bactericidal effect) is dependent on the presence of the targeted enzyme. These data 
indicate that pyruvate kinase is a viable drug target for the development of novel anti-
Staphylococcal therapeutics, but that more work needs to be performed to determine 
the cause of the bactericidal activity of 10d.  
 The work presented in Chapters 2 and 3, demonstrates that S. aureus 
carbohydrate uptake and fermentation might also be relevant targets for the 
development of novel therapeutics effective against MRSA. Due to its predicted 
essentiality and lack of human homologs, the S. aureus phosphotransferase system 
protein Hpr kinase (PtsH) has been put forth as a potential target for novel anti-MRSA 
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therapeutics (380). Our data shows that PtsH is a poor target, as loss of PtsH function 
(as it relates to carbohydrate uptake) did not affect in vitro growth or virulence of S. 
aureus in an SSTI model of murine infection. Our data indicates, that this is likely the 
result of the continued activity of a non-PTS glucose transporter (GlcU). Thus, to be 
effective, therapies for targeting S. aureus carbohydrate transporters would need to 
target both PTS and non-PTS transporters. On the other hand, fermentative metabolism 
might represent a highly relevant target for anti-Staphylococcal therapeutics, albeit 
without a discernable centralized target. Although we did not directly demonstrate the 
importance of Rex derepression in vivo, two Rex-related factors are known to contribute 
to S. aureus virulence (e.g., ldh1 and srrAB) (172, 236). Additionally, clinically relevant 
non-respiratory mutants of S. aureus are frequently associated with chronic S. aureus 
infections, suggesting that inhibiting S. aureus fermentative metabolism may be an 
effective treatment for typically recalcitrant MRSA infections (228, 315). 
 
Susceptibility of Diabetics to S. aureus Infections. 
 Diabetes mellitus (DM) is a group of metabolic disorders characterized by 
elevated blood glucose levels. Diabetes is a risk factor for infection (e.g., respiratory 
tract, skin and soft tissue, urinary tract, bloodstream, and endocarditis) and S. aureus is 
a predominant cause of several of these infections (e.g., skin and soft tissue, 
bacteremia, and endocarditis) (88, 306, 339, 340, 381). Moreover, diabetes worsens the 
outcomes of S. aureus infections (88, 337, 338). The current understanding of this 
association is that innate immune impairment exhibited by diabetics allows for greater 
dissemination and persistence of bacteria in the bloodstream and tissue of infected 
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hosts (308, 382). Furthermore, it is known that control of blood glucose levels dictates 
this susceptibility (i.e., high blood glucose is associated with susceptibility whereas 
controlled blood glucose levels is not) (88, 311, 383, 384). The data presented in this 
thesis implicate increased glucose availability as an alternative mechanism contributing 
to the increased susceptibility of diabetics to infection.  
   
Evolution of Bacterial Pathogens from Human Commensals. 
 Another important aspect of our work defining the metabolic adaptation of S. 
aureus to invasive infection is that it informs our understanding of the process by which 
pathogens can arise from human commensals. S. aureus belongs to a group of at least 
7 other skin colonizing Staphylococci. These species display a gradient of pathogenic 
potential: at the top is S. aureus, then comes S. epidermidis, in the middle is S. 
haemolyticus, S. saprophyticus, S. hominis, and S. lugdunensis, and on the low end is 
S. capitis and S. auricularis (20). Most of the work explaining this association has 
focused on the acquisition of a wide variety of traditional virulence factors by S. aureus. 
However, our data shows that the pathogenic potential of these organisms is positively 
associated their respective capacities for anaerobic (Chapter 3) and NO· resistant 
growth (data not shown) as well as the predicted size of their respective Rex-regulons 
(i.e., putative capacity to perform fermentative metabolism). These data reveal that low 
respiratory conditions may be a significant selective pressure acting on extracellular 
bacteria found at inflamed tissue sites and could help to explain the absence of 
respiratory metabolism and TCA cycle activity in similarly pathogenic Streptococci.   
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CAVEATS AND FUTURE DIRECTIONS 
 The work presented in this thesis has produced several clearly defined projects 
that could be investigated by future members of the lab. One such project is to identify 
the regulator responsible for the anaerobic induction of the unique glucose transporter, 
GlcC. Only two S. aureus regulators (e.g., Rex and SrrAB) have been shown to 
influence gene expression in response to low respiratory flux. However, the glcC 
promoter region is not predicted to encode a Rex binding sequence and SrrAB has not 
been reported to regulate glcC expression (246). These data suggest the participation 
of novel regulators in the induction of S. aureus anaerobic gene expression, and thus 
warrant the identification of the glcC regulator.  
 Another obvious extension of the carbohydrate transporter studies is to directly 
test the contribution of increased glucose availability to the enhanced pathogenesis of 
S. aureus in diabetics. Using Streptazotocin (STZ) we are able to induce Type I 
diabetes in laboratory mice. These mice exhibit worse outcomes and higher bacterial 
abscess burdens when infected subcutaneously with S. aureus. By comparing the 
percent increase in bacterial burden and/or abscess size for WT S. aureus infections in 
mice +/- STZ treatment to those infected with the quadruple glucose transporter 
deficient S. aureus mutant (∆G4), we can assess whether the host metabolic state 
impacts virulence by affecting substrate availability. 
 An important caveat to the work presented in Chapter 2, is that we never 
examined the S. aureus glycolytic mutants (e.g., ∆pyk or ∆pfkA) for defects in traditional 
virulence factor production. Instead, we assumed that the virulence defect for the S. 
aureus glycolytic mutants is a result of lost metabolic function. However, there are 
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several reasons to think that this assumption may be inaccurate. First, significant loss of 
carbohydrate uptake by S. aureus (i.e. the ptsH-H15A/∆glcU mutant) does not 
phenocopy the attenuation of the S. aureus glycolytic mutants. Secondly, despite not 
exhibiting any obvious loss of toxin production in vitro, or burden defect on day 7 in vivo, 
the S. aureus ∆G4 mutant infected mice exhibited a complete absence of open skin 
lesions throughout the course of infection. This suggests that diminished glucose uptake 
may affect S. aureus toxin production in vivo. This is not altogether surprising given that 
other researchers have found that extracellular glucose levels are inversely correlated 
with toxin production during in vitro growth of S. aureus (385). The mechanism for these 
observations has not yet been determined, but is hypothesized to be CcpA and RNAIII 
mediated. Further investigation into this mechanism is warranted and will be greatly 
facilitated by the use of our glycolytic and carbohydrate uptake deficient mutants.  
 Finally, a large amount of work still remains for the Rex-regulon project. 
Specifically, the SACOL1478-1476 operon still needs to be biochemically characterized 
and tested for its contribution to S. aureus virulence in vivo. Deletion mutants of adhE 
and adh1 should be generated and examined for in vitro growth defects, loss of ethanol 
production, and attenuation in vivo. These alcohol dehydrogenases should also be 
biochemically characterized with an emphasis on examining substrate specificity. Rex 
mediated repression of lukAB should be confirmed and examined for a contribution to 
human leukocyte lysis. Finally, Rex-overexpression should be examined for its effects 
on S. aureus virulence in vivo. Completion of these experiments, as well as many 
others, will provide additional evidence for S. aureus metabolic adaption to host tissue 
invasion.  
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